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CHAPTER 1
Abstract
The prospect of substituting damaged or diseased tissue by cell-based therapeutics has
created much excitement in the last decades, since cell-based therapeutics open up new pos-
sibilities in patient treatment towards regenerative medicine. However, the first generation
of cell-based therapeutics could not live up to market expectations and some were even
withdrawn due to low reimbursement levels. While these products might be considered as
market failures, identifying the obstacles early cell-based products were facing represents
a major opportunity to improve the market performance of future products. In general,
the inherent complexity of cell-based products in combination with limited experience
represents a major obstacle translating a possible candidate from bench to bedside. A
deeper insight was gained by the retrospective evaluation of the translational challenges
where they could be further classified in three categories: (1) pre-market challenges, (2)
manufacturing challenges and (3) post-market challenges.
A fundamental step towards commercialization is the process development (industrial
scale and grade) which affects all three translational challenge categories. Thus, looking
at the process development associated translational challenges is important. Currently,
process development for cell-based therapeutics is often done using a heuristic approach,
however, a more directed and systematic approach would be highly beneficial in order to
overcome the process development associated challenges. Such an approach would allow
for gaining process knowledge and improve process performance and, thus, improve market
performance.
Effective process development for cell-based therapeutics is extremely important for product
commercialization and could be achieved by implementing general bioprocess development
tools and strategies. Hence, this doctoral thesis addresses the question if bioprocess develop-
ment tools and strategies from the pharmaceutical industry can also be used for cell-based
products. While process development requirements differ between unit operations and
development stages, a general obstacle is to deal with limited material and time resources.
As a consequence, most of the applied tools follow the principles of miniaturization, paral-
lelization and automation. In order to demonstrate the power and versatility of bioprocess
development tools, the objective of this thesis is the development and implementation of
tools for different cell-based therapeutic manufacturing unit operations.
The first part of the thesis focuses on the unit operation cell separation, more specific, the
usage of cell partitioning in aqueous two-phase systems (ATPS) as cell separation method.
Here, the usage of a high-throughput screening (HTS) platform is used to investigate
the influence of the critical parameters polymer molecular weight and tie-line length on
I
the cell partitioning behavior of five model cell lines, followed by a technology transfer
project. Here, batch data (cell partitioning in ATPS) is transferred into a microfluidic
flow-through mode. The main scope of this project is the evaluation of 3D printing as a
process development tool, since it allows for a fast and cheap realization of tailored process
equipment. Whereas the second part of the thesis is focusing on cell formulation unit oper-
ations, namely, cell cryoperservation and bioprinting. A major clinical cell cryopreservation
topic is the cryomedia formulation, since it needs to be toxin- and xenogen-free. Thus, the
focus of the second part of this thesis is the development of a tool box to predict cryomedia
performance to shorten development time. Additionally, an analytical strategy, allowing
for evaluation of bioprinting process parameter on critical cell parameter, is developed.
The evaluation of cell partitioning in ATPS as separation method in industrial scale
cell downstream processing is the first central topic of this thesis. Cell partitioning in
ATPS represents a promising alternative cell separation method to tackle the bottleneck
condemned by limited availability of industrial scale methods, since it is scalable and
facilitates a label-free separation. Up to now, the usage of cell partitioning in ATPS
is limited due to its complex nature and not fully described partitioning theory. Thus,
a time intensive and empirical screening is necessary in order to find optimal process
parameter for each cell separation problem. First, a previously developed HTS platform
(batch mode) is used for the investigation of critical ATPS parameter on cell partitioning
behavior of five model cell lines aiming for a systematic and automated screening. The
previously developed HTS platform was extended by a cell barcoding strategy allowing for
a multiplexed high-throughput cell analysis in order to speed up the analytical strategy.
Followed by a case study investigating the influence of the molecular weight and tie-line
length on the resolution of the five model cell-lines in PEG-dextran ATPS. Both factors
have an influence on cell partitioning behavior. The highest resolution of the five model
cell lines could be achieved using low molecular weight PEG in combination with high
molecular weight dextran. Additionally, a countercurrent distribution model was applied
to calculate the theoretical purity and yield for the described separation issue. By applying
the screening conditions to the countercurrent distribution model, an isolation of four of
the five model cell lines is theoretically possible with high purity (> 99.9 %) and yield.
A technology transfer of batch HTS cell partitioning data into a microfluidic flow-through
mode is described in a subsequent project. Such a technology transfer is normally associated
with high investment costs. Aiming for a flexible process development approach with
low financial risk, the usage of 3D printing technologies as process development tool is
proposed in this study. In general, 3D printing technologies allow for the layer-by-layer
manufacturing of 3D objects. The advantage of those technologies is the relatively cheap
and fast realization of complex geometries. Thus, they represent a promising and versatile
tool for process development, since they enable a rapid manufacturing and implementation
of tailored equipment. In this project, 3D printing was used to manufacture tailored devices
complementing standard laboratory equipment for the realization of a cheap and flexible
microfluidic experimental set up. The following tailored equipment was designed and 3D
printed for the realization of the experimental set up:
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• replication master for microfluidic device manufacturing
• camera mount, using the existing camera shaft, allowing for implementation of a
small high performance camera
• manual tailor-made fractionator with optimal installation space enabling the integra-
tion on the microscope table
• frame for the microfluidic device: the frame consists of three parts, the bottom plate,
an outlet- and inlet bridge. The in- and outlet tubing were connected with the
microfluidic device and stabilized via the bridges using fittings.
Implementing these tailored equipment parts, analysis of cell partitioning in ATPS in a
microfluidic flow-through set up was possible. Cell suspension, top and bottom phase are
pumped individually into the microfluidic device using three pumps. The cell suspension
is focused at the interphase of the top and bottom phase allowing for cell partitioning.
Simultaneously, a video of the microfluidic channel near the outlet is recorded. Using
the developed snap shot analytic of the video material, an automatic estimation of cells
in top and bottom phase is performed. Additionally, live cell rate was determined via
flow cytometry by analyzing pooled samples. In order to provide a systematic process
development and performance evaluation, the technology transfer case study was performed
using the DMAIC (Define, Measure, Analyse, Improve and Control) framework. Using
this DMAIC framework a successful implementation of the developed microfluidic process
set up was performed. Additionally, two main factors influencing cell partitioning in the
flow-through mode were identified, namely, cell load and fluid velocity.
Process development of different cell formulation unit operations is the focus of the second
part of this thesis. Depending on the manufacturing strategy of cell-based therapeutics,
long-time storage of the cell product needs to be performed. Usually, the unit operation
cryopreservation is performed for this purpose, since it allows for stocking of living material
while maintaining critical cell characteristics (no genetic or metabolic alterations). While
cell cryopreservation is a well described topic in literature, cell cryopreservation process
development of cell-based therapeutics is currently rather time consuming and follows an
empirical approach. Aiming for a streamlined and more systematic cell cryopreservation
process development, a video-based tool for the characterization of the freezing and thawing
behavior was developed in the first formulation project. Freezing and thawing profiles are
critical process parameter influenced by many factors including e.g. cryomedia formulation
and scale up (working volume and container geometry). In order to enable rapid process
development for cryopreservation despite the high number of process variable, fast and
directed analytical tools are required. To evaluate the performance and flexibility of the
video-based tool, a cryopreservation case study was performed with the β-model cell line
INS-1E. Here, the freezing and thawing behavior of two working volumes (1 mL and 2 mL)
were analyzed. Additionally, cell recovery and proliferation were evaluated. As expected, a
delay in freezing and thawing behavior due to scale up was detected, resulting in a decrease
of process performance determined by live cell recovery. While a high live cell recovery
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(0.94 (±0.14) %) was achieved with 1 mL working volume, a decrease to 0.61 (±0.05) %
could be observed for the 2 mL working volume. These findings are in good agreement
with expectations, confirming the tool performance.
The objective of the consecutive second cryopreservation project is the development of a
tool box allowing for the prediction of cryomedia process performance by characterization
of media properties, freeze/thaw behavior (using the previously developed video-based
tool) and media toxicity. Using good manufacturing practice (GMP) compliant cryomedia
is an essential requirement for the cryopreservation of cell-based therapeutics, meaning it
needs to be chemically defined without the addition of animal-derived or toxic compounds.
For this reason, using the well described and often used cryoprotectants dimethyl sulfoxide
(DMSO) and fetal bovine serum (FBS) is not an option. Supplementing a cryomedia with
cryoprotectant agents is, however, crucial for cryopreservation process performance since
they protect cells from severe stress, e.g. non-physiological osmotic pressure conditions,
during freezing and thawing. Hence, development of an effective and GMP compliant
cryomedia formulation is necessary for cell-based therapeutics when long-term storage is
part of the manufacturing strategy. In this project, the usage of the developed predictive
tool box for cryomedia formulation screening is proposed. The project comprised a case
study evaluating the developed predictive cryomedia screening tool box including two
commercial, DMSO-free cryomedia, one negative (without any cryoprotectant) and one
positive (supplemented with DMSO and FBS as cryoprotectants) cryomedia example. The
case study was performed with the β-model cell line INS-1E. Additionally, a conventional
cryomedia performance assessment was done in order to evaluate the predictive tool box.
Using the tool box the commercial Biofreeze® media was classified as unsuitable for the
β-model cell line INS-1E due to media toxicity, while the second commercial cryomedia
CryoSOfreeTM was classified as possible candidate. These findings were confirmed by the
conventional screening proving the power and usefulness of the tool box. Thus, implement-
ing the predictive tool box will facilitates a fast pre-selection of possible candidates with
low sample volume and cell number, shortening the overall process development time for
the development of cryomedia formulations.
The focus of the third cell formulation project within this thesis is bioprinting. More
precisely the development of an analytical strategy for cell-based bioprinting applications.
Bioprinting is a relatively new field, however, it is believed to have a huge impact on
regenerative medicine and tissue engineering, since it enables the manufacturing of artificial
3D tissue. Great efforts are being made in this field to move from academic research
towards pharmaceutical industry or clinical applications. A critical hurdle to overcome this
transition process is the development of a robust and well-known process, while maintaining
critical cell characteristics (CCC). In order to gain process knowledge, a systematic and
more directed process development approach for 3D bioprinting applications is required
which includes the monitoring of CCC. Depending on the application, the critical cell
characteristics may vary. However, universal CCCs are cell viability and proliferation.
Flow cytometry represents a highly flexible, powerful and often used cell analysis method
capable of analyzing multiplex CCC issues in parallel and might also be useful in the
field of 3D bioprinting. However, flow cytometry analysis can only be performed with cell
suspensions and needs, therefore, a destruction of the cell-laden 3D-structure prior analysis.
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Hence, the objective of this project is the development of a flow cytometry-based analytical
strategy as a tool for 3D bioprinting research. The development of this anayltical strategy
was conducted using a model process with the β-model cell line INS-1E, a commercially
available alginate-based bioink and a direct dispensing system as 3D bioprinting method.
The destructive strategy enables the evaluation of cell viability and proliferation. By using
a flow cytometer set up including an autosampler, the strategy enables an automated
high-throughput screening. Following the development of the strategy, an evaluation of
the process steps was performed including: suspension of cells in bioink, 3D printing
and cross-linking of the alginate scaffold after printing. The evaluation showed that each
individual process step (using the selected process parameters) had a negative influence on
cell viability and must therefore be carefully monitored. This highlights the importance
of process optimization in 3D bioprinting and the usefulness of the flow cytometry-based
analytical strategy. The presented strategy has a great potential as a cell characterization
tool for 3D bioprinting and can even be extended to a multiplex CCC analysis. Thus, the
developed tool may contribute to a more directed process development in the field of 3D
bioprinting.
In summary, several process development tools and strategies for different process units
were developed within this doctoral thesis, demonstrating the applicability of general
bioprocess development tools for cell-based products. The presented methods facilitating a
more directed and systematic process development approach for cell-based therapeutics.
These powerful tools represent an opportunity to streamline process development time,
tackle translational hurdles and, ultimately, improve process understanding aiming for a
QbD approach in the cell therapy industry.
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CHAPTER 2
Zusammenfassung - German Abstract
Die Aussicht geschädigtes oder krankes Gewebe durch zellbasierte Therapeutika zu er-
setzen, hat in den letzten Jahrzehnten viel Aufsehen erregt. Der Grund hierfür ist, dass
zellbasierte Therapeutika neue Möglichkeiten in der Patientenbehandlung in Richtung der
regenerativen Medizin eröffnen. Die erste Generation zellbasierter Therapeutika konnte
den Markterwartungen jedoch nicht gerecht werden und wurde teilweise aufgund der
geringen Kostenrückerstattung wieder vom Markt genommen. Während diese Produkte
als Marktversagen betrachtet werden könnten, stellt die Identifizierung der Hindernisse,
mit denen die frühen zellbasierten Produkte konfrontiert waren, eine große Chance dar,
die Marktleistung zukünftiger Produkte zu verbessern. Im Allgemeinen stellt die inhärente
Komplexität zellbasierter Produkte in Kombination mit begrenzter Erfahrung ein großes
Hindernis dar, einen möglichen Kandidaten aus der Froschung in eine klinische Applika-
tion zu überführen. Ein tieferer Einblick wurde durch die retrospektive Bewertung der
translatorischen Herausforderungen gewonnen, wobei diese in drei Kategorien eingeteilt
werden können: (1) Herausforderungen vor dem Markt, (2) Herausforderungen während
der Herstellung und (3) Herausforderungen nach dem Markt.
Ein grundlegender Schritt in Richtung Kommerzialisierung von Produkten ist die Prozessen-
twicklung (industrieller Maßstab und Qualität), welche eine Auswirkung auf alle drei
Kategorien hat. Daher ist es wichtig Herausforderungen, die mit der Prozessentwicklung
assoziiert sind, zu betrachten. Derzeit wird häufig ein heuristischer Ansatz für die Prozessen-
twicklung von zellbasierten Therapeutika angewandt. Ein gezielter und systematischer
Ansatz wäre jedoch sehr vorteilhaft für die Bewältigung der Herausforderungen, die mit der
Prozessentwicklung assoziiert sind. Mit Hilfe solch eines Ansatzes könnte Prozesswissen
generiert und die Prozessleistung verbessert werden, was auch eine Marktleistungssteigerung
zur Folge hätte.
Eine effektive Prozessentwicklung für zellbasierte Therapeutika ist daher für die Produk-
tkommerzialisierung äußerst wichtig und könnte durch die Implementierung allgemeiner
Werkzeuge und Strategien der Bioprozessentwicklung erzielt werden. Aus diesem Grund
befasst sich diese Arbeit mit der Frage, ob Bioprozessentwicklungs-Werkzeuge und Strate-
gien aus der Pharmazeutischen Industrie auch für zellbasierte Produkte angewandt werden
können. Während sich die Anforderungen an die Prozessentwicklung zwischen den einzelnen
Grundoperationen und Entwicklungsstufen unterscheiden, stellt der Zeitdruck und das
limitierte Probenmaterial eine generelle Hürde dar. Daher folgen die meisten der eingeset-
zten Werkzeuge den Prinzipien der Miniaturisierung, Parallelisierung und Automatisierung.
Zur Demonstration der Leistungsfähigkeit und Vielseitigkeit von Bioprozessentwicklungs-
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Werkzeugen ist das Ziel dieser Arbeit die Entwicklung und Implementierung solcher
Werkzeuge für verschiedene Grundoperationen des Herstellungsprozesses von zellbasierten
Therapeutica.
Der erste Teil der Arbeit konzentriert sich auf die Grundoperation der Zelltrennung,
konkreter, die Verwendung der Zellverteilung in wässrigen Zwei-Phasen-Systemen (engl.
aqueous two-phase systems = ATPS) als Zelltrennungs-Methode. Hierbei wird mit Hilfe
einer Hochdurchsatz Screening Plattform (engl. high-throughput screening = HTS) der
Einfluss der kritischen Parameter Polymermolekulargewicht und Konodenlänge auf die
Zellverteilung von fünf Modellzelllinien untersucht, gefolgt von einem Technologietrans-
ferprojekt. Hierbei werden die Batch-Daten (Zellverteilung in ATPS) in einen mikroflu-
idischen Durchflussmodus überführt. Das Hauptziel dieses Projektes ist die Evaluierung
des 3D-Drucks als Prozessentwicklungswerkzeug, da er eine schnelle und kostengünstige
Realisierung von maßgeschneidertem Prozessanlagenequipment ermöglicht. Wohingegen
sich der zweite Teil der Arbeit auf Grundoperationen der Zellformulierung konzentriert,
im Speziellen auf die Zellkryokonservierung und den Bio-3D-Druck. Ein wichtiges Thema
der klinischen Zellkryokonservierung ist die Kryomedienformulierung, da sie toxin- und
xenogenfrei sein muss. Dementsprechend ist der Schwerpunkt des zweiten Teils dieser Arbeit
die Entwicklung einer Toolbox zur Vorhersage der Kryomedien-Leistung zur Verkürzung der
Entwicklungszeit. Zusätzlich wird eine analytische Strategie entwickelt, die eine Bewertung
der Prozessparameter des Bio-3D-Drucks hinsichtlich kritischer Zellparameter ermöglicht.
Die Evaluierung der Zellverteilung in ATPS als Trennmethode für die Zellaufarbeitung im
industriellen Maßstab ist das erste zentrale Thema dieser Arbeit. Zellverteilung in ATPS
stellt eine vielversprechende alternative Zelltrennungsmethode dar, da sie skalierbar ist
und eine Marker-freie Trennung ermöglicht. Daher könnte diese alternative Trennmethode
helfen den Engpass zu beseitigen, der durch die begrenzte Verfügbarkeit von Methoden im
industriellen Maßstab bedingt ist. Bisher ist die Verwendung der Zellverteilung in ATPS
als Trennmethode aufgrund ihrer komplexen Natur und der nicht vollständig beschriebenen
Verteilungstheorie eingeschränkt. Daher ist ein zeitintensives und empirisches Screening
für jedes einzelne Zelltrennungsproblem notwendig, um optimale Prozessparameter zu
finden. Zuerst wird eine zuvor entwickelte HTS-Plattform (Batch-Modus) eingesetzt, um
den Einfluss von kritischen ATPS-Parameter auf das Zellverteilungsverhalten von fünf
Modellzelllinien systematisch und automatisiert zu untersuchen. Die zuvor entwickelte
HTS-Plattform wurde um eine Zell-Barcodierungsstrategie erweitert, welche eine multiplexe
Hochdurchsatz-Zellanalyse ermöglicht, um die Analysestrategie zu beschleunigen. Danach
wurde in einer Fallstudie der Einfluss des Molekulargewichts und der Konoden-Länge auf
die Auflösung der fünf Modellzelllinien in PEG-Dextran-ATPS untersucht. Beide Faktoren
haben einen Einfluss auf das Zellverteilungsverhalten. Die höchste Auflösung der fünf
Modellzelllinien konnte mit niedermolekularem PEG in Kombination mit hochmolekularem
Dextran erzielt werden. Zusätzlich wurde ein Gegenstromverteilungs-Modell eingesetzt,
um die theoretische Reinheit und Ausbeute für das beschriebene Trennproblem zu berech-
nen. Die Trennung von vier der fünf Modellzelllinien ist theoretisch mit hoher Reinheit
(> 99,9 %) und Ausbeute, unter der Anwendung der Screening Bedingungen auf das
Gegenstromverteilungs-Modell, möglich.
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Im Folgeprojekt wird ein Technologietransfer von Batch-HTS-Zellverteilungsdaten in
einen mikrofluidischen Durchflussmodus beschrieben. Ein solcher Technologietransfer
ist in der Regel mit hohen Investitionskosten verbunden. Mit dem Ziel einer flexiblen
Prozessentwicklung mit geringem finanziellen Risiko wird in dieser Studie der Einsatz von
3D-Drucktechnologien als Werkzeug für die Prozessentwicklung vorgeschlagen. Generell
ermöglichen 3D-Drucktechnologien die schichtweise Herstellung von 3D-Objekten. Der
Vorteil dieser Technologien ist die relativ kostengünstige und schnelle Realisierung kom-
plexer Geometrien. Damit stellen sie ein vielversprechendes und vielseitiges Werkzeug für
die Prozessentwicklung dar und ermöglichen eine schnelle Herstellung und Implementierung
von maßgeschneidertem Equipment. In diesem Projekt wurde der 3D-Druck zur Herstellung
von maßgeschneiderten Teile zur Ergänzung von Standardlaborgeräten eingesetzt, um einen
kostengünstigen und flexiblen mikrofluidischen Versuchsaufbau zu realisieren. Folgendes
maßgeschneiderte Equipment wurde für die Realisierung des Versuchsaufbaus entworfen
und 3D-gedruckt:
• Replikationsmaster zur Herstellung von Mikrofluidiksystemen
• Kamera-Halterung zur Implementierung einer kleinen Hochleistungskamera über den
bereits vorhandenen Kameraschacht
• manueller, maßgeschneiderter Fraktionierer mit optimiertem Bauraum, wodurch die
Integration auf dem Mikroskoptisch möglich ist
• Halterung für das Mikrofluidiksystem: die Halterung besteht aus drei Teilen, der Bo-
denplatte, sowie aus einem Einlauf- und Auslauf-Steg. Die Ein- und Auslaufschläuche
werden mit dem Mikrofluidiksystem verbunden und über den Steg mit Hilfe von
Fittings stabilisiert.
Die Implementierung dieser maßgeschneiderten Equipmentteile ermöglicht die Analyse der
Zellverteilung in ATPS im mikrofluidischen Durchflussmodus. Die Zellsuspension, die Ober-
und Unterphase werden individuell mit Hilfe von drei Pumpen in das Mikrofluidiksystem
gepumpt. Die Fluidgeschwindigkeiten müssen so eingestellt werden, dass die Zellsuspension
an der Interphase der Ober- und Unterphase fokussiert wird, um eine Zellverteilung zu
ermöglichen. Gleichzeitig wird ein Video des mikrofluidischen Kanals in der Nähe des Aus-
lasses aufgenommen. Das aufgenommene Videomaterial wird dann mittles der entwickelten
Schnappschussanalytik (engl. snap shot analytic) automatisch ausgewertet. Hierbei erfolgt
die automatische Bestimmung der Zellzahl in jeweils der Ober- und Unterphase. Zusätzlich
werden gepoolte Proben mittels Durchflusszytometrie analysiert, um die Lebendzellzahl zu
bestimmen. Die Technologietransfer-Fallstudie wurde mit Hilfe des DMAIC-Frameworks
(engl. Define, Measure, Analyse, Improve and Control) durchgeführt, um eine systematische
Prozessentwicklung und Leistungsbewertung zu gewährleisten. Unter Verwendung dieses
DMAIC-Frameworks wurde eine erfolgreiche Implementierung des entwickelten mikroflu-
idischen Prozesses durchgeführt. Zusätzlich wurden zwei Hauptfaktoren identifiziert, die
einen Einfluss auf die Zellverteilung im Durchflussmodus haben: die Beladung an Zellen
am Eingang und die Fluidgeschwindigkeit.
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Die Prozessentwicklung verschiedener Zellformulierungs-Grundoperationen steht im Mit-
telpunkt des zweiten Teils dieser Arbeit. Je nach der Herstellungsstrategie von zellbasierten
Therapeutika muss eventuell eine Langzeitlagerung des Zellproduktes erfolgen. Hierfür
erfolgt in der Regel eine Kryokonservierung des Produktes, da diese die Lagerung von leben-
dem Material ermöglicht ohne das kritische Zellcharakteristika verändert werden (keine
genetischen oder metabolischen Veränderungen). Während die Zellkryokonservierung ein
ausführlich diskutiertes Thema in der Literatur ist, erfolgt die Prozessentwicklung von
Zellkryokonservierungsprozessen für zellbasierte Therapeutika derzeit meist empirisch
und ist demnach eher zeitaufwändig. Mit dem Ziel eines rationalisierten und system-
atischeren Prozessentwicklungsansatzes für die Zellkryokonservierung wurde im ersten
Formulierungsprojekt ein videobasiertes Werkzeug zur Charakterisierung des Einfrier- und
Auftauverhaltens entwickelt. Einfrier- und Auftauprofile sind kritische Prozessparameter,
die von vielen Faktoren wie z.B. der Kryomedia-Formulierung und dem Scale-up (Ar-
beitsvolumen und Behältergeometrie) beeinflusst werden. Eine generelle Voraussetzung für
die Prozessentwicklung ist eine schnelle Umsetzung, trotz der Vielzahl an Prozessparameter.
Somit werden schnelle und gerichtete Analysewerkzeuge benötigt. Um die Leistungsfähigkeit
und Flexibilität des videobasierten Tools zu bewerten, wurde eine Kryokonservierungs-
Fallstudie mit der β-Modellzelllinie INS-1E durchgeführt. Hierfür wurde das Einfrier- und
Auftauverhalten von zwei Arbeitsvolumina (1 mL und 2 mL) analysiert. Zusätzlich wurde
die Zellregeneration und -proliferation evaluiert. Wie erwartet, wurde eine Verzögerung im
Einfrier- und Auftauverhalten aufgrund vom Scale-up detektiert, was eine Verringerung der
Prozessleistung zur Folge hatte, welche anhand der Ausbeute an lebenden Zellen bestimmt
wurde. Während beim 1 mL Arbeitsvolumen eine hohe Ausbeute an lebenden Zellen (0,94
(±0,14) %) erzielt wurde, sank diese beim 2 mL Arbeitsvolumen auf 0,61 (±0,05) %. Diese
Ergebnisse stimmen mit den Erwartungen überein und bestätigen die Leistungsfähigkeit
des Werkzeugs.
Ziel des zweiten Kryokonservierungsprojektes ist die Entwicklung einer Toolbox zur Vorher-
sage der Kryomedia-Prozessleistung durch die Charakterisierung von Medieneigenschaften,
Einfrier-/Auftauverhalten (unter Verwendung des zuvor entwickelten videobasierten Tools)
und der Medientoxizität. Der Einsatz von good manufacturing practice (GMP)-konformen
Kryomedien ist eine wesentliche Voraussetzung für die Kryokonservierung von zellbasierten
Therapeutika, d.h. sie müssen chemisch definiert sein und dürfen keine tierischen oder toxis-
chen Substanzen beinhalten. Aus diesem Grund ist die Verwendung der häufig eingesetzten
und gut beschriebenen Kryoprotektiva Dimethylsulfoxid (DMSO) und fetales Rinderserum
(FBS) nicht möglich. Die Ergänzung des Kryomediums um ein Kryoprotektivum ist jedoch
entscheidend für die Leistungsfähigkeit des Kryokonservierungsprozesses, da dieses die
Zellen vor erheblichem Stress während dem Einfrieren und Auftauen schützt, z.B. vor
nicht-physiologischem osmotischen Druck. Daher ist die Entwicklung einer effektiven und
GMP-konformen Kryomedia-Formulierung für zellbasierte Therapeutika notwendig, wenn
eine Langzeitlagerung für den Herstellungsprozess notwendig ist. In diesem Projekt wird
für das Screening von Kryomedia-Formulierungen die Nutzung der entwickelten prädiktiven
Toolbox vorgeschlagen. Das Projekt umfasste eine Fallstudie zur Evaluierung der entwick-
elten prädiktiven Kryomedia-Screening-Toolbox mit zwei kommerziellen, DMSO-freien
X
Kryomedien, einer negativen (ohne Kryoprotektivum) und einer positiven (ergänzt durch
DMSO und FBS als Kryoprotektivum) Kryomedia-Kontrolle. Die Fallstudie wurde mit
der β-Modellzelllinie INS-1E durchgeführt. Zusätzlich wurde eine konventionelle Leis-
tungsbewertung der Kryomedien durchgeführt, um die prädiktive Toolbox zu evaluieren.
Mit Hilfe der Toolbox wurde das kommerzielle Biofreeze®-Medium aufgrund der Medien-
toxizität als ungeeignet für die β-Modellzelllinie INS-1E eingestuft, während das zweite
kommerzielle Cryomedia CryoSOfreeTM als möglicher Kandidat eingestuft wurde. Diese
Ergebnisse wurden durch das konventionelle Screening bestätigt, was die Leistungsfähigkeit
und Nützlichkeit der Toolbox belegt. Die Implementierung der prädiktiven Toolbox er-
möglicht somit eine schnelle Vorauswahl möglicher Kryomedium-Kandidaten mit geringem
Probenvolumen und Zellzahl und verkürzt somit die gesamte Prozessentwicklungszeit für
die Entwicklung von Cryomedia-Formulierungen.
Der Fokus des dritten Zellformulierungsprojektes innerhalb dieser Arbeit liegt im Bereich
des Bio-3D-Druck. Genauer gesagt auf der Entwicklung einer analytischen Strategie für zell-
basierte Bio-3D-Druck-Anwendungen. Bio-3D-Druck ist ein relativ neuer Forschungsbereich,
der jedoch voraussichtlich einen großen Einfluss auf die regenerative Medizin und das Tissue
Engineering haben wird, da diese Technologie die Herstellung von künstlichem 3D-Gewebe
ermöglicht. Innerhalb dieses Forschungsbereiches werden große Anstrengungen unternom-
men, um von der akademischen Forschung in Richtung der pharmazeutischen Industrie
oder zu klinischen Anwendungen überzugehen. Eine entscheidende Hürde zur Überwin-
dung dieses Übergangsprozesses ist die Entwicklung eines robusten und gut beschriebenen
Prozesses, während gleichzeitig kritische Zellcharakteristika (engl. critical cell characteristics
= CCC) nicht beeinträchtigt werden. Um Prozesswissen zu gewinnen ist ein systematischer
und zielgerichteter Prozessentwicklungsansatz für Bio-3D-Druck-Anwendungen erforderlich,
der auch die Überwachung von CCC beinhaltet. Je nach Anwendung können die kritischen
Zelleigenschaften variieren. Universelle CCCs sind jedoch Zellviabilität und Proliferation.
Die Durchflusszytometrie stellt eine hochflexible, leistungsfähige und häufig verwendete Zel-
lanalysemethode dar, die in der Lage ist, Multiplex-CCC-Probleme parallel zu analysieren
und eventuell auch im Bereich des Bio-3D-Drucks nützlich sein könnte. Allerdings kann
die Durchflusszytometrie nur mit Zellsuspensionen durchgeführt werden und erfordert
daher vorab eine Zerstörung der zellbeladenen 3D-Struktur. Ziel dieses Projektes ist daher
die Entwicklung einer Durchflusszytometrie-basierten Analysestrategie als Werkzeug für
die Bio-3D-Druck-Forschung. Die Entwicklung dieser Analysestrategie erfolgte mittels
eines Modellverfahrens mit der β-Modellzelllinie INS-1E, einer kommerziell erhältlichen
Alginat-basierten Biotinte und einem Extrusion-basierten Bio-3D-Druck-Verfahren. Die
destruktive Strategie ermöglicht die Bewertung der Zellviabilität und Proliferation. Durch
die Verwendung eines Durchflusszytometers mit integriertem Autosampler ermöglicht die
Strategie zusätzlich ein automatisiertes Hochdurchsatz-Screening. Im Anschluss an die
Strategieentwicklung erfolgte eine Evaluierung der Prozessschritte: Mischen der Zellen
in die Biotinte, 3D-Druck und Vernetzung des Alginat-Scaffolds nach dem Druck. Die
Auswertung ergab, dass jeder einzelne Prozessschritt (unter Verwendung der ausgewählten
Prozessparameter) einen negativen Einfluss auf die Zellviabilität hat und daher sorgfältig
überwacht werden muss. Dies unterstreicht die Wichtigkeit der Prozessoptimierung im
Bereich des Bio-3D-Drucks und den Nutzen der Durchflusszytometrie-basierten Analyses-
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trategie. Die entwickelte Strategie hat großes Potenzial als Zellcharakterisierungstool für
den Bio-3D-Druck und kann zusätzlich erweitert werden, wodurch eine Multiplex-CCC-
Analyse möglich wäre. Folglich könnte das entwickelte Analysetool zu einer gezielteren
Prozessentwicklung im Bereich des Bio-3D-Drucks beitragen.
Zusammenfassend wurden im Rahmen dieser Dissertation mehrere Prozessentwicklungs-
Werkzeuge und Strategien für verschiedene Grundoperationen entwickelt, die die Anwend-
barkeit allgemeiner Bioprozessentwicklungs-Werkzeuge für zellbasierte Produkte demon-
strieren. Die vorgestellten Methoden ermöglichen eine gezieltere und systematischere
Prozessentwicklung für zellbasierte Therapeutika. Diese leistungsstarken Werkzeuge bieten
die Möglichkeit, die Prozessentwicklungszeit zu verkürzen, translatorische Hürden zu über-
winden und letztendlich das Prozessverständnis für einen QbD-Ansatz (engl. Quality by
Design = QbD) in der Zelltherapieindustrie zu verbessern.
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CHAPTER 3
Introduction
The pharmaceutical industry was historically dominated by small molecule therapeutics.
However, changes in society and scientific achievements have always triggered commercially
relevant innovations and the pharmaceutical industry is no exception. One example is
the usage of biological therapeutics (recombinant peptides and proteins), such as mono-
clonal antibodies (mAbs) or insulin, for about two decades. The invention of biological
therapeutics represents a milestone in the healthcare sector and they have already proven
their commercial success. Nowadays, they are an integral part in e.g. cancer treatment. [1,
2] Currently, the healthcare sector is undergoing another exciting revolution towards
regenerative medicine which is an umbrella term for advanced therapeutic approaches
enabling the curing or replacement of damaged or diseased tissue rather than treating the
resulting symptoms. [1–3] Different strategies like cell and gene therapy can be used for
this purpose. Especially, cell-based therapies are much discussed in literature as promising
approach in the field of regenerative medicine. [1, 2, 4, 5] Thus, cell therapies are consid-
ered to be the third pillar of therapeutics in the pharmaceutical industry, besides small
molecule therapeutics and biopharmaceuticals. [1, 2, 4, 5] An increasing scientific interest
in regenerative medicine and cell therapy was also observed and manifests in a growing
number of publications, as displayed in fig. 3.1. Shown is the general use of the buzzwords
"cell therapy" and "regenerative medicine" over time (1980 - 2017), searching the scientific
database PubMed (https://www.ncbi.nlm.nih.gov/pubmed/).
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Figure 3.1: Number of publications in the field of "cell therapy" and "regenerative medicine"
over time (1980 - 2017). Data was generated by a PubMed search (https://www.ncbi.nlm.
nih.gov/pubmed/). The buzzwords "cell therapy" and "regenerative medicine" were entered in
order to generate the above graph (accessed: April 26, 2018). The general observation is that
usage of both buzzwords have increased over time, though, the term "cell therapy" was used
more often.
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In addition, an increasing number of clinical cell therapy trials are registered, comprising
multiple applications e.g. in oncology, immunology or neurology. [6, 7]
The idea of using cells in patient treatment is quite old and was manifested in the 80s by
the introduction of blood transfusion and bone marrow transplantation. [8–10] However,
the commercialization of cell-based therapies is still in its infancy, resulting in a low number
of authority approved cell-based therapeutics and penetration of the pharmaceutical
market. [1, 11] Keeping in mind, that launching a new conventional therapeutic on the
pharmaceutical market is time consuming, the novelty and complexity of cell therapies will
naturally expand the research and development (R&D) time-line. [1, 2] In retrospective, a
variety of crucial translational challenges are identified. In literature, much attention was
paid to the fact that most of the translational work was located in academia and small
biotechnology companies. They are limited in funding and often lack of experience in e.g.
commercialization and business strategies. [1, 12–14]
Despite these challenges, some cell therapeutics are already approved by authorities like
the Food and Drug Administration (FDA) and European Medicines Agency (EMA) and,
thus, commercially available. [14, 15] However, their commercial success is still behind the
expectations. [1]
3.1 Cell Therapeutics
The cell therapy industry is a promising and fast evolving sector within the healthcare
environment. Thus, the following paragraph is briefly discussing the penetration of the
market, concerning cell-based products, until Mai 2018 within the jurisdiction of the
European Union (EU).
While the sector is still in its infancy, some cell-based therapy manufacturing companies
were able to face the translational challenges and have already launched their products on
the market. [14, 16, 17] These products are extremely diverse in their nature and can be
categorized whether by their therapeutic indication (e.g. oncology, hematology, neurology,
etc.) or cell source (autologous / allogeneic). However, the EU regulatory discriminates
between products where cells are minimally manipulated and Advanced Therapy Medicinal
Products (ATMPs). The ATMPs are further divided into somatic cell therapy, gene therapy
and tissue engineered products. One difference between minimally manipulated cell-based
products and ATMPs is that ATMPs need a market approval by the EMA before becoming
commercially available. In order to obtain such an approval the company must demonstrate
the products safety and efficacy. [16]
Up to now, ten ATMPs were approved by the EMA. They are summarized in table 3.1
comprising three gene therapies, four tissue engineered products and three somatic cell
therapies. However, four ATMPs are already withdrawn from the market, mainly because
of poor commercial success. One example, often discussed in literature, is Provenge. [14–16,
18] Provenge is the trade name for an autologues dentric cell immunotherapy developed by
Dentron for the treatment of metastatic prostate cancer. It was approved by the EMA in
2013 and withdrawn from the market only two years later in 2015 due to the manufacturer
bankruptcy. In retrospective, some major obstacles were discussed, including high product
pricing and unprofitable market access strategy. Ultimately, Provenge could not conquer
the post-market challenges resulting in market failure. [14–18]
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Nevertheless, such a failure can provide important lessons for future products to push the
cell therapy industry towards their expected market volume.
3.2 Cell Therapy - Translational Challenges
Commonly, a new scientific approach is accompanied by a hype and high expectations.
At the same time, the translation of such a new scientific finding into a commercially
successful product is often difficult and prone to failure. Lack of knowledge often prolongs
the translational time-line, and even though first generation products are launched on the
market, the commercial success can fall short of expectations. Cell-based therapeutics are
no exception and have faced major translational challenges in the past. [1, 15, 16]
Analyzing and tackling those translational challenges is essential in order to avoid them in
future. In general, they can be divided into three categories: (1) pre-market challenges, (2)
manufacturing challenges and (3) post-market challenges. [15]
The first category of pre-market challenges are closely related with proper funding. In
general, developing a new therapeutic product usually starts with the pre-market phase
which comprises basic research up to clinical trials. During this time, a vast amount of
money is spend. While the pioneers in cell therapy industry were predominantly locate in
academic and small biotechnology companies with limited access to funding, big pharma
was mostly absent. Thus, some translational projects were struggling with inadequate
funding. [1, 7, 11, 13–16, 18–21] The novelty and complexity of cell-based therapeutics,
in combination with lack of experience on both sides, regulatory agencies and developer
additionally reinforced these funding associated challenges. [12, 13, 15]
Lack of knowledge and experience in process development was identified as a major obstacle
for the second category challenges, namely, manufacturing challenges. Yet, they are closely
connected with pre-market challenges since the foundation for a successful commercial
production must be established early in the R&D phase. [16] For example, in order
to produce cell therapeutics, a technology transfer from research grade methods into a
commercial scale process, which is in good manufacturing practice (GMP) compliance,
must be performed. [15, 16] However, not every research grade method can be successfully
transferred and implemented into a manufacturing process. Important requirements for a
technology transfer are e.g scalability or the possibility for automation. [16] Automation is
important since it has an impact on process robustness and reproducibility. Additionally,
automation minimizes laboratory costs and the risk of human failure, which is crucial for a
commercial GMP production. [1, 15, 16, 22–24] Raw material supply is another important
criteria which must be considered early on. Otherwise, agents might be in conflict with
GMP production e.g. when using xenogenic agents or the cost of goods (CoGs) might be
extremely high. [12, 15, 16, 25, 26] Distribution logistics also need to be addressed early on
in R&D since living cell material is highly sensitive with relatively short product shelf-life.
Depending on the product specifications, the cells can be shipped in culture or frozen.
In both cases, the shipping methods are part of the manufacturing process and must be
validated concerning GMP compliance and risk management. [15] These considerations
are often absent within the scientific mindset and cause trouble later on, thus, scientist
must think ahead during R&D. Similar observations were made concerning the analytical
strategy. [12, 15, 16, 20, 24, 27] Effective process development within a GMP environment
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is mainly knowledge based. Meaning, a full product characterization needs to be performed
in order to provide information about identity, potency, safety, sterility and purity. This
information is summarized as critical quality attributes (CQAs), which have to be closely
monitored and confirmed during process development. Thus, CQAs must be identified and
defined early on. In combination, analytical tools, covering all these aspects, needs to be
developed in parallel with the product itself. If this groundwork is not done during R&D,
it will cause problems during the development of a commercial relevant process. [12, 15,
16, 20, 24, 27]
After market introduction, cell therapeutic products might face the third category post-
market challenges. The adaption of cell therapeutics on the market is no major concern
during development. However, it does affect the commercial success. In retrospective,
different aspects hindering the widespread adaption of cell therapeutics could be identified:
high product prices and timid acceptance by physicians. [15, 28] A hindered adaption
of cell therapeutics by physicians could be observed due to the fact that they also had
no experience with it and the administration procedure can be quite complex. [15] Thus,
poor market adaption will result in low sales numbers and will, ultimately, lead to an
insufficient reimbursement level. [4, 15, 16, 28] Such reimbursement challenges occurred in
the past and even caused bankruptcies. A prominent example, often named in literature,
is the company Dentron. Short after launching their product Provenge on the market, the
company became insolvent due to high costs and low reimbursement level. This was not
an isolated case. Up to now, in total four advanced therapeutics were withdrawn after
approval from the European market due to commercial failure. [14, 15, 17, 18]
These cases highlight the need of a sufficient commercialization strategy, including an
efficient business model from the very beginning. Thus, analyzing the challenges, faced
by the cell therapeutic industry so far, is important to avoid them in future. Discussing
those challenges in separate categories has the advantage that they can be assigned to
individual project stages. Such an approach facilitates subsequent implementation of
gained knowledge. However, it is important to note that a lot of the obstacles could be
attributed to the location of first generation projects in academia and small to medium
sized biotechnology companies. Additionally, they are often closely related. For example,
not dealing with CoGs during R&D can lead to high manufacturing costs which later on
need to be reimbursed. [15, 16, 19]
Lately, a slight increased interest of the pharmaceutical industry in cell-based therapeutics
could be noted. The involvement of the big pharma is expected to be a booster for the
cell therapy industry, since they are capable of providing sufficient funding, have a great
expertise in business strategies and commercial scale process development, as well as, in
bioprocessing techniques. Especially, the cooperation between academic researcher and the
pharmaceutical industry seems to be a promising construct. [5, 14, 15, 19] An example is the
cooperation between the University of Pennsylvania and Novartis. Their partnership was
formed in 2012 and their chimeric antigen receptor T cell (CAR-T cell) therapy Kymrhia
(formerly CTL019) was successfully approved by the FDA in 2017. [5, 14, 19] Subsequently,
Novartis has already filed a marketing authorization application (MAA) to the EMA. [29,
30] Given that the FDA approval was in 2017, the commercial success on the US market
still needs to be proven. [31]
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However, it is not only the manufacturers who are decisive for the establishment of a
successful therapy industry. Other parties like the authorities are equally important
since e.g. the regulation of cell therapy products need to be adapted to their unique
attributes. Also, harmonization of the different national authority regulations would be
highly beneficial. [12, 13, 15] Ideally, the manufacturers and authorities work collectively
towards a more systematic and directed process development approach for cell-based
therapeutics, in order to minimize the manufacturing costs and patient risk. This could
be achieved by implementing process development tools and strategies, already used by
the biopharmaceutical industry. These tools should be adapted and evolve towards the
requirements of the cell-based therapy manufacturing process.[1, 15] Thus, a comprehensive
overview of the cell therapy manufacturing strategies is necessary.
3.3 Cell Therapy Manufacturing Strategies
The manufacturing strategy for cell therapeutics is highly dependent on whether it is an
autologous or allogenic product. The main difference between these two product categories
is the origin of the therapeutic cells. An autologous product is patient specific; meaning,
the patient is likewise cell donor and recipient. In contrast to the cell origin of allogenic
products, where the cell donor is universal and patients get the same cell therapeutic
product. [1, 20, 23, 24]
In general, a manufacturing process is a sequence of unit operations. Depending on
the manufacturing strategy and product specifications, the number and sequence of unit
operations can differ. Typical manufacturing strategies for both product categories are
shown in fig. 3.2. The processing steps for an autologous cell therapeutic product (left)
and an allogenic product (right) are shown as flow charts. Both strategies are generalized.
[1, 23, 24]
For the production of autologous product, patient tissue acquisition is typically performed
de-centralized in a healthcare environment (e.g. clinic) and, subsequently, shipped to
a central manufacturing facility. Since both process steps can influence the cell quality,
both patient biopsy for cell acquisition and shipping needs to be performed by specialized
personal. After the introduction of the starting material in the manufacturing facility, cell
release from tissue matrix is performed if needed. Typically, cell therapy comprises a specific
or well defined heterogeneous cell population. Thus, cell isolation is performed to purify
the cell suspension obtained by a biopsy, followed by the cell cultivation in order to expand
the purified cell population. Depending on the product, cell manipulation might need to be
performed prior to cell harvest e.g. cell differentiation in case of stem cells. Subsequently,
cell downstream processing is done, typically comprising a reduction of volume, washing step
and the isolation of a specific cell population or well defined heterogeneous cell suspension.
Additionally, cell formulation and release testing is performed before the patient-specific
cell therapeutic product is returned to the healthcare site for administration of the product
to the patient. [1, 23, 24]
The manufacturing process for allogenic cell therapeutic products is more similar to
biopharmaceutical processes. Here, a master cell bank (MCB) and working cell bank
(WCB) is generated from the tissue of a single donor during R&D. This procedure of donor
biopsy, material shipping to R&D site, cell release for tissue and cell isolation as well as
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Figure 3.2: General manufacturing strategies for an autologous cell therapeutic product
(left) and an allogenic product (right). The typical processing steps are shown as flow charts.
Adapted form: [1, 23, 24]
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the generation of the MCB/WCB is done once during development. The generation of
MCB/WCB is a concept for long-term storage of the starting material for production
with a defined cell quality. The actual process starts with thawing cell material from the
WCB for the cell cultivation process in order to expand the cell population. If needed an
optional cell manipulation step can be introduced before harvesting the cells. Subsequently,
cell downstream processing is performed. This typically involves a reduction of volume,
washing step and isolation of a specific cell population if cell manipulation was performed.
Then cell formulation and product filling is executed. Cell cryopreservation is performed
in order to store the product. Thus, the product shipping is independent from production
and can be done when requested. The cell therapeutic administration is done by specially
trained physicians in a healthcare environment. [1]
Obviously, the two manufacturing strategies do not only differ in product processing, but
also in infrastructure requirements. For allogenic products the infrastructure is similar to
the biopharmaceutical infrastructure concerning quality assurance, storage and delivery. In
case of autologous products the quality assurance infrastructure needs to be more elaborate.
Tracking of sample probe and cell quality is extremely important since the patient cell
samples differ in quality and there is a higher risk of cross contamination. Additionally,
product identity must be assured during the whole process. Process scheduling is another
important factor for autologous products. Coordination of patient biopsy, manufacturing
and cell therapeutic administration needs to be closely coordinated involving the e.g. clinic
and manufacturing site. [1, 23, 24] Batch-size and up-scale strategies also differ between
autologous and allogenic cell therapeutic products. Again, allogenic products are similar
to biopharmaceuticals. Up scaling in order to meet the market demand is normally done
by increasing batch volume. This approach is not an option for autologous products, since
each batch represents a patient-specific dose. Thus, scaling out rather than scaling up is
performed. Scaling out is a parallelization approach, meaning multiple smaller batches are
produced at the same time. [1, 24, 27]
Besides the differences, both product manufacturing strategies must be in compliance with
current good manufacturing practice (cGMP) in order to get a market approval by the
authorities. For cell therapeutics it is especially important to avoid the usage of xenogeneic
agent in production e.g. fetal bovine serum (FBS) as media supplement or xenogeneic
monoclonal antibodies (mAbs) for separation. Such agents pose a safety issue for patients
since they can transmit diseases or cause an immune reaction. [12, 26]. Additionally,
extractables and leachables should be avoided during production. [16, 22] Automation is
another GMP relevant topic since it minimizes the process risk profile due to the avoidance
of human intervention. [1, 16, 22–24] Using closed systems for e.g. cell cultivation is
equally important concerning minimizing the risk of process contamination and product
tracking. [1, 24] An aseptic work flow is especially recommended since living cell products
cannot be sterilized. [32] A widespread tool in the biopharmaceutical production for the
unit operation cell culture is the usage of closed bioreactors. The implementation of that
knowledge would be highly beneficial for the cultivation of cell therapeutics. However,
several aspects need to be considered for the cultivation of cell therapeutic products. In
general, cell can grow in suspension, adherent as monolayers or as 3D tissue, resulting in
different cultivation strategies. The majority of cell therapeutics are suspension cell lines
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or grow adherent as monolayers, thus, 3D tissue cultivation is not discussed in this section.
The cultivation of suspension cell lines is typically performed in closed, stirred tanks.
The biopharmaceutical industry has gained a comprehensive knowledge using this type of
bioreactors including upscaling, in-line monitoring, automated control and mass transfer
which can be applied processing suspension cell therapeutics. Cultivation of adherent cell
populations require a suitable substrate for cell attachment. For this purpose, hollow fiber
and fixed or packed bed bioreactors can be used, as well as stirred tank bioreactors in
combination with microcarrier as attachment substrate. Challenging aspects of this unit
operation are the uniformly cell seeding and de-attachment of cells from substrate before
harvesting. While these process steps are routinely performed in research scale, expertise
must be gained for manufacturing scale. [1, 24, 33]
3.3.1 Cell Separation
Cell therapeutic downstream processing (DSP) is located after the cell harvest and comprises
several unit operations including volume reduction, cell washing and isolation of the target
cell population. [1, 34] Decreasing the process volume reduces processing times for the
subsequent steps and also results in an appropriate sample volume for patient administration.
The elimination of media components is achieved by washing the cells. This is especially
important if serum was supplemented to the media for cell culturing. [35] Subsequently,
cell seperation is performed in order to isolate the target cell population. This crucial unit
operation is directly linked to patient safety e.g. for stem cell applications. Here, the risk
of teratoma formation is extremely high if the cell separation does not achieve an entire
depletion of undifferentiated cells. [36]
Currently, the availability of commercial scale cell DSP methods is limited and represents a
bottleneck in cell therapy production. Yet, the cell therapy industry is mainly focusing on
upstream processing (USP) development. To close the crucial juncture between research
and commercialization, major efforts must be made in the field of cell DSP. [1, 34]
While multiple cell separation methods are available for research purpose, scalable methods
for clinical applications are still lacking. [1, 34, 37] In general, cell separation methods
are categorized into two main groups: the (1) physically-based and (2) affinity-based
methods. [38] In the first category of physically-based separation methods, cells are
separated according to their physical properties e.g. cell size and density. A common
method within this group is the density-gradient centrifugation e.g. using percoll or ficoll
as density media. [38–40] The cell separation within the second group is based on the
recognition of characteristic cell surface antigens by specific antibodies. Prominent methods
are the fluorescence activated cell sorting (FACS) which is a derivate of flow cytometry
and the magnet activated cell sorting (MACS). In general, both methods are dependent
on the existence of specific cell marker unique for the target cell population and the
availability of respective antibodies. The main difference between these two methods is
the antibody labeling determining the separation mode. For FACS the labeling is done
with fluorochromes. Cells are separated according to the fluorescence signal emitted by the
fluorochrome. In case of MACS, the antibodies are linked to magnetic particles. By using
a magnetic field, cells binding an antibody with magnetic tag can be restrained and, thus,
separated by non-binding cells. Both methods can be performed as negative or positive
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selection. Negative selection is performed in a flow through mode. Here, the target cell
population can be found in the flow through, while the contaminant cell populations are
depleted. [1, 38, 41]
Up to now, few clinical scale DSP methods are available including a MACS set up [1,
42–44] and different centrifugation-based systems [1, 34, 36, 37, 45]. One example is the
Elutra Cell Separation System (Terumo BCT). This counter-flow centrifugal elutriation
system separates cells in five fractions due to size and density. It is a closed system for
small-scale applications mainly suitable for autologous cell therapy products. [1, 42, 43,
46–48] Another centrifugation-based system for small-scale cell production is the Cell Saver
(Haemonetics Corporation) [1, 40, 44], while the kSep (Sartorius) is a larg-scale system for
allogenic cell therapy manufacturing. [1, 35, 48]
However, the integration of only one cell separation step in the manufacturing process
is likely insufficient to achieve the needed cell purity. [42, 46] The DSP approach for
biopharmaceuticals commonly includes three subsequent and orthogonal separation methods
to significantly improve product purity. [49–51] Implementation of this approach in cell
therapy DSP is restricted, since the availability of clinical scale cell separation methods
differing in separation mode is still limited. Addressing this critical shortcoming is important
and will contribute to master the obstacles faced in cell therapy process development.
Re-engineering existing cell separation methods by optimizing key process parameter could
be done, as well as developing alternative strategies. [1, 48] Though, both scenarios must
follow the general requirements: scalability, closed systems, possibility of automation,
minimal processing time and the physiological properties of cells must not be altered. Thus
label-free cell separation methods are favorable since knowledge about the relationship
between cell surface marker and their cellular function is often missing. Additionally, the
use of antibodies in DSP can pose a safety issue. [1, 39, 41, 52]
Cell Partitioning in Aqueous Two-Phase Systems (ATPS)
Cell partitioning in aqueous two-phase systems (ATPS) represents such an alternative
label-free cell separation method. [53, 54] The phenomenon of phase separation in an
aqueous system was first described by Beijerinck in 1896. [55] He recognized that by
mixing of two aqueous polymer solutions above a certain concentration, formation of
a biphasic system will occur. The usage of ATPS for partitioning of bio-material, e.g.
proteins or cells, was made decades later by Albertsson. [53] Major advantages of using this
partitioning phenomenon as alternative separation method are the scale up possibility and
that ATPS provide relative mild process conditions. However, the widespread adaption is
limited since the partitioning of bio-material in ATPS is quite complex and not yet fully
described. Extensive empirical screening for adequate separation conditions is necessary
and need to be adapted for each separation issue individually. [41, 56, 57] Nowadays,
time-consuming work can be compensated by using modern automated high-throughput
screening (HTS) platforms to expand the commercial use of ATPS-based bio-material
separation techniques. [58–60]
Fundamental as well as application-oriented work was done on protein and cell partitioning
in ATPS from the 50s to the 80s by Albertsson and Walter, among others. [53, 54] Up to
now, the theory is not fully understood since bio-material partitioning in ATPS is quite
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complex. However, Albertsson assumed that the bio-material partitioning in ATPS is
driven by physiochemical characteristics including size, hydrophobicity, electrochemical and
bio-specific affinity. ATPS properties need to be adapted and optimized for each separation
application individually. [53] While the ATPS characteristics are unique for each separation
problem, some general requirements must be met in case of cell applications. Water
content and osmotic pressure of both phases are important to maintain cell viability and
physiological functions, while surface tension is associated with unspecific cell adsorption
at the interphase. Thus, ATPS with low surface tension are favorable to facilitate high
cell recovery. [53, 54, 61] Buffered polymer-polymer systems are most commonly used for
cell applications. Especially, the usage of Dextran-polyethylene glycol (PEG) systems
supplemented with salt additives (e.g. sodium chloride, sodium phosphate) to adjust
osmotic pressure is extensively described in literature. [56, 62, 63]
Depending on process requirements regarding purity and recovery of the target cell popula-
tion, a multi-stage rather than a single-stage setup needs to be performed. Countercurrent
distribution (CCD) is a promising multi-stage liquid-liquid extraction method for cell
applications and was first described by Craig and Post. [64] Using a CCD apparatus, the
bottom phase is retained while the top phase is transferred. In each extraction stage, cell
partitioning is achieved by mixing the ATPS with subsequent phase separation by gravity.
Depending on the partitioning behavior of the target cell population, the interphase is
retained or transferred. In the case of a predominantly partitioning of the target cell
population between the top and interphase, the interphase is retained. While the inter-
phase is transferred if the target cell population can mainly be found in the bottom and
interphase. [65] Phase settling by gravity is the main advantage of this method since it
allows a cell partitioning according to the physiochemical properties. In contrast, using
centrifuge-based methods density-based partitioning will predominantly occur. Addition-
ally, CCD facilitates low pressures and shear forces resulting in relatively low process
related decrease in cell viability loss. [54, 63, 66]
3.3.2 Formulation
The formulation of cells is another unit operation which is rarely discussed within the cell
therapy community. [67] It is located between cell DSP and fill/finish with the main purpose
to stabilize the cell-based product and to provide physiological conditions e.g. osmotic
pressure. The list of commonly used excipients includes buffers, salts, polymers, proteins
and preservatives. [1, 67–69] Ideally, product formulation is suitable for storage and shipping,
as well as for patient administration since it streamlines the administration procedure
done by physicians. Using products without the need of an additional washing step right
before administration is favorable since it minimizes the risk of product contamination.
Additionally, there is no need for specialized clinic personal to perform this task which
might lead to a higher adaption of cell therapy products by physicians. [67]
Considering the cell type, type of cell therapy product (autologous / allogeneic), patient
administration strategy (injection, sheet of cells, intravenously or more complex ways)
and storage conditions is important to meet manufacturing and end product requirements.
Thus, an integrated product and process development (IPPD) approach is necessary for
the development of a cell therapy formulation. [67] This applies in particular if long-time
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storage of the cell-based product is required which can only be achieved by performing
a cryopreservation. [1, 68–70] Here, the addition of cryoprotectant agents is necessary in
order to achieve high post-thaw cell survival. However, the type and concentration of
cryoprotectant agent do have an effect on optimal freezing and thawing parameter. [71]
Another aspect which should be considered is the compatibility of cryoprotectant agents and
packaging material e.g. when using dimethyl sulfoxide (DMSO) as cryoprotectant agent.
DMSO is a widely used cryoprotectant agent. [1, 68, 71] However, DMSO can interact with
polymeric packaging materials highlighting the need of an IPPD approach. [68]
Cryopreservation
Maintaining critical cell characteristics during long-term storage of cells is a challenging
issue within the allogenic cell therapy manufacturing process. Here, bulk production is
performed rather than on-demand production, resulting in the need of a cell storage strategy
for the starting material as well as the final product. [1] Commonly, cryopreservation is
performed when long-term storage of cells is needed to facilitate continuous access to cell
material with unchanged characteristics [1, 72, 73] e.g for cell culture maintenance [72],
biopharmaceutical production [74, 75] or reproduction medicine [71, 76]. In the production
of allogenic cell therapy products cryopreservation is performed twice. Establishing a
MCB/WCB with the production cell material involves cryopreservation. Additionally,
cryopreservation of the end product is performed in order to prolong the product shelf-life.
Effective cell cryopreservation usually comprises slow freezing, storage at ultra-low temper-
atures and fast thawing of cells. [1, 72, 74, 75, 77, 78] The advantage of this approach is the
complete shut down of cell metabolism at ultra low temperatures, hindering any changes
in cell characteristics e.g. genetic or metabolic. However, freezing and thawing induces
severe cell stress. During sample phase transition osmotic effects as well as intra- and
extracellular ice formation can occur, leading to cell membrane damages or cell death. [72,
79] In order to ensure high post-thaw cell survival, the cryopreservation process must be
optimized with regards to minimize severe cell stress.
Critical cryopreservation process parameter are well described in literature and include
cell loading [80], cell suspension condition (e.g. suspension, monolayer or colony) [71, 78,
81], process volume [73, 75, 77, 82, 83], freezing/thawing profile [73, 74, 77, 84–86] and
cryomedia formulation (e.g. typ of cryoprotectant agents and concentration) [71, 87]. Thus,
systematic screening of process parameter is necessary in order to optimize a cryopreserva-
tion process. Moreover, the critical process parameter can influence each other. [71, 72,
74, 75, 78] In addition, a systematic process development approach is highly beneficial for
clinical applications like cell therapy products, since they must be manufactured in a GMP
environment. [1] In order to meet the GMP requirements, a storage infrastructure must
be available. This includes freezing of cells in a controlled manner, subsequent storage in
a highly monitored environment and additional monitoring of critical cell characteristics
during the whole process. [1, 72–75, 77, 78, 81, 84, 88, 89]
The cryomedia formulation represents a bottleneck for clinical applications since chemically
defined formulations without animal-derived or toxic components should be used. Thus,
commonly used cryoprotectant agents like DMSO and FBS should be excluded. [1, 90–93]
In general, cryoprotectant agents can be categorized in to groups: (1) extracellular and
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(2) intracellular cryoprotectant agents. [91, 93–98] Sugars and high molecular polymers
e.g. PEG are extracellular cryoprotectant agents since they are not able to penetrate the
cell membrane. Intracellular cryoprotectant agents like DMSO, glycerol or 1,2-propanediol
facilitate this ability. [91, 93, 98] Effective DMSO- and FBS-free cryomedia formulations
have already been described in literature. [99–102] However, optimal cryopreservation
conditions differ between cell lines and need to be optimized individually. [75, 86, 95] For
this purpose, type and concentration of cryoprotectant agents need to be screened within a
systematic IPPD approach. Using this approach would be highly beneficial since critical
process parameter can influence each other. [71, 72, 74, 75, 78] For example, the type and
concentration of cryoprotectant agents influences the optimal freezing/thawing profiles. [71]
Additionally, they might have an influence on media viscosity, causing complications in
subsequent process steps. For example, fill/finish and administration of the product to
the patient will be affected if high molecular polymers are used in a concentration which
causes an increase in media viscosity.
Bioprinting
Fueled by further developments of three dimensional (3D) printing technologies towards
biological applications, bioprinting is considered to be a key technology in the field of tissue
engineering and regenerative medicine. The possibility to deposit biological material in a
layer-by-layer manner allows for the production of biological 3D structures and nourishes the
idea of producing artificial human tissue, which is of great interest to the pharmaindustry
and the regenerative medicine sector. [103–105] Potential applications of such artificial
tissue are very diverse and include the usage of them as tool for pre-clinical pharmacology
and toxicological screenings, as customized patient-specific disease models, as therapeutic
graft for tissue repair/replacement or as advanced cell-containing drug delivery systems. [1,
16, 106–108]
Traditionally, design of a desired 3D object is done using a computer-aided design (CAD)
approach. Additionally, medical imaging technologies like computed tomography (CT)
and magnetic resonance imaging (MRI) enable the creation of patient-specific designs in
the field of regenerative medicine. [109, 110] Incorporating living material into such a 3D
object represents a sophisticated and highly complex task due to the fragile nature of cells.
Addressing these new challenges requires comprehensive knowledge in cell biology, material
sciences and engineering. Multiple aspects including e.g. choice of material and 3D printing
technology need to be considered, in order to print a "functional" artificial tissue. [106]
A cornerstone in the field of bioprinting is the availability of 3D printing technologies suitable
for biological applications. Currently, several 3D printing technologies are applied in the
field of bioprinting including robotic dispensing, inkjet printing, and stereolithography. [106,
109, 111] While these technologies differ in their modality, they share the frequent use of
hydrogels as bioinks. Hydrogels have traditionally been used in the field of tissue engineer
since they provide a cell-friendly environment if proper formulated. However, the hydrogel
printability needs to be considered when used as bioink for bioprinting applications as
well as compatibility with cell material. Each 3D printing technology differs in terms
of bioink properties e.g. rheology, shape fidelity or cross-linking options. Additionally,
cell type specific requirement need to be met concerning e.g. mechanical stiffness of the
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hydrogel. [106, 109, 112, 113] Thus, a systematic process development approach considering
material, printing process and post-printing behavior would be highly beneficial as depicted
in fig. 3.3. [114–116]
PROCESS DEVELOPMENT
STARTING
MATERIAL
- cell type(s)
- bioink
PODUCTION
PROCESS 
- 3D printing technology
- sacrificial material
- cross-linking
POST-PRINTING
PROCESSING
- cultivation / proliferation
- monitoring of critical cell 
characteristics
ARTIFICIAL
TISSUE
Figure 3.3: Essential consideration in bioprinting process development for the production of
an artificial tissue.
For example, bioink compositions providing an optimal cell-friendly environment do often
not meet printability requirements. One approach overcoming this hurdle would be to
introduce hydrogel components allowing for cross-linking in combination with the use of
a sacrificial material. Here, the sacrificial material is optimized towards printability and
holds the bioink in shape during the process. During an additional step the bioink becomes
cross-linked. [109, 117, 118] Additional considerations may need to be taken into account
when bioprinting is used as a platform for commercial production e.g. CoG and material
origin of hydrogel components.
3.4 Process Development
Developing an efficient and regulatory compliant manufacturing process is crucial for the
commercial success of pharmaceutical products. Thus, a comprehensive and knowledge-
based process development approach plays an integral part translating a therapeutic agent
from bench to bedside. Currently, the cell therapy industry is lacking process development
experience which is associated with translational challenges. However, experiences can
be drawn from the protein bioprocessing field. Additionally, using general concepts and
tools will facilitate a more directed and sophisticated process development approach for
cell therapy products. [1, 69]
Cell therapeutics are inherently expensive products and represent an unique manufacturing
challenge due to the highly sensitive nature of the living material. Thus, streamlining the
production process and reducing manufacturing costs while maintaining critical quality
attributes (CQAs) of the cells is an extremely sophisticated task. [69] Using a knowledge-
based approach to link critical process parameters (CPPs) with CQAs would, therefore, be
highly beneficial. [1, 119] Such an integrative approach has already been described by the
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international council for harmonization of technical requirements for pharmaceuticals for
human use (ICH) in the guideline ICH Q8 [120] and is referred to as Quality by Design
(QbD). The QbD paradigm combines a scientific knowledge-based product and process
development approach with risk assessment, in order to investigate relationships between
CPPs and CQAs. The identification and description of these relationships allows for better
process understanding and, ultimately, process control to minimize product variations.
Thus, QbD will secure the quality, safety and efficacy of a therapeutic product in order
to minimize the patient risk. Briefly, the Quality Target Product Profile (QTPP) is the
starting point of the QbD framework. It is a summary of essential product characteristics e.g.
dosage strength or route of administration and basis for the identification of CQAs which is
done subsequently. Additionally, CPPs are analyzed and evaluated during risk assessment
in order to develop a control strategy. Thus, a robust and reproducible manufacturing
process is achieved by monitoring and controlling CPPs in combination with QCAs. [1, 7,
13, 16, 20, 21, 37, 119–122]
Describing CQAs for cell-based products, however, represents an unique cell characterization
challenge due to the complex nature of living cells. [69, 121] Therefore it is important
to address the development of a cell characterization strategy in combination with assay
optimization/adaption in early process development. [1, 26, 27] The strategy should include
simple QCAs like e.g. pH or cell density as well as more complex QCAs like e.g. cell
population purity and identity. Additionally, applicability of the developed analytical
methods during process development and process monitoring would be highly beneficial.
Following these requirements automation of the analytical methods is necessary to eliminate
human failure and reduce processing time. [119]
3.4.1 Cell Analytic
The development of an analytical strategy representing all QCAs of a cell-based product is
essential within the QbD framework. Thus, the availability of cell analytic methods as tool
for process development represents a bottleneck in the field of cell-based products. [27]
A pool of different cell analytic methods is currently available and used in e.g. research
and drug discovery screening platforms. [123–126] However, method applicability must be
validated and optimized for each application individually.
One important cell-based product QCA is cell viability or to be precise, the live cell content.
A lot of cell quantification methods are currently available allowing for live cell enumeration.
In general, they are classified in indirect and direct methods. [127]
The indirect cell quantification methods are based on the measurement of a signal having
linear dependence with the cell number. Depending on their underlying principle, they
are further sub-classified in (1) DNA-based, (2) protein-based and (3) metabolite-based
methods. The first sub-categorie methods (DNA-based) use fluorescent agents intercalat-
ing into the cellular DNA. The intercalation of such agents into the DNA results in an
emission of a fluorescence signal showing a linear dependence with the cell number. [127]
In general, these kind of methods do not allow for distinguishing between live and dead
cells. However, several commercial DNA-based cell quantification assays are commercially
available e.g. CyQuant® Direct Cell Proliferation. This assay combines a DNA-binding
fluorescent dye with a quenching agent only penetrating dead cell membranes. Suppressing
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the dead cell signal facilitates live cell quantification. [128, 129] Total protein concentration
(protein-based) can also be used for cell quantification. However, using these method does
not facilitate live cell number. [127] In contrast, metabolite-based methods exclusively
enable estimation of live cell number since dead cells lack of metabolic activity. Several
metabolic assays are commercially available, including the colorimetric assays such as e.g.
MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl- tetrazoliumbromide) and AlamarBlue
(resazurin-based) and ATP-based (adenosine triphosphate) methods. While the colorimetric
assays rely on the metabolic transformation of a substrate (e.g. AlamarBlue: resazurin
(blue) transformed into resorufin (pink)), ATP-based assays need a luminescence measure-
ment. ATP is present as energy reservoir in living cells and can be used as co-factor for the
enzyme luciferase in the presence of Mg2+. Briefly, luciferin is catalyzed by the enzyme
luciferase to oxyluciferin in the presence of Mg2+ and ATP, resulting in a luminescence
signal. The signal can be measured and correlates with the ATP content and, subsequently,
with live cell content. [123, 124, 130] Knowing the underlying mechanism is important for
the selection of a cell quantification assay for cell-based products, since the mechanism
directly correlates with the assay applicability and potential drawbacks. [125, 126, 131]
For example, metabolic assays are prone to deviate from correct cell number since the
metabolic activity varies e.g. during cell cycle and age. Additionally, metabolic assays
tend to be not suitable for 3D applications. [123, 130, 131] DNA-based assays tend to be
more reliable for non-synchronized cell cultures. [132]
The direct methods include several techniques. The most commonly used is the microscopic
cell counting. Manual microscopic cell counting is routinely performed in cell culture
laboratories using a hemocytometer in combination with dye exclusion, in order to distin-
guishing between live and dead cells. Trypan blue is such a dye which cannot penetrate the
membrane of live cells, thus, only dead cells become stained blue. Additionally, impedance-
based cell quantification setups and light scattering-based cell quantification using flow
cytometry methods are available. [127, 128, 133]
Especially, flow cytometry is considered to be a highly beneficial analytical tool for cell-
based products, since it allows for analyzing multiple cell characteristics and parallel
cell quantification. [27, 128, 133] It is basically a flow-through fluorescence microscope.
Briefly, cell samples are hydrodynamically focused, thus, single cells pass the laser beam.
The emitted light is then collected via an array of photo-detectors and optical filters
and visualized as histograms or dot-plots. Depending on the equipment set up (multiple
laser and filter) and staining strategy, cell morphology, cellular physiology, surface and
intracellular protein expression can be analyzed. For example, surface protein expression
is analyzed using fluorophore-labeled antibodies. [134] A simultaneous cell quantification
is, however, not routinely performed using a flow cytometer. Different strategies are
available to facilitate parallel cell quantification. Spiking samples with a counting standard
facilitate the enumeration of the cell number and represents a low investment solution. [133]
Equipping the flow cytometer with an autosampler is associated with a higher investment.
However, using an autosampler allows for cell quantification if a defined sample volume is
measured and calibrated. [128] Another major advantage of a flow cytometer equipped with
an autosampler is the HTS applicability and automation. [134, 135] The usefulness of HTS
flow cytometry has already been demonstrated by different HTS applications e.g. stem cell
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research [136, 137], drug screening [135] and cell downstream process development [60].
Establishing an analytical strategy for process development of cell-based products is ex-
tremely important. In general, the strategy should represent all QCAs and, therefore,
comprise several analytical methods. The applicability of each method must be evaluated
and, if necessary, optimized for each application. Several requirements need to be consid-
ered early on. For example, the underlying mechanisms of a method should be known.
Automation and HTS compatibility is also a general requirement for the applicability of
a cell characterization method in process development for cell-based products. [125, 126,
131] By using e.g. autosampler, multiwell plates and protocols without wash steps a lot
of methods can be optimized towards HTS applicability. [124, 132] Additionally, method
validation must be performed before an analytical method can be implemented in the
process development. The validation should be performed according to the guideline ICH
Q2 which comprises the evaluation of method accuracy, precision, specificity, detection
limit, quantification limit, linearity, range and robustness. [138] Especially, the evaluation
of robustness towards process related components is important. For example, cell quantifi-
cation assays may interfere with media components or media characteristics (e.g. density,
viscosity) may cause alterations when liquid handling is required. [123, 128]
3.4.2 High-Throughput Screening (HTS)
The usage of high-throughput screenings (HTSs) as a scientific tool is state-of-the-art
for over two decades in various disciplines including e.g. stem cell research [136, 139],
compound library screenings in pharmaceutical drug discovery campaigns [125, 126, 140–
146] and toxicology screening of biomaterial for e.g. tissue engineering applications [147].
Additionally, the pharmaceutical industry is tackling cost and time pressure using HTS
in process development for biopharmaceuticals. [148–155] This approach is referred to
as high-throughput process development (HTPD). [148] Typically, a HTS platform is
developed implementing the approaches of automation, miniaturization, parallelization as
well as standardization. The core-piece of such a platform is most of the time a robotic
liquid handling station with an integrated analytical strategy. Usually, multiwell plates
(e.g. 96 Well or 384 Wells) are used as standardized consumables. An integral part of
the platform development is establishing and validating a suitable scale-down model. For
biopharmaceutical HTPD there are scale-down models for up and downstream process
units already available e.g. scale-down bioreactor models for optimization of optimal
cultivation process parameter [154, 155] and column scale-down models for chromatography
optimization [152, 153]. Additionally, a data handling and storage strategy needs to be
implemented in order to interpret the results correctly. [141, 147, 148, 150, 151]
The development of a HTS platform is a highly sophisticated task, since it is quite complex
and requires expensive equipment. Thus, expertise is necessary in order to prevent failure
and/or misinterpretation of experimental data. [142, 144] Another bottleneck during HTS
platform development is the availability of inexpensive analytical methods. An analytical
strategy addressing all scientific questions need to be developed and implemented. Such
a strategy is typically tailored for each HTS campaign and comprises several analytical
methods which all need to be suitable and validated in advance. [125, 141, 144, 147, 148,
156]
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However, once a HTS platform is developed, systematic screenings with low sample volume
can be performed in a short period of time. Due to automation, human failure is minimized
resulting in higher reproducibility and accuracy. Additionally, using a HTS platform means
standardization of screening protocols resulting in a better comparability between different
HTS campaigns. [140, 141, 147] Thus, HTS represents a highly beneficial tool in process
development especially in early process development in a QbD environment, where process
knowledge needs to be established with only little material. [148–150]
A HTPD approach would be highly valuable for cell-based therapeutics. Streamlining
process development while generating process knowledge would help to overcome transla-
tional challenges. Yet, the automated handling of living material will naturally increase the
complexity of a HTS platform. However, experiences were already made with cell-based
HTS assays for toxicity screenings and upstream process development for biopharmaceuti-
cals. [147, 151, 154, 155] This expertise should be applied during process development for
cell-based therapeutics.
3.4.3 3D Printing
The possibility to build 3D objects in a layer-by-layer manner has created much excitement
in the last decades and is summarized in the umbrella term 3D printing. It is even
believed that 3D printing is a disruptive technology and might revolutionize the way of
manufacturing, contributing to another industrial revolution. [157–159]
The first 3D printing method, namely stereolithography, was described and patented by
Hull in the 1980s. [160, 161] Stereolithography uses the principle of photopolymerization.
Here, a liquid photosensitive monomer resin is placed in tank while thin layers of resin
are cured via ultraviolet (UV) radiation on a building platform. By moving the building
platform step-wise in z-direction, a 3D object is manufactured. [105, 162–164] Due to
the fast evolving and highly innovative nature of the 3D printing field, nowadays various
methods besides stereolithography are available including the prominent methods e.g.
inkjet printing and fused deposition modeling (FDM). The inkjet technology originally
derived form 2D applications. In the field of 3D printing, liquid polymer resin is deposited
by a printhead in x- and y-direction (2D), which is repeated for each layer. Usually, liquid
photosensitive monomer resins are used and also cured by UV radiation. [163, 164] While
stereolithography and inkjet technologies are using liquid polymer resin, FDM printers
are equipped with solid polymer filament. The filament is fed to a moving printhead (x-
and y-direction) and simultaneously liquified due to the printhead temperature which is
usually set about 1 °C higher than the melting point of the filament material. Thus, a
thin layer of material is deposited on the built-table which is moved in z-direction in order
to create the 3D object. [105, 162–164] Fueled by adaptation of 3D printing methods to
all kind of economy/society branches, nowadays, commercial 3D printers are available in
different price ranges. Additionally, 3D contract manufacturer services can be used. [157]
The application of 3D printing ranges from e.g. aerospace, automotive, prosthetic, dental
implants, art, education to life science/biotechnology. [158, 165, 166]
3D printing enhances an inexpensive and creative problem solving in a short time, which is
highly contributing to innovations in academic biotechnology/life science applications. [167]
For example, 3D printed replication master for microfluidic devices [168, 169] or direct 3D
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printing of microfluidic devices [170, 171] speed up design optimization. Additionally, a
surface treatment of 3D printed devices can be performed if necessary e.g. immobilization of
enzymes on 3D printed bioreactor surfaces for enzyme cascade testing [172] or incorporating
an active substance in the raw material prior to printing [173]. A huge advantage of the 3D
printing approach is the possibility to tailor tools or labware for the specific applications
e.g. designing and printing a tailored multiwell plate to enhance oxygen transfer [174, 175]
or designing a simple orientation tool for automated zebra fish screening [176]. While for
the orientation tool for automated zebra fish screening a rapid prototyping approach was
used, 3D printed end-use devices for integration of automated screening platforms have
already been described e.g. a Tip2Worl interface for integration of a commercial density
sensor in a robotic liquid handling station platform [177] or designing and 3D printing
of a stalagmometer for automated protein hydrophobicity determination using a HTS
platform [178]. Those examples highlight the power and usefulness of 3D printing as a tool
in HTPD.
The main advantages of using 3D printing as a tool in HTPD are the design freedom, the
inexpensive and rapid production of tailored equipment. Additionally, the 3D printing
approach also digitises 3D objects which is another advantage. In general, 3D printing
starts with designing a 3D object using the computer-aided design (CAD) approach or
medical 3D information of e.g. computed tomography (CT) scans. This information is
than transferred into the stl-format which is further sliced to generate a g-code which is
used by 3D printers. The digital nature is highly beneficial to share the designed objects
within collaborations and for storage. Thus, the file can be printed on-demand which
revolutionizes the supply chain management. Another advantage is that theoretically one
3D printer can manufacture a wide range of different designs. [157–159, 161, 162, 164, 167,
174, 175]
However, these advantages are only beneficial if the 3D printing approach is implemented
in the work flow of a company or academic institute e.g. scientists need to be trained in
CAD if they want to use the whole benefit of 3D printing. [167] Once the 3D approach
is implemented the limitation of printable material represents a major challenge. In
the beginning, mainly plastic materials were used for 3D printing. However, the field
is constantly evolving and new materials and corresponding 3D printing methods are
described. For example, metal printing is nowadays an option e.g. for orthopedic implant
applications. [165, 179, 180] In general, the material needs to be compatible with the
experimental set up which can differ for each biotechnological application. For example,
martial which comes in contact with cells needs to be biocompatible [175, 179] while
other applications need solvent resistant materials [171]. Thus, an integrative approach is
necessary for a 3D printing campaign considering the experimental requirements, suitable
material and 3D printing method. Currently, another challenging aspect of 3D printing
is the need for post-processing of the printed objects which can be difficult and cause
time delay. [158, 165] Other aspects like cyber security, intellectual property, real-time
monitoring of the 3D printing process and validation of 3D printed object quality are rarely
discussed at the moment, but will probably become more prominent in future. [158, 181]
While those challenges are constantly tackled by new inventions, the 3D printing field is
considered to become even more important. An exciting trend is expected towards printing
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of functional devices due to hybrid material printing e.g. sensors which would be highly
beneficial for biotechnological applications and the HTPD approach. [162, 180]
CHAPTER 4
Research Proposal
Cell-based therapeutics have gained increasing interest over the last decades since they
enable the replacement of damaged or ill-functioning tissue. They are even believed to
have a huge impact on the healthcare sector and are considered to be the fourth pillar
in patient treatment besides small molecules, medical devices and biopharmaceuticals.
While first generation cell-based therapeutics are already on the market, the inherent
complexity of living cells and lack of experience are still representing major obstacles
translating a promising cell-based therapeutic from academia to a commercially available
product. In order to tackle these translational challenges, problems that have arisen during
product development so far, were analyzed and underlying causes could be identified by
the cell therapy community. In general, three categories of translational challenges could
be identified: (1) pre-market challenges, (2) manufacturing challenges and (3) post-market
challenges. However, the general lack of experience in combination with an heuristic process
development approach could be identified as a major root-cause in all three categories.
Therefore, one key question is whether process development tools and strategies from
the pharmaceutical industry can be applied for cell-based products. By using these tools
and strategies the process development will be streamlined and optimized by enabling a
systematic and more directed process development approach which is highly beneficial
for the cell therapy industry and will contribute to a more widespread use of cell-based
therapeutics. Thus, the main focus of this thesis is to validate whether the application
of general process development tools from the pharmaceutical industry is possible for
cell-based products.
The first part of this thesis is focusing on the unit operation cell separation. Here, the
availability of scalable and label-free separation methods represents a bottleneck in process
development. Evaluating alternative cell separation methods will open up new possibilities
in downstream processing. Cell partitioning in ATPS represents an alternative method.
However, the partitioning mechanism is yet not completely understood, resulting in a high
screening effort for optimal key process parameter. Consequently, the question arises if
HTS-platforms can be used to overcome the screening bottleneck. For this purpose, a
previously developed HTS-platform is to be used to systematically investigate the influence
of key parameter e.g., polymer molecular weight and tie-line length on cell partitioning
behavior. While process development is normally associated with high investment costs, the
usage of 3D printing methods might decrease the financial risk during process development.
Thus, the question arises if 3D printing methods can be used as manufacturing tool in
an early process development stage since they enable a fast and relative cost-effective
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production of prototypes and equipment parts. For this purpose, 3D printing is to be used
for the development of a microfluidic set up, to investigate the possibility for a technology
transfer from batch ATPS cell partitioning into a microfluidic flow-through-mode. Using
3D printing technologies enables a faster and cheaper implementation of process equipment
contributing to "Time To Market" demands.
The second part of this thesis is focusing on different unit operations in the field of cell
formulation, namely, cell cryopreservation and bioprinting. Currently, cryopreservation is
already used whenever cells need to be accessed with unaltered characteristics over a long
period of time, e.g. for cell culture maintenance and biopharmaceutical, since it allows for
long-time storage of living material. However, there is an urgent need for cryopreservation
process optimization for clinical applications, especially, the formulation of cryomedia. This
thesis is tackling the question if a predictive tool box for cryomedia evaluation towards
process performance can be used for this purpose. Such an approach will enable a fast
screening of cryomedia candidates with an decreased sample volume. Additionally, the
possibility of implementing an automated image processing tool for the characterization
of freezing/thawing profiles is to be investigated. Such a tool would be highly beneficial
in order to gain process knowledge and might be used for optimization purpose. While
cryopreservation is a storage approach, bioprinting methods can be used for manufacturing
of artificial 3D tissue. The relatively young field of bioprinting is considered to have a
huge impact in life sciences. However, huge effort in bioprinting process development need
to be done for clinical applications. One important key factor is the integration of an
analytical strategy in order to evaluate/monitor critical cell parameter (e.g. cell viability)
during bioprinting process development. Flow cytometry is a versatile and powerful cell
characterization tool, since it allows for analyzing multiple critical cell parameter in parallel
and is capable of automation. Thus, the question arises whether it can also be used as
analytical tool in the field of bioprinting. To answer this question, an analytical strategy
to evaluate critical cell parameter (e.g. cell viability) in bioprinting process development
by means of flow cytometry shall be developed.
In summary, the presented thesis aims at a systematic and more directed process develop-
ment approach for cell-based therapeutics. This is accomplished by means of using the
following process development tools and strategies: a HTS approach enabling an automated
and systematic process optimization using low sample volume, applying 3D printing to
speed up process set up development, miniaturization and developing of an analytical
strategy to investigate critical bioprinting process parameter.
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Aqueous two-phase systems (ATPS) have been a useful tool in downstream processing for
cellbased products, since they facilitate labelfree, scalable, and costeffective separation of
cells. Here, the authors report the extension of the previously developed high-throughput
screening (HTS) platform by a cell barcoding procedure, to enable multiplexed cell parti-
tioning analysis. Further, a case study demonstrated the influence of polymer molecular
weight and tie-line length on the resolution of five model cell lines using a countercurrent
distribution model.
Biotechnol J. 2018 Feb;13(2). doi: 10.1002/biot.201700250. Epub 2017 Nov 22.
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Process Development using 3D printing & the DMAIC Framework
Additive manufacturing technologies represent a promising tool in biotechnology process
development since they allow for the fast acquisition of tailored equipment. In this study,
a successful technology transfer from batch cell partitioning in ATPS data was performed
towards a microfluidic flow-through mode using the additive manufacturing approach.
First, missing equipment parts were identified, designed and manufactured using different
3D printer. Subsequently, the tailored equipment was implemented in the process setup
consisting of conventional laboratory equipment and experiments were conducted. The
technology transfer study was performed using the DMAIC (Define, Measure, Analyze,
Improve, Control) framework. Thus, critical process parameter, namely, cell load and
fluid velocity were identified influencing cell partitioning in ATPS flow-through mode in
comparison to the batch data.
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Video Analysis-based Tool
In this study, a video-based analytical tool was developed for the characterization of
freezing and thawing behavior in cryopreservation process development. Evaluation of
the usefulness and flexibility of the developed tool was done based on a scale up case
study with the cell line INS-1E. Here, the influence of sample working volume on process
performance was investigated. Increasing the volume from 1 mL to 2 mL led to a delay
in freezing and thawing behavior resulting in a cell recovery loss. We believe that the
developed tool is powerful and will facilitate more directed and systematic cryopreservation
process development.
Bioprocess and Biosystems Engineering Feb 2019; 42, doi:10.1007/s00449-019-02071-3
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Cell Cryopreservation is an important unit operation whenever cell long-time storage is
required. While the cryopreservation process and its critical parameter is well described
in literature, performing cell cryopreservation for clinical applications are facing higher
requirements. One of these is the cryomedia formulation without the use of toxic or
animal-derived components. Thus, the commonly used cryoprotectans dimethyl sulfoxide
(DMSO) and fetal bovine serum (FBS) are excluded from use. Cryoprotectant, however,
are crucial for cell survival. For this reason, screening for optimal, alternative cryome-
diaformulations are necessary. In this study, a tool box for the prediction of cryomedia
process performance was developed in order to speed up development time. The tool box
enables the characterization of media properties, cell response and physical behavior. A
case study, using the developed tool box, was performed with four cryomedia including a
positive control (DMSO & FBS as cryoprotectant), negative control (culture media) and
two commercially available DMSO-free cryomedia. The tool box data indicated that the
commercial Biofreeze® media shows inferior performance for INS-1E, while the second
commercial cryomedia CryoSOfreeTM is clearly a possible candidate.
in preparation
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Bioprinting is considered to be a key technology in the field of tissue engineering and
regenerative medicine since it allows for the manufacturing of 3D cell-laden objects. However,
extensive process development in terms of material, process strategy and process parameter
is likely to be necessary before 3D printed, artificial tissue becomes clinically relevant. In
this study, a flow cytometry-based analytical strategy (destructive method) was developed
regarding critical cell characteristics including cell viability and proliferation. The developed
strategy can be used as analytical tool for bioprinting process development and might even
be integrated in an automated screening platform since it is HTS-applicable.
Bioprinting 2018 Sep; 11, e00023. https://doi.org/10.1016/j.BPRINT.2018.e00023
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Abstract
The availability of clinical-scale downstream processing strategies for cell-based products
presents a critical juncture between basic research and clinical development. Aqueous
two-phase systems (ATPS) facilitate the label-free, scalable, and cost-effective separation of
cells, and are a versatile tool for downstream processing of cell-based therapeutics. Here, we
report the application of a previously developed robotic screening platform, here extended
to enable a multiplexed high-throughput cell partitioning analysis in ATPS. We investigated
the influence of polymer molecular weight and tie-line length on the resolution of five
model cell lines in charge-sensitive polyethylene-glycol (PEG)-dextran ATPS. We show,
how these factors influence cell partitioning, and that the combination of low molecular
weight PEGs and high molecular weight dextrans enable the highest resolution of the five
cell lines. Furthermore, we demonstrate that the separability of each cell line from the
mixture is highly dependent on the polymer molecular weight composition and tie-line
length. Using a countercurrent distribution model we demonstrate that our screenings
yielded conditions that theoretically enable the isolation of four of the five cell lines with
high purity (>99.9%) and yield.
Keywords: aqueous two-phase systems (ATPS), cell separation, high-throughput flow
cytometry, high-throughput screening, polymer molecular weight, tie- line length
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6.1 Introduction
Cell-based therapeutics for a variety of diseases and from a variety of cell sources have
made their way to clinical trials. The availability of clinical-scale downstream processing
strategies for cell-based products represents a crucial juncture between basic research and
clinical development. For clinical applications, cell-based products often need to be enriched
to high purities, since certain contaminants can cause severe side effects, such as teratoma
formation or graft-versus-host-disease (GvHD). [2, 182–186] The most widely applied cell
purification methods are based on affinity-purification. These methods, however, require
large amounts of clinical-grade antibodies, presenting a significant cost-factor. [185, 187,
188] Likewise, antibody-labels remaining on the cell surface, pose considerable regulatory
obstacles for the treatment of patients, as they may cause adverse reactions. [184, 185]
Aqueous two-phase systems (ATPS) present a gentle, cost-effective, scalable, and label-
free method for cell purification. ATPS are aqueous solutions consisting of one or more
compounds, e.g. different polymers, which form two immiscible phases above a certain
threshold (e.g. concentration, temperature). The two phases have distinct physicochemical
properties, consequently, biomolecules partition between them according to their respective
physicochemical properties. By now, they are well established in downstream processing
of biopharmaceuticals, such as protein- and DNA-based pharmaceuticals. [54, 189, 190]
Polyethylene-glycol (PEG)-dextran ATPS have been successfully used to separate cells
according to their surface properties, and it is well established that ATPS facilitate the
separation of different cell types with high selectivity and resolution. [53, 54] In multi-stage
experiments, e.g. countercurrent distribution (CCD), even complex cell mixtures were
effectively separated. [54, 66] While the mechanisms underlying cell partitioning in ATPS
are not fully understood, there is strong evidence that surface charge and lipid composition
play a major role in cell separation. [53, 54] Several independent publications indicate
that surface charge-dependent cell separation is possible in ATPS containing isotonic
concentrations of phosphate (so called charge-sensitive ATPS), and partitioning coefficients
could be correlated to the cells electrophoretic mobility. Charge-independent cell separation,
on the other hand, can be achieved in ATPS containing isotonic concentrations of NaCl
(charge-insensitive ATPS), and partitioning coefficients have been correlated with the
cells membrane lipid composition, i.e., membrane hydrophobicity. [53, 54, 191, 192] One
of the current theories states that these phenomena are based on different partitioning
properties of the respective salts. While sodium chloride partitions almost equally between
the phases, sodium phosphate has a stronger affinity to the dextran-rich bottom phase,
resulting in an interfacial electrostatic potential difference (Donnan potential). [193, 194]
The Donnan potential is highly dependent on salt-composition, tie-line length (TLL),
polymer type, and molecular weight. [53, 54, 195] At the same time, TLL and polymer
molecular weight significantly influence cell partitioning when using salts that partitioning
equally between the phases. [53, 54] A key factor in cell partitioning is the interfacial
tension [196], which is directly correlated with TLL and polymer molecular weight [197].
The interaction of all these parameters in respect to cell partitioning and the resolution of
different cell populations is, however, unclear. In previous work, we developed an integrated
high-throughput screening (HTS)-platform for the analysis of cell partitioning in ATPS.
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We investigated the influence of TLL, salt composition, and pH on the resolution of several
model cell lines and described strategies for fast and directed HT-downstream process
development [60]. In this work, we used this HTS-platform to investigate the influence of
the PEG and dextran molecular weights in dependence of the TLL on cell partitioning
in ATPS. Using different CellTracker dyes in a combinatorial fashion for cell barcoding,
enables multiplexing of several cell lines in a single experiment, and results in a substantial
decrease in time and material consumption. Moreover, batch variability can be eliminated
by analyzing numerous cell lines in the same experiment. The present work describes
how TLL in dependence of the polymer molecular weight influence the resolution of five
barcoded model cell lines in charge-sensitive ATPS, characterizes suitable screening ranges
and shows how these data can be used to design purification strategies for the various cell
populations.
6.2 Experimental Section
6.2.1 Disposables
For ATPS preparation, 1.3 mL deep well plates (Nalgene Nunc, Rochester, NY, cat.
260252) and for flow cytometry, 96-well U-bottom plates (BD Falcon, Franklin Lakes,
NJ, cat. 353910) were used. Polypropylene flat-bottom microplates (Greiner Bio-One,
Kremsmünster, Austria, cat. 655261) were used for all other purposes.
6.2.2 Software and Data Processing
Evoware 2.5 SP2 standard (Tecan, Crailsheim, Germany) was used to control the Tecan
Freedom Evo 200 liquid handling station. Advanced applications such as sampling and
cell resuspension were realized via visual basic scripts that were directly fed into Evoware.
For data storage Excel 2013 (Microsoft, Redmond, WA, USA) was used. Matlab R2014a
(The MathWorks, Natick, ME, USA) and Excel 2013 were used for data evaluation and
visualization. Statistical data analysis was performed with Matlab R2014a. The BD
LSR Fortessa Cell Analyzer was controlled using BD FACSDiva 8.0 (BD Biosciences, San
Jose, CA, USA). In addition, BD FACSDiva 8.0 was used to calculate the compensation
of spectral overlap and for raw data analysis. Flow cytometry data visualization was
performed with Flow Jo V10 (Tree Star, Ashland, OR, USA).
6.2.3 Preparation of Buffers and Stock Solutions
For the preparation of buffers and stock solutions, ultra-pure water (0.55 µS/cm) obtained
from an Arium®proUV water system (Sartorius Stedim Biotech, Goettingen, Germany)
was used. Stock solutions of 2 and 20 % dextran 70,000 (Carl Roth Kalrsruhe, Germany,
cat. 9228.2, Batch No.: 215229323), 2 and 20 % dextran 500,000 (Pharmacosmos A/S,
Holbaeck, Denmark, cat. 5510 0500 9007, Batch No.: HT3229), 40 % PEG 4,000 (Merck
Millipore, Billerica, MA, USA, Cat. 8.17066.5000, Batch No.: K46660006524), 30 % PEG
8,000 (Sigma Aldrich, St. Louis, MO, USA, cat. P2139, Batch No.: 059Ko121), and
20 % PEG 20,000 (Sigma Aldrich, cat. 95172-250G-F, Batch No.: BCBP5677V) were
prepared in ultra-pure water and dissolved on a magnetic stirrer overnight. 500 mM sodium
phosphate (NaPi) buffer stock solutions with pH 6.6, and 7.4 were prepared as described
before [60]. Sodium chloride (NaCl) (Merck Millipore) was prepared as a 500 mM stock
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solution. Sterile filtration (Ø 0.22 µm) was performed for all buffers and stock solutions.
Polymer solutions were stored at 4°C whereas buffers were stored at room temperature.
The flow cytometry staining buffer was prepared directly before use and consisted of
phosphate buffered saline (PBS) (Life Technologies, Carlsbad, CA, USA) supplemented
with 2 mM EDTA (Life Technologies) and 0.5 % bovine serum albumin (BSA) (Miltenyi
Biotech, Bergisch Gladbach, Germany).
6.2.4 Cell Culture
Unless otherwise stated cell culture reagents were purchased from Life Technologies. The
murine fibroblast cell line L929 was purchased from CLS (Cell lines Service Eppelheim,
Germany, cat. 400260), and the rat ileum cell line IEC-18 was purchased from ATCC
(cat. CRL-1589). The human lung carcinoma cell line A549 (ATCC, cat. CCL-185) and
the human colorectal carcinoma cell line HCT 116 (ATCC, cat. CCL-247) were a gift
from Prof. Hartwigs lab. The rat beta-cell line INS-1E [198] was kindly provided by
Prof. Maechler from the Department of Cell Physiology and Metabolism at the University
of Geneva Medical Centre, Switzerland. All cell lines were propagated at 37°C in a
humidified 5 % CO2 incubator. L929, A549 and HCT 116 cells were grown in DMEM
with GlutaMAX supplemented with 10 % FBS and 1 % Penicillin/ Streptomycin. IEC-
18 cells were cultivated in DMEM with GlutaMAX supplemented with 5 % FBS, 1 %
NEAA, 1 % Penicillin/ Streptomycin, and 0.1 U per mL bovine insulin (Sigma-Aldrich,
cat. I1882). INS-1E cells were cultivated in RPMI 1640 with GlutaMAX supplemented
with 10 % FBS, 1 % sodium pyruvate, 1 % Penicillin/ Streptomycin, 10 mM HEPES, and
50 µM beta mercaptoethanol (Sigma Aldrich). All cell lines were split every 3-4 days to a
concentration of 2 x 104 cells per cm2 for a maximum of 20 passages, with the exception of
INS-1E which were seeded at a concentration of 7 x 104 cells per cm2. In order to obtain
maximal reproducibility between different screenings, all cell lines were seeded at a density
of 2.7 x 105, 48 hours prior to the screening.
6.2.5 Cell Barcoding and Viability Staining
In order to enable multiplexing of several cell lines and eliminate inter-experimental variabil-
ity, the five cell lines were stained with different CellTracker (CT) dyes (LifeTechnologies) in
a combinatorial fashion. For staining, cells were trypsinized and resuspended in serum-free
medium to a final concentration of 2 x 106 cells per mL. The CellTracker dyes were added
to a final concentration of 3 µM for CellTracker Violet BMQC, 0.2 µM for CellTracker
Green CMFDA, and 0.05 µM for CellTracker Deep Red, respectively. The cell lines were
stained in a combinatorial fashion as follows: L929: CellTracker Violet BMQC and Cell-
Tracker Green CMFDA, INS-1E: CellTracker Deep Red, IEC-18: CellTracker Deep Red
and CellTracker Violet BMQC, HCT 116: CellTracker Violet BMQC, A549: CellTracker
Deep Red and CellTracker Green CMFDA. The cells were stained at 37 °C for 30 min
and subsequently resuspended in culture medium and incubated at 37 °C for 20 min to
remove excess dye molecules and inactivate unbound, amine-reactive CellTracker Deep
Red dye molecules. Prior to flow cytometric analysis, cells were stained with the viability
dye 7-AAD (Biolegend, San Diego, CA, USA), according to the manufacturers instructions.
Dead cells were gated using heat inactivated controls (70 °C, 10 min).
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6.2.6 Cell Quantification using High-Throughput Flow Cytometry
Flow cytometric cell quantification was performed as previously described [60].
6.2.7 Liquid-Handling Calibration
Liquid handling calibration was performed for all buffers and stock solutions as described
previously [60]. Calibration was performed in the range of 50-1,000 µL. Variation coefficients
were below 1.6 % for all aqueous solutions and below 3 % for the more viscous polymer
solutions.
6.2.8 HT-Binodal and Tie-Line Determination
A HTS-method for binodal determination based on could-point titration has previously
been established in our group and was performed as described [60].
6.2.9 Automated High-Throughput Screening of Cell Partitioning in Aqueous Two-Phase
Systems
The automated HTS-method was used as described in a previous publication [60]. The
entire HTS was performed on a Tecan Freedom Evo® 200 liquid-handling station (LHS).
Subsequently, the sample plates were transferred to the high-throughput sampler of the BD
LSR Fortessa for cell quantification and analysis. ATPS were prepared in a 1.3 mL 96-well
plate with a final volume of 637 µL. After mixing and addition of cells (1 x 106 cells per
well), phases were allowed to settle by gravity (20 min, RT) and sampling was performed
as previously described. During the sampling procedure samples were fivefold diluted in
staining buffer. After adding an equal volume of staining buffer containing 7-AAD for
viability staining and incubation for 10 minutes at RT in the dark, flow cytometric analysis
was performed.
6.2.10 Statistical Data Analysis
Pre-processing of screening data was performed as described in previous work [60]. A
two-sided students t-test was performed to determine differences in means, provided that
equal variances were asserted by an F -test. Error propagation was considered throughout
our analyses [199].
6.3 Results
We previously developed a fully automated screening set-up that integrates cell partitioning
in ATPS on a Tecan liquid-handling station and cell quantification and analysis at the single
cell level using high-throughput flow cytometry. [60] In the present study, we investigated
the influence of PEG and dextran molecular weight at a defined TLL on the resolution
of five cell lines in charge-sensitive ATPS. The following cell lines were chosen for this
study: the murine fibroblast cell line L929, the rat ileum cell line IEC-18, the human
lung carcinoma cell line A549, the human colorectal carcinoma cell line HCT 116, and
the rat beta-cell line INS-1E. Due to their different origins, we expected these cell lines
to differ significantly in their cell surface properties. We used a barcoding strategy that
enabled multiplexing of several cell lines in a single experiment (fig. 6.1 A). By using
three different CellTracker dyes in a combinatorial fashion, the cell lines were successfully
barcoded (fig. 6.1 B). Spill-over between barcoded cell lines can result in inaccurate
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analysis of cell partitioning, however, this was not observed here. We determined that
spill-over was < 0.1 % in all experiments. The gating-strategy used for data deconvolution
is shown in fig. 6.2. Partitioning factors were calculated based on the live cell counts of
each cell line. Cell viability was high throughout the screening (> 98 % viable cells), and
comparable between the cell lines.
Cell barcoding with
Cell TrackerTM dyes
Pooling of stained
cell lines
ATPSscreening Flow cytometry &
data deconvolution
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Figure 6.1: Cell barcoding for multiplexing of partitioning analysis in ATPS. (A) Scheme of
the barcoding strategy. Several cell lines are stained with CellTracker dyes in a combinatorial
fashion and pooled, before HT-partitioning analysis in ATPS. Cell quantification and analysis
is performed by HT-flow cytometry. After data deconvolution, the partitioning factors of each
cell type can be determined. (B) Efficient labelling of five cell lines with three CellTracker
dyes. A549 cells were stained with CellTracker Green CMFDA and CellTracker Deep Red,
INS-1E cell were stained with CellTracker Deep Red, IEC-18 cells were stained with CellTracker
Deep Red and CellTracker Violet BMQC, HCT 116 cells were stained with CellTracker Violet
BMQC, and L929 cells were stained with CellTracker Green CMFDA and CellTracker Violet
BMQC.
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Figure 6.2: Deconvolution method for barcoded cell lines. Single cells are gated for CellTracker
Violet BMQC staining and then further gated into single cell lines based on CellTracker Green
CMFDA and CellTracker Deep Red staining. The live cell population of each cell line was the
gated based on 7-AAD staining. FSC-A: Forward scatter peak area, SSC-A: side scatter peak
area, FSC-H: Forward scatter peak height.
6.3.1 Characterization of PEG-Dextran ATPS
Phase diagrams are essential to determine suitable screening ranges in ATPS research,
since they enable the selection of suitable volume ratios and TLL. The ATPS used in this
work consisted of different combinations of PEG 4,000, 8,000, and 20,000, and dextran
70,000 and 500,000, buffered with isotonic concentrations of sodium phosphate. Phase
diagrams were determined using a HTS-method described in previous studies [128] (fig. 6.3
& table 6.1). Binodal curves were fitted to eq. (6.1) using least square regression.
y = a× exp(b× x0.5 + c× x3). (6.1)
All binodal curves could be fitted with a Pearson’s r2 of at least 0.99. A change in shape
and location of the binodal in dependence of the polymer molecular weight was observed.
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y  = 12.17 × exp(-0.27 × x0.5 - 0.00010 × x3)
fit parameters: 
a: 12.17 (11.88 / 12.46)
b: -0.27 (-0.29 / -0.25) 
c: -0.00010 (-0.00012 /- 0.000075) 
r2 of 0.998
y  = 9.96 × exp(-0.28 × x0.5 - 0.00011 × x3)
fit parameters: 
a: 9.96 (9.3 / 10.62), 
b: -0.28 (-0.33 / -0.24), 
c: -0.00011 (-0.00017 / -0.00005), 
r2 of 0.972
y  = 10.41 × exp(-0.35 × x0.5 - 0.00019 × x3)
fit parameters: 
a: 10.41 (9.92 / 10.89)
b: -0.35 (-0.40 / -0.31)
c: -0.00019 (-0.00026 / -0.00012)
r2 of 0.993
y  = 7.23 × exp(-0.32 × x0.5 - 0.00027 × x3)
fit parameters: 
a: 7.23 (6.98 / 7.48) 
b: -0.32 (-0.34 / -0.29) 
c: -0.00027(-0.00032 / -0.00021) 
r2 of 0.996
y  = 9.04 × exp(-0.49 × x0.5 - 0.00051 × x3)
fit parameters: 
a: 9.04 (8.43 / 9.65) 
b: -0.49 (-0.56 / -0.42) 
c: -0.00051 (-0.00084 / -0.00018) 
r2 of 0.992
y  = 6.44 × exp(-0.55 × x0.5 - 0.00057 × x3)
fit parameters: 
a: 6.44 (5.82 / 7.05)
b: -0.55 (-0.64 / -0.46)
c: -0.00057 (-0.00094 / -0.00019) 
r2 of 0.987
Figure 6.3: Phase diagrams of different PEG and dextran molecular weights. Blue circles
represent binodal data points determined by HTS cloud point titration. Fit parameters of
equation 1 with 95 % prediction bounds and Pearsonťs r2 are shown in parentheses. (A)
PEG 4,000 and dextran 70,000 (fit parameters: a: 12.17 (11.88 / 12.46), b: -0.27 (-0.29 /
-0.25), c: -0.00010 (-0.00012 /- 0.000075), r2 of 0.998), (B) PEG 4,000 and dextran 500,000 (fit
parameters: a: 9.96 (9.3 / 10.62), b: -0.28 (-0.33 / -0.24), c: -0.00011 (-0.00017 / -0.00005), r2
of 0.972), (C) PEG 8,000 and dextran 70,000 (fit parameters: a: 10.41 (9.92 / 10.89), b: -0.35
(-0.40 / -0.31), c: -0.00019 (-0.00026 / -0.00012), r2 of 0.993), (D) PEG 8,000 and dextran
500,000 (fit parameters: a: 7.23 (6.98 / 7.48), b: -0.32 (-0.34 / -0.29), c: -0.00027(-0.00032 /
-0.00021), r2 of 0.996), (E) PEG 20,000 and dextran 70,000 (fit parameters: a: 9.04 (8.43 /
9.65), b: -0.49 (-0.56 / -0.42), c: -0.00051 (-0.00084 / -0.00018), r2 of 0.992), (F) PEG 20,000
and dextran 500,000 (fit parameters: a: 6.44 (5.82 / 7.05), b: -0.55 (-0.64 / -0.46), c: -0.00057
(-0.00094 / -0.00019), r2 of 0.987). 95 % prediction bounds of the fit parameters are shown in
parentheses. (G-H) Overlay of binodal fits.
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Table 6.1: Summary of ATPS compositions used to investigate the influence of polymer
molecular weight and TLL.a)
Molecular weight Total system composition Bottom phase composition Top phase composition TLL
PEG dextran PEG dextran PEG dextran PEG dextran
# [Da] [Da] [% (w/w)] [% (w/w)] [% (w/w)] [% (w/w)] [% (w/w)] [% (w/w)] [% (w/w)]
1 4,000 70,000 6.00 8.00 3.16 14.74 8.72 1.53 14.30
2 4,000 70,000 6.00 8.50 2.76 16.06 9.17 1.10 16.30
3 4,000 500,000 6.00 4.50 2.92 12.64 7.21 1.30 12.13
4 4,000 500,000 6.00 5.50 2.52 14.13 7.97 0.62 14.57
5 4,000 500,000 6.00 6.50 2.15 15.57 8.65 0.25 16.64
6 8,000 70,000 3.75 7.60 2.67 10.45 5.24 3.65 7.27
7 8,000 70,000 3.75 8.00 2.30 11.69 5.90 2.54 9.84
8 8,000 70,000 3.75 8.75 1.82 13.38 6.80 1.44 12.94
9 8,000 500,000 3.75 4.75 2.40 8.61 4.88 1.52 7.52
10 8,000 500,000 3.75 5.50 1.85 10.68 5.49 0.74 10.59
11 8,000 500,000 3.75 6.75 1.35 12.70 6.41 0.14 13.55
12 20,000 70,000 3.00 5.20 1.38 9.24 3.98 2.76 6.99
13 20,000 70,000 3.00 6.00 1.02 10.57 4.94 1.53 9.86
14 20,000 70,000 3.00 7.50 0.58 12.60 6.30 0.55 13.34
15 20,000 500,000 2.75 3.25 1.02 7.96 3.49 1.23 7.17
16 20,000 500,000 2.75 4.75 0.72 9.55 4.60 0.37 9.97
17 20,000 500,000 2.75 6.50 0.35 12.11 5.50 0.08 13.08
a) All ATPS were buffered with 0.11 M sodium phosphate, pH 7.4. TLL: tie-line length.
With increasing PEG molecular weight, the binodal shifts towards lower PEG and dextran
concentrations. This trend was observed for both dextran molecular weights. These findings
are in good agreement with literature [53] (fig. 6.3 G & H). We chose three screening
points from each phase diagram, with TLL of 7, 10 and 13 % (w/w), with the exception of
the phase diagrams of PEG 4,000. Due to the flatness of the binodals, even systems close
to the critical point had TLL of ≥ 12 % (w/w). Thus, we chose TLL of 12, 14 and 16 %
(w/w) for PEG 4,000 - dextran 500,000 and 14 & 16 % (w/w) for PEG 4,000 dextran
70,000.
6.3.2 Influence of Cell Barcoding on Their Partitioning in PEG-Dextran ATPS
Cell barcoding enables the evaluation of numerous cell lines in a single experiment. As
cell partitioning in ATPS is primarily dependent on cell surface properties, we chose a
barcoding reagent that does not bind to the cell surface, as for example described by [135].
Instead, we chose the CellTracker dyes, which are cell permeant fluorescent probes that
are retained inside living cells after a glutathione S-transferase-mediated reaction, with the
exception of CellTracker Deep Red, which is an amine-reactive dye. Even though amine
reactive dye do not exclusively bind to proteins inside the cell, CellTracker Deep Red was
used at relatively low concentrations (50 nM) compared to manufacturers recommendations
(250 nM - 1 µM). Thus, we expected that the CellTracker dyes can be used for cell barcoding
without significantly altering their partitioning behavior. To confirm this assumption, we
mixed CellTracker Violet BMQC stained and unstained HCT 116 cells and CellTracker
Deep Red stained and unstained INS-1E cells, and studied their partitioning in a number
of ATPS. We chose ATPS composed of 4 % PEG 8,000, 5 % dextran 500,000, 0.11 M
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NaPi, pH 7.4, with a TLL of 10.4 and of 4 % PEG 8,000, 4 % dextran 500,000, 0.11 M
NaPi, pH 7.4, with a TLL of 6.9, which were previously shown to enable cell separation
based on surface charge [54]. In addition, we chose a ATPS consisting of 4 % PEG 8,000,
4 % dextran 500,000, 0.01 M NaPi, 0.138 M NaCl, pH 6.6, with a TLL of 6.9 which was
previously shown to enable cell separation based on their membrane lipid composition [54].
In fig. 6.4, the fold change of the percentage of stained HCT 116 and INS-1E cells after
partitioning is shown. No significant enrichment or depletion of the CellTracker stained
cell populations was observed (p > 0.05).
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Figure 6.4: Influence of cell barcoding on partitioning in charge-sensitive and charge-
insensitive ATPS at different TLL (#1: 4 % PEG 8,000, 4 % dextran 500,000, 0.01 M
NaPi, 0.138 M NaCl, pH 6.6, TLL: 6.9; #2: 4 % PEG 8,000, 4 % dextran 500,000, 0.11 M NaPi,
pH 7.4, TLL: 6.9; #3: 4 % PEG 8,000, 5 % dextran 500,000, 0.11 M NaPi, pH 7.4, TLL: 10.4).
Two of the cell lines were barcoded with different CellTracker dyes and mixed with an equal
number of unstained cells of the same cell line. HCT 116 (A) was stained with Cell Tracker
Violet BMQC and INS-1E (B) was stained with CellTracker Deep Red. Partitioning analysis
was performed in HTS and the fold change of the percentage of stained cells was calculated
compared to a PBS control. Error bars represent 1 s.d. of 4 technical replicates. Pairwise
t-test showed no significant changes of partitioning due to CellTracker staining (p > 0.05).
Error bars are within symbol size.
6.3.3 Resolution of Five Model Cell Lines in Charge-Sensitive ATPS in Dependence of TLL
and Polymer Molecular Weight
The aim of this case study was to investigate the influence of TLL and polymer molecular
weight on the resolution of different cell lines. To do so, the partitioning of five cell lines
that differ in species and tissue type was investigated in charge-sensitive ATPS at different
TLL and different combinations of PEG and dextran molecular weights. The partitioning
factor P of each cell line towards the top or bottom phase was defined as the fraction of
cells in that phase compared to the total cell number added. For the top phase, P can be
calculated using eq. (6.2).
P = CountTP × VTP
CountC × VC (6.2)
TP: top phase, C: PBS control, V: volume
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In fig. 6.5 the partitioning factors of each cell line in dependence of TLL and polymer
molecular weight in charge-sensitive ATPS is summarized. The screenings revealed a
number of trends. Firstly, in the presence of NaPi, cells generally partitioned between
top phase and interface, which is well described for charge-dependent cell partitioning.
Furthermore, partitioning factors decrease with increasing PEG molecular weight, while
an increase in dextran molecular weight results in an increase of cell recovery in the top
phase. Even though ATPS consisting of PEG 4,000 and either dextran 70,000 or 500,000
had considerably higher TLL very high partitioning factors were observed. Secondly, when
comparing the partitioning factors for a given molecular weight combination, partitioning
factors decrease with increasing TLL. This trend is more pronounced for ATPS consisting
of PEG 8,000 than PEG 4,000 and either dextran 70,000 or 500,000. In ATPS consisting
of PEG 20,000 and either dextran 70,000 or 500,000, less than 7 % of either cell line was
recovered in the top phase. In ATPS consisting of dextran 500,000, cells were almost
completely adsorbed at the interface, while in ATPS consisting of PEG 4,000 and dextran
70,000 approximately 25 % of the cells partitioned to the bottom phase, which is not
consistent with charge-dependent cell partitioning and might be a consequence of strong
exclusion effects due to high PEG molecular weight. These ATPS were thus not included
in further analyses. Thirdly, the same overall trends were observed when comparing the
partitioning factors of the five cell lines in a given ATPS. The cell line A549 has the
strongest affinity for the top phase, followed by HCT 116, L929, IEC-18, and INS-1E.
However, absolute partitioning factors as well as differences between partitioning factors
change in dependence of TLL and molecular weight of the polymers. This means that the
resolution, i.e., separability, between the cell lines changes. Next, we determined enrichment
/ depletion factors for each cell line.
In fig. 6.6, the fold change of the percentage of each cell line in dependence of TLL and
polymer molecular weight is summarized. The fold change of each cell line was determined
using eq. (6.3).
fold change = %cell lineXTP%cell lineXC
(6.3)
%cell line X: ratio of each cell line, TP: top phase, C: PBS control
We observed up to threefold enrichment of A549 cells in the top phase and > 30-fold
depletion of INS-1E cells from the top phase. Moreover, the resolution of the five cell
lines changes in dependence of TLL and polymer molecular weight. For example, in
ATPS consisting of PEG 4,000 dextran 70,000 large differences exist between the fold
change-values of IEC-18 and INS-1E, while those values are close to identical in ATPS
consisting of PEG 8,000 and dextran 70,000. This indicates that by changing the polymer
molecular weight and TLL of charge-sensitive ATPS, the separation of two cell types might
be possible even if initial screenings indicate that they are not. In order to evaluate the
separability of the five cell lines in more detail, CCD-curves were calculated. CCD is a
well-established technique in liquid-liquid extraction, and has successfully been applied in
cell separation [54, 66]. In CCD, the top phase is sequentially transferred, while the
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Figure 6.5: Partitioning factors of five model cell lines in ATPS containing 0.11 M NaPi, pH
7.4, in dependence of PEG and dextran molecular weight and TLL. ATPS compositions are
summarized in table 6.1. Heat maps represent the mean percentage of live cells in each phase
(3 technical replicates). TLL: tie-line length.
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Figure 6.6: Fold change of the percentage of five model cell lines compared to a PBS control
in the top phase of charge-sensitive ATPS in dependence of polymer molecular weight and TLL.
ATPS compositions are summarized in table 6.1. Error bars represent 1 s.d. of 3 technical
replicates. TLL: tie-line length.
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bottom phase is retained. Between transfers, the ATPS are mixed and allowed to settle, to
achieve phase separation. Dependent on the application, the interface is either transferred
or retained. Since cells partition between one of the bulk phases and the interface, the
interface is retained when cells partition between top phase and interface, and transferred
when the cells partition between interface and bottom phase. As a consequence, cells that
partition mainly into the top phase move faster through the CCD-apparatus than cells
that partition mostly to the interface. As a result, the two cell types are separated.
Based on the data shown in fig. 6.5, CCD-curves were calculated by applying eq. (6.4) [54]:
F (r) = n!
r!(n− r)!P
r(1− P )n−r (6.4)
where F represents the fraction of the total cell population appearing in each theoretical
cavity (r) of the CCD-apparatus, and n the total number of transfers. The experimental
validation of the model was reported in previously work [200]. We calculated CCD-curves
with 60 transfers for each cell line. The results are shown in fig. 6.7. The distribution
between the 60 theoretical cavities is strongly dependent on the partitioning factors, and
thus directly influences the resolution of the five cell lines [53, 54]. In ATPS in which
high partitioning factors were obtained, e.g., ATPS #3 and #9 the calculated CCD-curves
are skewed towards the right, and only cell lines with the lowest partitioning factors, i.e.,
IEC-18 and INS-1E can be separated from the mixture. In ATPS #9 A549 and HCT 116
have partitioning factors of 1 and thus do not distribute in CCD. In ATPS in which very
low partitioning factors were obtained, e.g., ATPS #7 and #8 the calculated CCD-curves
are skewed towards the left and very little resolution can be obtained, whereas in ATPS in
which intermediate partitioning (~ 0.5) factors were obtained, e.g., ATPS #1 and #4 the
calculated CCD-curves are symmetrical and distribute evenly. Moreover, we observed that
the resolution varies with TLL and polymer molecular weight at comparable partitioning
factors. In ATPS #1 and #4 for example, intermediate partitioning factors were obtained,
however, in ATPS #4 A549 and HCT 116 cell can be separated but not in ATPS #1. This
demonstrates that the combination of PEG and dextran molecular weights can influence
the separability of different cell types. Finally, the calculated CCD-curves indicate that
we identified conditions that enable peak separation of four of the five cell lines from the
mixture, indicating that very high purities and yields can be obtain with 60 transfers.
ATPS #5 enables the isolation of A549 with > 99.9 % purity and yield, and ATPS #2
enables the separation of L929 cells with > 99.9 % purity and > 45 % yield. Moreover,
ATPS #9 enables the isolation of IEC-18 with > 99.9 % purity and > 95 % yield and
ATPS #3 enables the isolation of INS-1E with > 99.9 % purity and yield.
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Figure 6.7: CCD-curves. CCD-curves were calculated for each cell line based on the
partitioning factors determined by HTS, with 60 theoretical transfers for ATPS #1-11. The
corresponding ATPS composition and TLL are summarized in table 6.1. TLL: tie-line length
in % (w/w).
6.4 Discussion
The aim of the present work was to investigate the influence of polymer molecular weight
at a defined TLL on the resolution of five model cell lines in charge-sensitive ATPS. Prior
to the screenings, phase diagrams for all PEG and dextran molecular weight combinations
were determined. We chose charge-sensitive ATPS consisting of different combinations
of PEG 4,000, 8,000, and 20,000, and dextran 70,000 and 500,000, with three TLL per
combination. Trends in location and shape on the binodals are in good agreement with
literature [53]. Higher polymer molecular weights result in a shift of the binodal towards
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lower concentrations of PEG and dextran, and the larger the difference in the molecular
weights of PEG and dextran, the more asymmetric is the binodal curve [53]. Furthermore,
the influence of the barcoding strategy on the cell partitioning was evaluated prior to
the screenings. We expected that staining with CellTracker dyes has no significant effect
on the partitioning behavior, since CellTracker Green CMFDA und CellTracker Violet
BMQC are cell permeant fluorescent probes that are retained inside living cells after a
glutathione S-transferase mediated reaction, thus, the cell surface remains unaltered. As
cell partitioning is largely dependent on cell surface properties, these dyes should not
influence cell partitioning. CellTracker Deep Red, however, is an amine reactive dye and,
thus, binds to cell surface proteins, which might influence cell partitioning by altering cell
surface properties. It was thus evaluated whether significant effects are observed at the
concentration used in this study. Partitioning studies showed no significant changes in
partitioning factors due to CellTracker staining. Consequently, CellTracker dyes are an
excellent tool for multiplexing in screenings investigating cell surface properties and enable
a substantial decrease in time and material consumption. Moreover, batch variability can
be eliminated by analyzing numerous cell lines in the same experiment, and the longevity
(>72 h) and nontoxicity of the dyes enables prolonged screening times. Since our data
indicate that relatively low concentrations of amine-reactive dyes do not significantly alter
cell partitioning in here investigated ATPS, it might be feasible to apply more complex
barcoding strategies, as for example described by Krutzik et al. [135], which enables a further
increase in throughput. Subsequently, we investigated the influence of polymer molecular
weight and TLL on the resolution of five model cell lines in ATPS containing sodium
phosphate, i.e., charge-sensitive ATPS. In contrast to smaller biomolecules, such as proteins
and nucleic acids, cells partition between either top or bottom phase and the interface,
depending on the ATPS composition [54]. The interfacial tension is one of the major
driving forces in the partitioning of molecules and particles in ATPS, as it acts to minimize
the interfacial area. Accordingly, TLL and polymer molecular weight, which determine
the interfacial tension in a given ATPS, play a major role cell partitioning in ATPS [197].
The adsorption of cells and other particles at the interface reduces the interfacial area,
and consequently the total free energy of the system. Thus, partitioning into either phase
can only take place if the interaction with the cell surface is strong enough to pull the
cells out of the interface. The higher the interfacial tension, the stronger the required
interactions to enable partitioning to either bulk phase [53, 54, 197]. These interactions
can be influenced by the type and concentration of salts is added. An extensive amount
of work have been done investigating the influence of phosphate salts and NaCl on cell
partitioning [53, 54]. One observation was the correlation between the cells electrophoretic
mobility, due to charge-associated surface properties, and cell partitioning [53]. It has
been shown that salts with polyvalent anions, e.g., phosphate have a higher affinity for
the dextran-rich bottom phase that the PEG-rich top phase, while salts of halides, for
example, NaCl, partition almost equally between the phases [201]. It was further proposed
that unequal partitioning of a salt results in the generation of an interfacial electrostatic
potential difference (Donnan potential), and molecules and particles partition in such ATPS
according to their surface charge [54, 191, 194, 202]. In PEG-dextran ATPS containing
phosphate with moderate interfacial tensions cells can, therefore, be separated based on
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surface charge differences (charge-dependent partitioning). Cells have a negative net surface
charge and consequently partition into the top phase in ATPS containing phosphate [189,
194]. This phenomenon was observed throughout the screenings. Both interfacial tension
and Donnan potential have been shown to increase with increasing TLL, but have opposite
effects on cell partitioning [195, 197, 203]. While the Donnan potential pulls the cells into
the top phase, the interfacial tension promotes cell adsorption at the interface. However,
the increase of interfacial tension with TLL is stronger than the increase of the potential
difference between the phases. Thus, at some distance from the critical point, the increase
in interfacial tension offsets the increase in electrostatic potential difference [54]. Forciniti
and several others [53, 197, 203] described a logarithmic increase of the interfacial tension
with increasing TLL, and an increase in interfacial tension with polymer molecular weight
at a given TLL, while a linear correlation between Donnan potential and TLL has been
described in several publications [195, 204, 205]. These finding correlate well with the data
presented in this work. With increasing TLL and polymer molecular weight, cell adsorption
at the interface increased. Although this theory of a charge-dependent partitioning is
supported by the findings of different groups [54, 191, 194, 202], doubts have been expressed
about the existence of an electrochemical potential in ATPS [206]. Despite the debate
about the existence of Donnan potentials and their significance in cell partitioning, the
data presented here show a clear influence of sodium phosphate on cell partitioning and
the resolution of different cell types.
At a PEG molecular weight of 20,000 Da no partitioning into the top phase was observed,
even at low TLL. This indicates that the interfacial tension was too high for specific
cell partitioning. Interestingly, the change of dextran molecular weight from 500,000 to
70,000 Da, at a given PEG molecular weight, did not result in an increase of partitioning
factors, as assumed due to a decrease in interfacial tension, but a decrease. Our data
showed that combinations of low PEG molecular weights, i.e., ≤ 8,000 Da, and high
dextran molecular weights, i.e., 500,000 Da, at TLL between 10 and 15 % (w/w) enable
high resolution of the five model cell lines. This is in good agreement with the findings of
Albertsson [53], who described increased partitioning to the top phase when decreasing the
PEG molecular weight. We assume that a further decrease in PEG molecular or an increase
in dextran molecular weight might result in higher partitioning factors and in changes in
resolutions. This, however, needs to be validated in future work. Furthermore, our data
indicate that sodium phosphate-dependent, i.e., charge-dependent, cell separation is the
major driving force, independent of TLL and polymer molecular weight, since the order of
the affinity the five model cell lines exhibited to the top phase is independent of TLL and
polymer molecular weight. However, the resolution between the five cell lines, which was
evaluated by the calculation of CCD-curves, changes with TLL and polymer molecular
weight. Thus, comprehensive screenings are necessary to investigate the separability of two
cell populations. As hypothesized by Walter et al. [54], factors other than surface charge
may play a minor role in charge-sensitive ATPS, and we assume that their contribution
is dependent on TLL and polymer molecular weight. In addition, a number of other
factors, such as phase densities and viscosities, and cell size and density may play a role [53].
However, the exact role and interaction of all of these factors need to be further investigated.
In addition, the calculated CCD-curves indicate that the differences in partitioning factors
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can be used for cell separation. Our data show that we identified conditions that enable
peak separation of each of the five cell lines from the mixture in a single CCD-run, with
the exception of HCT 116 where two consecutive CCD-runs are necessary. Likewise, it
should be noted that partitioning ratios of cells are highly dependent on vessel geometry,
fill volume, mixing efficiency, and phase separation time. Thus, these conditions need to
be identical in batch- and CCD- experiments, otherwise predicted CCD-curves will not be
accurate [54]. While the calculation of fold-change values are an excellent means to evaluate
separability of certain cell populations, CCD-models enable the estimation of obtainable
purities, yields and overall processing time, and are thus an excellent tool for downstream
process development of cell-based products. Finally, it should be noted that Walter et
al. [207] showed that cell age, cell cycle stage, and the use of enzymes for cell dissociation
can influence cell partitioning [207–209]. Therefore, the effect of these parameters on cell
partitioning needs to be considered when designing a purification process.
6.5 Conclusions
We investigated the influence of TLL and polymer molecular weight on cell partitioning in
charge-sensitive ATPS. We showed that the interfacial tension, which is directly dependent
on TLL and polymer molecular weight, is a main factor in cell partitioning. The present
study showed that combinations of low PEG molecular weights and high dextran molecular
weights enable high resolution of different cell lines. Moreover, we showed that the order of
the affinity the five model cell lines exhibited to the top phase is independent of TLL and
polymer molecular weight, indicating that the major driving forces remain the same in
ATPS containing phosphate. However, the separability of the cell lines strongly depends
on TLL and polymer molecular weight. Thus, comprehensive screenings are necessary to
investigate the separability of specific cell populations. Finally, we demonstrated that the
combination of a HTS-platform for the investigation of cell partitioning in ATPS with the
here described barcoding strategy and the application of CCD-modelling, is a powerful
tool to study factors in cell separation and enables fast and directed downstream process
development for cell-based products.
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Abstract
Early process development in biotechnology research and pharmaceutical industry is al-
ways related with high investment costs. Especially, the lack of experience and process
knowledge in emerging fields, such as cell therapy, pose a financial risk. However, using the
aspiring additive manufacturing (AM) technologies could be a shortcut during research and
development. AM technology is an umbrella term for manufacturing methods building an
object in a layer-by-layer manner. They represent a promising and versatile tool for process
development in the field of biotechnology. Since they are relative cheap and facilitate a
fast manufacturing of tailor-made equipment within a short cycle time.
Here, we demonstrate the power of AM as a tool in process development based on a
technology transfer case study. The transfer of high-throughput (HTS) batch data for cell
partitioning in aqueous two-phase systems (ATPS) into a microfluidic flow-through process
was performed using an AM approach. Thus, standard lab-equipment was complemented
with tailor-made and 3D printed devices, in order to create a flexible and cheap process set
up. The technology transfer was conducted within the DMAIC (Define, Measure, Analyse,
Improve and Control) framework to provide a systematic process development and process
performance evaluation. Implementation of the developed microfluidic process set up was
successful. Additionally, two main factors influencing cell partitioning in the ATPS case
study were identified, namely, cell load and fluid velocities.
Keywords: additive manufacturing (AM), process development, cell separation, tech-
nology transfer, microfluidics
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7.1 Introduction
The additive manufacturing (AM) technology has evolved constantly over the last decades
and is considered to gain even more importance in the near future. The possibility to print
in 3 dimensions triggers all kinds of innovations and inspires new ways in designing and
material usage. [210–212] Especially, the research and development (R&D) environment
and academia values these advantages. AM facilitates a flexible and fast production of
self-developed equipment and prototypes, leading to an over-all shortening in development
time. [161, 175] Academic research in the field of Biotechnology has, at present, focused
mainly on 3D printing of tailor-made lab equipment [167–178, 213, 214] including molding
tools for the production of microfluidic devices [168, 169, 171, 213] and tailored multiwell
plates [173, 175, 176]. In particular, the implementation of 3D printed devices into high-
throughput screening (HTS) platforms poses an increase of value e.g. rapid prototype
development [161, 170, 171, 173, 175–178]. HTS technologies are state-of-the-art in
biotechnology research and an integral part in process development of the pharmaceutical
industry. [59, 140, 141, 143, 149–151, 215] Combining HTS with AM technologies promotes
creativity and flexibility among this community and contributes to the concept of knowledge
based process development. Process development in research and industry needs to be
structured, systematic and must deal with limited resources concerning time, personal,
budget and sample volume. [215–217] Thus, it is important to keep focused during process
development using AM technologies, since the possibilities and creativity seems almost
limitless. One approach to channel the creativity without getting lost in the possibilities,
using AM technologies as tool in process development, is to apply the DMAIC (Define,
Measure, Analyse, Improve and Control) methodology. DMAIC is the six sigma framework
structuring process improvement projects in its five stages. Six sigma is, in general,
applied when an already running process needs to be improved. [218–221] Using six
sigma is not exclusive for manufacturing process improvement e.g. in pharmaceutical
industry [219, 222] it can also be applied when a workflow needs to be improved e.g. in
a clinic environment [223–225]. A controversial discussion is ongoing whether six sigma
should be used in R&D, since it seems to decrease flexibility. [226] However, using the
DMAIC methodology as a roadmap in process development projects, without the rigid
six sigma approach, is highly beneficial. [221, 223–225, 227] The first stage define gives a
precise and comprehensive view of the project. Subsequently, the initial situation and goals
are described. Additionally, a timeline might be specified and project members are selected.
In the measure phase the process is defined more specific and a suitable and validated
analytical strategy must be implemented. Then, the process is evaluated concerning process
performance. In the analytic phase a root-cause investigation is performed, leading to an
identification of main factors for process failure or poor process performance. In the improve
phase the main factors are verified and corrective actions are planned and implemented.
The final control phase is used to evaluate the process optimisation and implementation
of an ongoing monitoring system to guarantee high process performance. [219, 224, 225]
Thus, using the well-established tools of HTS and the DMAIC methodology in combination
with the promising AM technologies is highly beneficial for process development. Such an
approach does not only contribute to the concept of knowledge based process development,
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it also speeds up project cycle times in addition to the unlimited freedom of creativity in
process set up.
Here, we report the usage of AM technologies as tool in early process development. This
was done based on a case study comprising a feasibility analysis of the technology transfer of
cell partitioning in aqueous two-phase (ATPS) systems batch HTS data into a flow-through
microfluidic process. Cell partitioning in ATPS is known as a method for cell separation
for regenerative medicine. However, the applicability is limited since the underlying
mechanisms are not fully understood. [53, 54, 189–191] In a previous study, a HTS platform
was developed to perform a systematic empirical screening for suitable systems. [60] The
findings of the HTS study were now transferred in a microfluidic process. Aiming a fast
realisation with low investment costs, 3D printing, as a tool for equipment production, was
used in combination with the DMAIC approach.
7.2 Materials and Methods
7.2.1 Stock Solutions
Preparation of all stock solutions and buffers, needed for the ATPS production, were
done using ultra-pure water (0.55 µS/cm) obtained from an Arium®proUV water system
(Sartorius Stedim Biotech, Goettingen, Germany). Stock solutions of 20 (w/w) % Dextran
500,000 (Pharmacosmos A/S, Holbaeck, Denmark) and 30 (w/w) % PEG 8,000 (Sigma
Aldrich, St. Louis, USA) were prepared. 500 mM sodium phosphate (NaPi) buffer with
pH 6.6 and 7.4 were prepared as described before. [60] Sodium chloride (NaCl) (Merck,
Darmstadt, Germany) was prepared as 500 mM stock solution. All stock solutions and
buffers were sterile filtered (Ø 0.22 µm) and stored at room temperature, except the
polymer stock solutions which were stored at 4 °C. The flow cytometry staining buffer
consisting of phosphate-buffered saline (PBS) (Thermo Fisher Scientific, Waltham, USA)
was supplemented with 0.5 % bovine serum albumin (BSA) (Miltenyi Biotech, Bergisch
Gladbach, Germany) and 2 mM EDTA (Thermo Fisher Scientific) and stored at 4 °C.
Stock isotonic percoll (SIP) was prepared by mixing percoll (GE Healthcare, Piscataway,
USA) and 10 x PBS in a 9:1 volume ratio.
7.2.2 Software and Data Processing
BD LSR Fortessa Cell Analyzer was controlled by BD FACSDiva 8.0 (BD Biosciences,
San Jose, USA). Flow cytometry data were analysed and visualised using FlowJo V10
(Tree Star Inc., Ashland, USA). The Tecan Freedom Evo 200 was controlled using Evoware
2.5 SP2 standard (Tecan, Crailsheim, Germany). Cetoni NeMESYS syringe pumps were
controlled using QmixElements Version: 20140708 (cetoni GmbH, Korbußen, Germany).
For data storage Excel 2013 (Microsoft, Redmond, WA, USA) was used. Matlab R2015a
(The MathWorks, Inc., Natick, USA) was used for data evaluation and visualisation. The
construction work was done with the 2D/3D CAD software SolidEdge (Siemens PLM
Software, Plano, USA). The GoPro Hero4 camera (GoPro, Inc., San Mateo, USA) was
controlled via the GoPro App version 2.6.3.312 (GoPro, Inc.) and a Samsung Galaxy Note
Pro SM-P900 (Samsung, Seoul, South Korea).
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7.2.3 Additive Manufacturing
An additive manufacturing approach (AM) was used for the fabrication of tailor-made
laboratory equipment. The construction work was done with the 2D/3D CAD software
SolidEdge (Siemens PLM Software). Depending on the requirements of the designed
lab-equipment part, different AM technologies were used. Parts with a high resolution
tolerance were printed in house with the inexpensive stereolithography desktop 3D printer
form 1+ (Formlabs Inc., Somerville, USA) using the MadeSolid Black Resin (Redresin,
Barcelona, Spain). In order to keep investment costs low, fabrication of medium and
low resolution tolerance were outsourced. Parts with medium resolution tolerance were
manufactured by Sculpteo Pro (Issy-les-Moulineaux, France) using a plastic laser sintering
approach (material: polished black plastic). Parts with low resolution tolerance were
manufactured by Proform AG (Marly, Switzerland) using a stereolithography approach
(material: Accura Xtreme).
7.2.4 Microfluidic Device Production
The microfluidic device was produced as previously described [168, 169] using the two
component polydimethylsiloxane (PDMS) curing system Elastosil 601 (Wacker Chemie,
Burghausen, Germany) with the exception that the chip bonding was performed in a sterile
hood to reduce particle load in the surrounding area.
7.2.5 ATPS Preparation
ATPS were prepared under sterile conditions with a total volume of 20 mL prior to use
according to table 7.1 in a 50 mL reaction tube using water for injection (WFI) (Thermo
Fisher Scientific). ATPS were mixed and centrifuged for 20 min at 4000 rpm for phase
separation. Top and bottom phase were taken and kept under sterile conditions prior to
use.
Table 7.1: Characterization of the used ATPS
system NaCl NaPi
Dextran MW 500,000 [% (w/w)] 5.0 5.0
PEG MW 8,000 [% (w/w)] 4.0 4.0
salt supplementation 0.14 M NaCl, 0.01 M NaPi (pH 6.6) 0.11 M NaPi (pH 7.4)
density top phase [g/cm3] 1.0194 ±0.0016 1.0235 ±0.0001
density bottom phase [g/cm3] 1.0450 ±0.0002 1.0522 ±0.0008
∆ density [g/cm3] |0.0256| |0.0287|
viscosity top phase [Pa*s] 3.66 ±0.04 3.6 ±0.08
viscosity bottom phase [Pa*s] 25.11 ±0.64 26.62 ±0.27
∆ viscosity [Pa*s] |21.45| |23.02|
7.2.6 Viscosity and Density Measurements
Viscosity measurements of the ATPS top and bottom phases were done using a RheoScope 1
(Thermo Fisher Scientific, Waltham, USA) equipped with a cone-plate sensor (diameter
50 mm, angle 1 °) at room temperature (shear stress: 0.1 - 10 Pa). Density was measured
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at room temperature using the density sensor MicroLDS (Integrated Sensing Systems, Inc.,
Ypsilanti, USA).
7.2.7 Cell Culture
The promyelocytic cell line HL-60 was purchased from CLS (Cell Lines Service, Eppelheim,
Germany). Cell culture reagents were purchased from Thermo Fisher Scientific, unless
otherwise stated. Culture media consisted of RPMI 1640 with GlutaMAX supplemented
with 15 (v/v) % fetal bovine serum (FBS), 1 (v/v) % sodium pyruvate, 1 (v/v) % non-
essential amino acids (NEAA), and 0.5 (v/v) % Penicillin/Streptomycin. Cells were
propagated at 37 °C in a 5 % CO2 incubator and split every 3 - 4 days to a concentration
of 1.5 x 105 cells/mL. All experiments were done with undifferentiated cells.
7.2.8 Cell Density Characterisation
Density gradient centrifugation using percoll is a well-known cell separation method. [38, 39,
228, 229] In this study, an alternated protocol was used for cell density analysis, where each
gradient step was prepared separately. The procedure is depicted in supplementary data
7.1. The gradient from 60 (v/v) % - 30 (v/v) % SIP (16 gradient steps) with a total step
volume of 650 µL was prepared in 1.5 mL reaction tubes (Eppendorf, Hamburg, Germany)
using a Tecan Freedom Evo® 200 liquid-handling station (LHS). Followed by a gentle,
manual overlaying of each gradient step with 100 µL cell suspension (8 x 106 cells/mL
in PBS supplemented with 1 mM EDTA). Reaction tubes were centrifuged for 20 min at
4000 g. Afterwards, a 30 µL sample was taken at the middle of the reaction tube and
diluted in 250 µL flow cytometry staining buffer. Cells were stained with the viability dye
7-AAD (Biolegend) according to the manufacturers instructions. Dead cells were gated
using heat inactivated controls (70 °C, 10 min). The flow cytometry analysis was performed
using an LSR Fortessa by BD Bioscience equipped with a BDTM high-throughput sampler
in combination with 96-well U bottom plates (BD FalconTM, Franklin Lakes, USA). A
defined sample volume of 100 µL was analysed and the following settings were applied:
sample flow rate: 3 µL/s, sample volume: 100 µL, mixing volume: 100 µL, mixing speed:
250 µL/s, four mixing cycles and a wash volume of 800 µL. Density measurements of the
SIP gradient steps was performed as described above.
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Supplementary Data 7.1: Overview of the cell density characterisation procedure. After SIP
step gradient perpetration in individual tubes, the SIP is gently overlaid with cell suspension.
By centrifugation the cells are distributed according to their density. Sampling is done in the
centre of the tube, diluted and live cell count is analysed by high-throughput flow cytometry
(HT-flow cytometry).
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7.2.9 Flow Cytometry Analysis
Flow cytometry was performed using a LSR Fortessa from BD Bioscience. Prior to analysis,
cells were resuspended in flow cytometry staining buffer and stained with the viability dye
7-AAD (Biolegend, San Diego, USA), according to the manufacturers instructions. Dead
cells were gated using heat inactivated controls (70 °C, 10 min).
7.3 Results and Discussion
In the present work, the power of 3D printing as a tool in early process development was
demonstrated. This was done based on a case study comprising a feasibility analysis for
the technology transfer of batch HTS data into a flow-through microfluidic process. The
basis of the project was the findings of a previous batch HT screening of cell partitioning
in ATPS. [60] Aiming at fast realization with low investment costs, 3D printing, as a tool
for equipment production, was used in combination with the DMAIC approach. Following,
the DMAIC stages are presented.
Define
In the define phase, the initial situation for the technology transfer was described. A general
concept was conceived, bottlenecks identified and solution approaches developed. Driving
force for the initiation of this technology transfer project was the successful identification of
ATPS suitable for cell partitioning of the model cell line HL-60 via batch HT screening. [60]
Two ATPS were selected for the technology transfer project. Both systems consisted
of 5 (w/w) % dextran (MW 500,000) and 4 (w/w) % PEG (MW 8,000), but differed
in salt supplementation. One ATPS was supplemented with 0.14 M NaCl and 0.01 M
NaPi (pH 6.6). Using this ATPS, HL-60 cells were found in the interphase in the batch
experiments. The second ATPS was supplemented with 0.11 M NaPi (pH 7.4), here, cells
were detected predominantly in the top phase (65 %) and in the interphase. [60]
First, a general microfluidic process set up was developed. (fig. 7.2) The cell suspension,
top and bottom phase were pumped individually in the microfluidic device with three in-
and outlets. Fluid velocities were chosen so that cells are focused at the interphase. To
analyse the cell partitioning between top and bottom phase, a video was recorded near
the outlet of the microfluidic device, using a microscope camera. Automatization of the
video analysis was realized via a snap shot analytic which enabled the estimation of cells
in top and bottom phase. Additionally, live cell rate were determined via flow cytometry
by analysing pooled samples as performed in the batch screening.
Aiming at fast implementation of the process set up with low initial investment costs, four
equipment bottlenecks were identified, while the key equipment (microscope, flow cytometer,
three piston pumps and molding tool for the microfluidic device production) were on hand.
Missing parts were a suitable camera integrated in the microscope, a replication master
for the production of the microfluidic device, a fractionator for sampling flow cytometry
probes and a frame for the microfluidic device. 3D models of the designed equipment are
shown in fig. 7.3. The Eclipse TS 100 microscope (Nikon GmbH, Düsseldorf, Germany)
was used for the process set up. The microscope has an integrated camera shaft, however,
a suitable camera was not available in the group. Hence, a low investment solution was
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designed, using an inexpensive GoPro Hero4 (GoPro, Inc., San Mateo, USA). The camera
was installed over the camera shaft using a designed and 3D printed camera mount. A
10 x magnification objective needed to be installed between the shaft and the camera.
The mount was printed using the desktop stereolithograpy 3D printer form 1+ (Formlabs
Inc.). (fig. 7.3 A) For the production of the microfluidic device the previously developed
molding tool was used. [168] However, the design for the replication master needed to be
Flow Cytometry 
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Top Phase
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Microfluidic 
Device
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Snap Shot 
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ATPS Batch 
Screening Results
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Figure 7.2: Overview of the developed process set up. Previously, cell partitioning in ATPS
was screened and optimal systems were chosen for the technology transfer into a microfluidic
process. Cell suspension, top and bottom phase is pumped individually in the microfluidic
device with three in- and outlets. During the process a video near the outlet is recorded using
the microscope camera. The video is then automatically analysed via the developed snap
shot analytic. The snap shot analytic enables the automatic estimation of cells in top and
bottom phase. Additionally, live cell rate is determined via flow cytometry by analysing pooled
samples.
customized. The molding tool is designed to produce microfluidic devices in a microtiter
plate format. Thus, the replication master was designed in microtiter plate format with
two identical microfluidic channels with 3 in- and outlets. The channels were designed as
described by Tsukamoto et al. [230] (channel length = 50 mm; channel width = 0.5 mm;
channel height = 0.1 mm). Since the replication master has a low resolution tolerance, it
was manufactured by Proform AG using a stereolithography approach. (fig. 7.3 B) For
sampling of probes for the flow cytometry analysis, a manual tailor-made fractionator was
designed and 3D printed by Sculpteo Pro. The fractionator was designed with optimal
installation space, leading to the opportunity to integrate it on the microscope table. The
three microfluidic outlets were connected, thus, samples could be fractionated in 1.5 mL
tubes. (fig. 7.3 C) To stabilize the flexible PDMS microfluidic device on the microscope
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table, a frame was designed and 3D printed by Sculpteo Pro. The frame consisted of
three parts, the bottom plate, an inlet- and outlet bridge. The in- and outlet tubing
were connected with the microfluidic device and stabilized via the bridges using fittings.
(fig. 7.3 D)
A B
C D
Figure 7.3: 3D models of designed equipment, needed for the process set up. A Camera
mount: small high performance camera was used and installed via mount using the existing
camera shaft. B Microfluidic replication master: the replication master was designed in a
microtiter plate format with two identical microfluidic channels with 3 in- and outlets. C
Manual tailor-made fractionator: the fractionator was designed with optimal installation space,
leading to the opportunity to integrate it on the microscope table. The three microfluidic outlets
were connected, samples can be fractionated in 1.5 mL tubes. D Frame for the microfluidic
device: the frame consists of three parts, the bottom plate, an outlet- and inlet bridge. The in-
and outlet tubing were connected with the microfluidic device and stabilized via the bridges
using fittings.
Besides the missing equipment parts, an automated video analysis tool needed to be
developed. Automatic counting of the cells in the top and bottom phase was realized
using a snapshot analytic in Matlab. The method is divided into two steps: (i) Detection
of the phase boundary using Hough-Transformation and (ii) Counting of the cells using
regional maximum. Per experiment, 30 snapshots of the video were taken over the duration
of the video in the same timely distance. For the detection of the phase boundary (i),
the images were first converted into a gray color image and inverted. The images were
opened morphologically and converted into a binary image based on a threshold. With
the Hough-Transformation the phase boundary could be located. The proceeding for
the automatic cell counting in a snap shot (ii) is shown in fig. 7.4. First, the image
area representing the microfluidic channel was selected. (fig. 7.4 A) Then, the image is
converted into a gray scale image. For the deblurring of the background a minimum filter
is used to find the darkest pixel in an area. (fig. 7.4 B) The deblurred image is further
converted into a binary image. (fig. 7.4 C) On the basis of the binary image the cells are
detected. The diameter of a cell of 6 pixels was used as a value for the separation into cells
or agglomerates. The distance between the objects were measured. If the distance was
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higher than the diameter the objects were declared as a single cell, otherwise the objects
were declared as agglomerates. The number of detected cells were then exported in a excel
file and detected cells were drawn into the original image. (fig. 7.4 D) Cells detected in
the bottom phase are indicated as blue, while agglomerates are marked as green. Only one
agglomerate (magenta) was detected in the top phase.
250 µm
A
B
C
D
Figure 7.4: Working steps of the snap shot analytic script for the automatic cell counting in
the bottom and top phase. A Selection of the essential image area, B usage of minimum filter
to find the darkest pixel in each region, C subtraction of the background, conversion into a
binary image, D original image with indicated detected cells and agglomerates. Cells detected
in bottom phase are indicated blue, agglomerates are indicated green. Agglomerates in top
phase are indicated magenta.
Measure
In the measure phase, the experimental set up was specified and the snap shot analytic was
validated. Subsequently, the conduction and evaluation of the cell partitioning experiments,
using the developed flow-through microfluidic set up, were realized.
First, the top and bottom phase was prepared as described earlier. Additionally, the HL-60
cell suspension was prepared with a final concentration of 20 x 106 cells/mL in 1 mM
EDTA in PBS. Each fluid was pumped individually using 3 Cetoni NeMESYS syringe
pumps (cetoni GmbH). For the top and bottom phase, the pumps were equipped with
a 500 µL syringe, while the pump for the cell suspension was equipped with a 100 µL
syringe. The top phase was introduced into the microfluidic device via the upper inlet and
the bottom phase via the bottom inlet. The cell suspension was introduced in the middle
inlet. The cells were focused at the interphase by applying suitable velocity patterns for
the three fluids. In general, two velocity patterns were evaluated as described in table 7.2.
The TS 100 microscope (Nikon GmbH) with the integrated GoPro Hero4 camera (GoPro,
Inc.) was used for video recording of the microfluidic channel outlet. The following camera
settings were applied: 120 fps, field of view = narrow. Three videos were taken after 5 min,
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each 30 s (n = 3; sample size = 30 snap shots; total = 3 x 30 = 90 snap shots). The videos
were analysed using the described snap shot analytic. Additionally, fractionated samples
were pooled and live cell ratio was evaluated using the earlier described flow cytometry
method (live/dead staining using 7-AAD).
Table 7.2: Velocity patterns of the experimental procedure
Velocity pattern NaCl NaPi
TP / cell suspension / BP*
fast [µL/s] 0.25 / 0.02 / 0.055 0.25 / 0.02 / 0.055
slow [µL/s] 0.1 / 0.01 / 0.02 0.02 / 0.0004 / 0.0015
*TP = top phase; BP = bottom phase
The implementation of the developed experimental set up was confirmed by a proof of
concept experiment. (fig. 7.5) Microscopic pictures of the microfluidic device inlet, the
centre of the channel and the outlet were taken. Cells were focused successfully at the
channel inlet branch and partitioned in the bottom phase channel downstream. Just in
front of the channel outlet, a video was taken and analysed via the developed snap shot
analytic described earlier. Using this video-based tool cells were detected and counted in
top and bottom phase individually, additionally, cell agglomerates were excluded. Fraction-
ing of flow cytometry probes could be realized exactly as planned using the 3D printed
fractionation device. Accordingly, the implementation of the process set up was successful.
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Figure 7.5: Proof of concept. Pictures of the microfluidic device inlet, the centre of the
channel and the outlet. Top phase, cell suspension and bottom phase were pumped individually.
The velocities are chosen that the cells are focused at the interphase and channel downstream
partitioned in the bottom phase (centre picture). Just before the outlet, a video was taken and
analysed via the developed snap shot analytic. Using this video-based tool, cells are detected
and counted in top and bottom phase individually, additionally, cell agglomerates are excluded.
Live/dead analysis using flow cytometry in combination with 7-AAD staining was done with
the pooled sample.
Subsequently, the snap shot analytic was evaluated by analysing the cell detection hit
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ratio. For this purpose a comparison of manual cell counting and the automatic snap shot
analytic was performed. Cell counting of 20 snap shots was done by 3 different individuals
in comparison to the developed snap shot analytic. Hit ratio (HR) calculation was done as
described in eq. (7.1):
HR = counts
actual counts
(7.1)
The ranges of the hit ratio determination is shown in fig. 7.6. Manual counting performed
by three individuals showed overestimation (HR > 1) as well as underestimation (HR < 1)
of cells and a wide range of the hit ratio. In contrast, the snap shot analytic showed only a
slight underestimation of cells with a narrow hit ratio range. Thus, the developed snap shot
analytic can be implemented in the process set up. The advantages of this approach (e.g.
economy of time, objective cell counting and small range) outweigh the small systematic
error of cell underestimation.
0.8 0.9 1 1.1 1.2 1.3 1.4
automatic
individual 3
individual 2
individual 1
HR
Figure 7.6: Cell detection hit rate (HR) ranges of three individuals (manual counting) and
the automatic detection via the developed snap shot analytic. The hit ranges were calculated
using 20 video frames.
Following the successful implementation of the developed flow-through microfluidic process
set up, cell partitioning experiments were performed. Evaluation was done concerning
transferability of batch data. Experiments were performed with two ATPS differing in
the salt supplementation (table 7.1) and two velocity profiles (table 7.2). Shown is the
total count of 3 x 30 = 90 snap shots and the partitioning coefficient (q) in top and bottom
phase as time series plot for each experiment (fig. 7.7). Partitioning coefficient (q) is
calculated according to eq. (7.2):
qx =
cell count in x
total cell count
(7.2)
x = top or bottom phase
In green is shown qtop and in blue qbottom, while the orange line represents the over-
all mean (n = 90). Raw data as well as the mean of each sample with 30 snap shots
(n = 30) is plotted for both total cell count and q. The results for the experiment with
NaCl supplemented ATPS with the fast velocity profile is shown in fig. 7.7 A & C.
No trend in total cell counts were observed, however, the total mean (3 x 30 = 90) was
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relatively low with 9.9 cells per snap shot (fig. 7.7 A). Cells predominantly partitioned in
the bottom phase with a total qbottom of 0.99 (fig. 7.7 C), while in batch experiments
cells predominantly were found in the interphase. [60] Thus, results were not in compliance
with the batch data. Total cell counts were slightly higher with a total mean (3 x 30 = 90)
of 17.13 cells per snap shot for the experiment with NaPi supplemented ATPS with the fast
velocity profile. A decrease in total cell number was observed (fig. 7.7 B). Additionally, a
fluctuation of the partitioning coefficient could be observed with a total qbottom of 0.66.
In contrast, batch data showed a predominantly cell partitioning in the top phase (65 %)
(fig. 7.7 D). [60]
The results for the experiment with NaCl supplemented ATPS with the slow velocity profile
is shown in fig. 7.7 E & G. A slight decrease of total cell counts were observed with a
total mean (3 x 30 = 90) of 21.08 cells per snap shot (fig. 7.7 E). Cells also predominantly
partitioned in the bottom phase with a total qbottom of 0.88 (fig. 7.7 G). Total qbottom
decreased 0.11 in comparison with the fast velocity pattern experiment. Much higher
total cell counts were observed for the experiment with NaPi supplemented ATPS with
the slow velocity profile with a total mean (3 x 30 = 90) of 58.81 cells per snap shot, in
addition, a decrease in total cell count was observed (fig. 7.7 F). A decrease in qbottom
and consequently an increase in qtop was also observed (qbottom = 0.67) (fig. 7.7 H).
7.3 Results and Discussion 67
raw data
mean (n = 30)
30 60 90
0
20
40
0
20
40
snap shots
to
ta
l 
c
e
ll 
c
o
u
n
ts
A
q (top / bottom)
q
mean
 (n = 30)
30 60 90
0
0.5
1
0
0.5
1
snap shots
q
u
o
ti
e
n
t 
(q
)
C
raw data
mean (n = 30)
30 60 90
0
20
40
0
20
40
snap shots
to
ta
l 
c
e
ll 
c
o
u
n
ts
B
q (top / bottom)
q
mean
 (n = 30)
30 60 90
0
0.5
1
0
0.5
1
snap shots
q
u
o
ti
e
n
t 
(q
)
D
raw data
mean (n = 30)
30 60 90
0
20
40
0
20
40
snap shots
to
ta
l 
c
e
ll 
c
o
u
n
ts
E
q (top / bottom)
q
mean
 (n = 30)
30 60 90
0
0.5
1
0
0.5
1
snap shots
q
u
o
ti
e
n
t 
(q
)
G
raw data
mean (n = 30)
30 60 90
0
100
200
0
100
200
snap shots
to
ta
l 
c
e
ll 
c
o
u
n
ts
F
q (top / bottom)
q
mean
 (n = 30)
30 60 90
0
0.5
1
0
0.5
1
snap shots
q
u
o
ti
e
n
t 
(q
)
H
NaCl NaPi
fl
o
w
 p
a
tt
e
rn
: 
fa
s
t
fl
o
w
 p
a
tt
e
rn
: 
s
lo
w
68 Chapter 7
Figure 7.7: Evaluation of the influence of salt supplementation in ATPS on cell partitioning
using the developed flow-through microfluidic process set up. Shown is the total count of
3 x 30 = 90 snap shots and the partitioning coefficient (q) in top and bottom phase as time
series plot. On the left side is shown the results of the experiments using ATPS supplemented
with NaCl and on the right side the results of the NaPi supplemented ATPS. Evaluated were
two different velocity profiles: fast (top) and slow (bottom). A Time series plot of the total
cell count of the cell partitioning experiment with NaCl supplemented ATPS applying the
fast velocity pattern. top: plotted raw date, bottom: mean of sample (sample = 3, n =
30). The orange line represents the overall mean (n = 90). B Time series plot of the total
cell count of the cell partitioning experiment with NaPi supplemented ATPS applying the
fast velocity pattern. top: plotted raw date, bottom: mean of sample (sample = 3, n = 30).
The orange line represents the overall mean (n = 90). C Time series plot of the partitioning
coefficient (q) in top (green) and bottom (blue) phase of the cell partitioning experiment
with NaCl supplemented ATPS applying the fast velocity pattern. top: plotted raw date,
bottom: mean of sample (sample = 3, n = 30). The orange line represents the overall mean
(n = 90). D Time series plot of the partitioning coefficient (q) in top (green) and bottom
(blue) phase of the cell partitioning experiment with NaPi supplemented ATPS applying the
fast velocity pattern. top: plotted raw date, bottom: mean of sample (sample = 3, n =
30). The orange line represents the overall mean (n = 90). E Time series plot of the total
cell count of the cell partitioning experiment with NaCl supplemented ATPS applying the
slow velocity pattern. top: plotted raw date, bottom: mean of sample (sample = 3, n =
30). The orange line represents the overall mean (n = 90). F Time series plot of the total
cell count of the cell partitioning experiment with NaPi supplemented ATPS applying the
slow velocity pattern. top: plotted raw date, bottom: mean of sample (sample = 3, n = 30).
The orange line represents the overall mean (n = 90). G Time series plot of the partitioning
coefficient (q) in top (green) and bottom (blue) phase of the cell partitioning experiment
with NaCl supplemented ATPS applying the slow velocity pattern. top: plotted raw date,
bottom: mean of sample (sample = 3, n = 30). The orange line represents the overall mean
(n = 90). H Time series plot of the partitioning coefficient (q) in top (green) and bottom
(blue) phase of the cell partitioning experiment with NaPi supplemented ATPS applying the
slow velocity pattern. top: plotted raw date, bottom: mean of sample (sample = 3, n = 30).
The orange line represents the overall mean (n = 90).
In addition to the cell partitioning behaviour, cell viability is a critical process parameter.
The evaluation of the process influence on cell viability was done using flow cytometry
analysis in combination with a 7-AAD staining. The results are shown in fig. 7.8. A
cell viability loss could be observed for all experiments. Higher cell viability loss was
observed for fast velocity profiles (∼7 %) in comparison to slow velocity profile experiments.
However, cell viability loss was higher for ATPS supplemented with NaCl (fast = 29.11;
slow = 21.7) than for NaPi (fast = 23.3; slow = 16.33) supplementation.
During the measurement phase a general problem with cell aggregation in tubing between
pump and microfluidic device was observed. If visible cell agglomeration was acknowledged,
the experiment was prematurely terminated. For this reason, experiments were performed if
a variation in cell number per snap shot could be seen in data before the visual observation.
Examples of trend in total cell counts per snap shots are shown in fig. 7.9. Depicted
are the time series plots of two experiments with the same experimental set up. Both
experiments were done with NaPi supplemented ATPS and the slow velocity pattern.
However, an increase of total cell number was observed (fig. 7.9 A) as well as a decrease
7.3 Results and Discussion 69
in cell number (fig. 7.9 B). Consequently, trends were also observed for the partitioning
coefficients. Lower total cell number per snap shot leads to a convergence of qbottom and
qtop (fig. 7.9 C & D).
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Figure 7.8: Evaluation of cell viability loss caused by microfluidic flow-through cell partitioning
experiments. Flow cytometry analysis in combination with 7-AAD staining was performed.
Tested were two ATPS differing in their salt supplementation (NaCl/NaPi) and two velocity
patterns (fast/slow).
70 Chapter 7
raw data
mean (n = 30)
30 60 90
0
100
200
0
100
200
snap shots
to
ta
l 
c
e
ll 
c
o
u
n
ts
A
q (top / bottom)
q
mean
 (n = 30)
30 60 90
0
0.5
1
0
0.5
1
snap shots
q
u
o
ti
e
n
t 
(q
)
C
raw data
mean (n = 30)
30 60 90
0
100
200
0
100
200
snap shots
to
ta
l 
c
e
ll 
c
o
u
n
ts
B
q (top / bottom)
q
mean
 (n = 30)
30 60 90
0
0.5
1
0
0.5
1
snap shots
q
u
o
ti
e
n
t 
(q
)
D
Figure 7.9: Trends in total cell number for experiments with ATPS supplemented with NaPi
and a slow velocity pattern. Shown is the total count of 3 x 30 = 90 snap shots and the
partitioning coefficient (q) in top and bottom phase as time series plot. A Increase in total
cell number. B Decrease in total cell number. C Partitioning coefficient for increasing total
cell number. D Partitioning coefficient for decreasing total cell number.
Analyse
In the analyse phase an evaluation of the collected data was done regarding poor process
performance. The successful implementation of the developed process set up could be
confirmed through the proof of concept experiment. Using the rapid prototyping approach,
missing equipment was identified, designed, 3D printed and implemented inexpensively
and without any delay. Thus, 3D printing is an excellent tool for process development with
the opportunity to optimise the set up or adapt it to new applications.
Continuous cell partitioning in ATPS using a microfluidic approach has been described
in literature earlier. [230–234] However, in contrast to the literature three mayor issues,
namely cell viability loss, batch data incongruity and trends in cell load, were identified in
this work. The brainstorming technique was applied to identify underlying mechanisms,
leading to the issues. Groundwork for the brainstormed reasons were a systematic process
consideration and the process understanding. The knowledge gained is summarized in
fig. 7.10 as fishbone diagram. Cell viability is a critical cell parameter which is known to
be compromised by processing cells in a flow system. As indicated by the flow cytometry
results, slower velocities might lead to a less pronounced loss of cell viability. [235–239]
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Fluid velocities are also considered to be the major cause for the disagreement with the
batch data. [231] Both systems show a more pronounced cell partitioning in the bottom
phase independent of salt supplementation. Whereas, the batch HTS data shows a
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Figure 7.10: Fishbone-diagram: relationships between process parameter and occurring
issues.
more pronounced cell partitioning into the top phase when supplemented with NaPi and
adsorption to the interphase in NaCl supplemented ATPS. Thus, fluid velocities of the
phases are identified as critical process parameter (CPP) influencing multiple aspects of the
process and should be investigated in more detail in the improve phase. The variation of
cell loading represents a major practical issue. In addition, the results indicate an influence
of cell loading on cell partitioning. Both increase and decrease of cells per snap shot (cell
load) were observed. The observation of visible cell agglomerates in the tubing supports
the theory of sedimentation/agglomeration of cells in the tubing. Cell sedimentation/ag-
glomeration theoretically leads to a decrease in cell load, while introducing accumulated
cells into the microfluidic device leads to a drastic increase in cell load.
Outlook Improve & Control
Two critical process parameters were identified in the analyse phase, namely, fluid velocities
and cell load. Subsequently, optimisation approaches were developed. As discussed
earlier, flow velocity studies should be performed to evaluate optimal process parameters.
Additionally, the fluctuating cell load must be addressed. Yamada et al. [231] proposed
an alternative channel design with only two in- and outlets to do so. Cells are suspended
in one phase and focused via a pinched region. Changing the channel design presents
no problem, since the replication master was part of the rapid prototyping approach.
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Using the proposed two-channel design in combination with density optimized ATPS, cell
sedimentation could be prevented. Cell sedimentation becomes obsolete when cells are
suspended in fluids with higher or same density than cells. Thus, cell density was evaluated,
as described in the supplementary data 7.1, in addition to ATPS characterization
(table 7.1). The results are summarized in fig. 7.11 . The main cell peak were found
between 1.05 1.07 g/cm3. Top phase of both systems and the bottom phase of the NaCl
supplemented ATPS are not suitable since they display density < 1.03 g/cm3. Bottom
phase of the NaPi supplemented ATPS might be suitable with 1.0522 ± 0.0008 g/cm3,
however, density optimization could be done using the previously described density HTS
platform. [177] Changing ATPS composition towards higher fluid density, phases will
probably increase the phase viscosity as well. Higher density and viscosity is not favourable
concerning cell stress in flow systems. For this reason, the influence of phase properties in
combination with phase velocities should be investigated in a further study.
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Figure 7.11: Cell density analysis using a percoll step gradient approach (n = 8). Cell counts
are shown over density. Additionally, densities of top and bottom phase of the used ATPS
supplemented with NaCl or NaPi are shown. PBS density is shown as reference. TP = top
phase; BP = bottom phase.
7.4 Conclusions
A process set up for cell partitioning in ATPS using a microfluidic flow-through approach
was developed. The project realization was done within the DMAIC framework using AM
technologies as tool for manufacturing of missing and tailor-made equipment, needed for
the implementation of the process set up. The developed and implemented set up enables
cell partitioning in ATPS in a microfluidic flow-through device. Cell suspension, top and
bottom phase are individually pumped into a microfluidic device with three in and outlets.
Cells are focused at the interphase near the inlet and partition channel downstream. Cell
partitioning monitoring is done using a microscopic camera and a developed snap shot
analytic for automated cell determination in top and bottom phase. For the evaluation of
the critical cell parameter viability, samples are taken at the outlet and analysed via flow
cytometry.
In the define phase missing equipment was identified, designed and manufactured using
different AM technologies. Aiming low initial investment costs, only an inexpensive desktop
3D printer was used in house. Whenever the printer resolution was not sufficient, the
3D printing process was outsourced to service contractors. The collected data in the
measurement phase was used in the analyse phase for the root-cause-investigation since
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poor process performance compared to batch experiments was detected, two main factors
were identified. Cells seemed to sediment and aggregate in tubing prior to the entry into the
microfluidic device, leading to fluctuating cell loading. Additionally, higher fluid velocity
has a negative influence on cell partitioning behaviour and cell viability. To improve the
process performance a change in microfluidic channel design is suggested in combination
with a more detailed fluid velocity study. Reducing the number of in- and outlets enables
the suspension of cells in the phase with lower partitioning coefficient. Due to higher
phase density, cell sedimentation/agglomeration is inhibited while cells can be focused via
a pinched region enabling cell partitioning channel downstream.
Finally, we demonstrated that the AM approach is a powerful tool for process development
increasing implementation creativity and reducing project cycle time when combined with a
structured approach like the DMAIC framework. We expect that 3D printing will facilitate
faster, cheaper, and more creative process development in the biotechnology environment.
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Abstract
The continuous availability of cells with defined cell characteristics represents a crucial issue
in the biopharmaceutical and cell therapy industry. Here, development of cell banks with a
long-term stability is essential and ensured by a cryopreservation strategy. The strategy
needs to be optimized for each cell application individually and usually comprises controlled
freezing, storage at ultra-low temperature, and fast thawing of cells. This approach is
implemented by the development of master and working cell banks. Currently, empirical
cryopreservation strategy development is standard but a knowledge based approach would
be highly advantageous.
In this article, we report the development of a video-based tool for the characterisation of
freezing and thawing behaviour in cryopreservation process to enable a more knowledge
based cryopreservation process development. A successful tool validation was performed
with a model cryopreservation process for the β-cell line INS-1E. Performance was evaluated
for two working volumes (1.0 mL and 2.0 mL), based on freezing-thawing rates (20 °C
to -80 °C) and cell recovery and increase of biomass, to determine tool flexibility and
practicality. Evaluation confirmed flexibility by correctly identifying a delay in freezing
and thawing for the larger working volume. Further more, a decrease in cell recovery from
0.94 (± 0.14) % using 1.0 mL working volume to 0.61 (± 0.05) % using a 2.0 mL working
volume displays tool practicality.
The video-based tool proposed in this study presents a powerful tool for cell specific
optimisation of cryopreservation protocols. This can facilitate faster and more knowledge
based cryopreservation process development.
Keywords: automated image processing, controlled freezing, cryopreservation, process
development tool, thawing
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8.1 Introduction
In the upcoming era of cell therapy, any bioprocess step dealing with cells needs to be
challenged and potentially reengineered to serve large scale operations. One of the unit
operations used is the so-called cryopreservation step. Cryopreservation is an essential
technology for long-term storage of eukaryotic cells and is applied when continuous access
of cells with consistent cell characteristics, concerning genetic and metabolic changes, is
crucial. [72] This includes cell line maintenance for routine cell culture applications [72],
biopharmaceutical production [74, 75], reproductive medicine [71, 76] and cell therapy
in the field of regenerative medicine [1, 73, 84]. Usually, the concept of cell banking is
applied to manage the robust and controlled supply of cells with defined characteristics.
This includes cell storage at ultra-low temperatures in a controlled and well defined pro-
cess environment, while monitoring the critical cell characteristics. [1, 72, 74, 75, 77, 78]
Ultra-low temperature storage stops cell metabolism completely. However, freezing and
thawing induces severe cell stress because of intra- and extracellular ice formation as well
as osmotic effects. In turn, this stress leads to cell membrane damages and, ultimate, to
cell death. [72, 79] Therefore, cryopreservation process optimisation is necessary for the
development of an effective cell bank displaying high post-thaw cell viability.
Process parameters influencing post-thaw cell viability are well described in literature. [71,
72, 74, 75, 78, 80, 81] The list of critical parameter includes cell loading [80], cell characteris-
tics (e.g. suspension cells, monolayer or colony growth) [78, 81, 240], cryoprotectant agents
and agent concentration [71, 87], process volume [73, 75, 77, 82, 83], and freezing/thawing
rates [73, 74, 77, 84–86]. Additionally, a controlled freezing process is preferable to ensure
cell viability and process robustness. [73, 74, 77, 81, 84, 89] It is reported that slow cooling
rates in combination with dimethyl sulfoxide (DMSO) as cryoprotectant and fast thawing
results in relatively good recovery for a number of mammalian cell lines [72, 74, 75].
However, process optimization is required for each cell line individually, as cell behaviour
differs between cell lines. [72, 74, 75, 86]
Complex interplay between process parameters, such as the effect of cryoprotectant agents
or sample volume on freezing and cooling rates, and their combined effect on process per-
formance hinders the advancement of cell-specific cryopreservation strategy development.
A tool for systematic and empiric screening freezing and thawing behaviour would be
beneficial but is currently missing. [71, 72, 74, 75, 241]
Digital image processing is widely used for optical sample analysis. In life science re-
search it has been applied to crystallisation process development and monitoring [242–244],
quantification of cell growth [245–247], analysis of neuronal calcium signaling [248], cell
migration analysis [249], and blastocyst stage prediction of human embryo development [76].
Digital image processing has also been used in cryopreservation process development to
monitor osmotic cell response [250] and to determine nucleation temperature during cryop-
reservation [79] as a function of different process parameters such as cryoprotectant agent
types. This indicates applicability of digital image processing for cryopresentation process
development, but expensive cryomicroscopy equipment limits general usability [79, 250].
In this study, we report the development and experimental validation of a video analysis
tool for the characterisation of cryopreservation sample freezing and thawing behaviour. To
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improve general usability, off-the-shelf imaging equipment and entry-level image processing
algorithms were used. This resulted in an automated image-based tool for the detection of
the frozen over state and complete thawing of samples. A case study with the β-cell line
INS-1E and DMSO as a cryoprotectant was used to validate the performance. This was
performed with a working volume of 1.0 mL and 2.0 mL to demonsrate flexibility of the
developed tool. Subsequently, intact viable cell monitoring during the cryopreservation
process was performed to determine the influence of freeze and thaw behaviour on cell
recovery and proliferation as a function of increasing working volume. The results obtained
by the proposed digital imaging tool were in good agreement with literature values, which
shows its applicability for cryopreservation strategy development.
8.2 Materials and Methods
8.2.1 Stock Solutions
Cell culture reagents were purchased from Thermo Fisher Scientific (Waltham, USA),
unless otherwise stated. Culture media consisted of RPMI 1640 with GlutaMAX supple-
mented with 10 (v/v) % FBS, 1 (v/v) % sodium pyruvate, 1 (v/v) % Penicillin / Strepto-
mycin, 10 mM HEPES, 2 mM L-Glutamine and 50 µM β-mercaptoethanol (Sigma-Aldrich,
St. Louis, USA). Cryomedia consisted of RPMI 1640 with GlutaMAX supplemented
with 20 (v/v) % FBS, 1 (v/v) % sodium pyruvate, 10 (v/v) % DMSO (Sigma-Aldrich),
1 (v/v) % Penicillin / Streptomycin, 10 mM HEPES, 2 mM L-Glutamine and 50 µM
β-mercaptoethanol (Sigma-Aldrich). Both media were stored at 8 °C. Phosphate-buffered
saline was purchased from Thermo Fisher Scientific and stored at room temperature. All
stock solutions were kept under sterile conditions.
8.2.2 Software and Data Processing
The software iTools Version 9.57.11 (Eurotherm, Worthing, UK) was used to control the
EF600M 105 & 106. For data storage Excel 2013 (Microsoft, Redmond, WA, USA) was
used. MATLAB R2015a (The MathWorks, Inc., Natick, USA) was used for data evaluation
and visualization.
8.2.3 Controlled Freezing and Thawing
Freezing evaluation studies were preformed with cryomedia and a working volume of 1.0 mL
and 2.0 mL. An identical freezing profile (table 8.1) was applied for all runs. For experi-
ments with 1.0 mL working volume, an EF600M 106 (55 x 1.8 mL cryovials, 1.0 mL max.
fill; Grant Instruments, Cambridgeshire, UK) and 1.8 mL cryovials (VWR International
GmbH, Bruchsal, Germany; height (h) = 40 mm, diameter (d) = 12 mm, h/d = 3.33,
u-bottom ) were used. Experiments with 2.0 mL working volume were performed using
an EF600M 105 (1 x SBS microplate; Grant Instruments) in combination with a tailored
adapter for tissue cryovials (FluidiX Ltd, Cheshire, UK; h = 26 mm, d = 15 mm, h/d = 1.73,
flat-bottom). The adapter was designed according to a 24 well SBS microplate (fig. 8.1).
Both instruments were controlled via iTools Version 9.57.11 (Eurotherm). Thawing was
performed, for both working volumes, in 37 °C pre-warmed water bath.
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Table 8.1: Freezing profile applied to a working volume of 1 and 2 mL
Increments Temperature
start temp. 20 °C
cool from 20 to - 5 °C at 2 °C min-1
cool from - 5 °to - 7 °C at 1 °C min-1
hold at - 7 °C for 10 min
cool from - 7 °to - 80 °C at 1 °C min-1
hold at - 80 °C
To monitor freezing/thawing behaviour, all runs were preformed with opened cryovials.
Video monitoring was done for all freezing and thawing runs using a GoPro Hero4 (GoPro,
Inc., San Mateo, USA) controlled via the GoPro App version 2.6.3.312 (GoPro, Inc.) and
a Samsung Galaxy Note Pro SM-P900 (Samsung, Seoul, South Korea). Following camera
settings were applied: field of view: narrow; resolution: 1080 p; frames per second: 25.
Figure 8.1: Schematic illustration of the tailored tissue vial adapter placed on the EF600M
105 cryo-head. The adapter design is based on a 24 well SBS microplate, three tissue vials are
depicted.
8.2.4 Video Analysis
An automated image-based method was developed to detect the time point where the
samples were frozen over. It was realised using a snapshot analytic method in MATLAB,
which was divided into two steps: (i) pre-processing and (ii) analysis of the pixel intensity
values to detect the frozen over state.
Pre-processing (i) was necessary to locate the vials in the image. As a result of design
differences of the two cryo devices, two different vial area detection methods were employed.
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The adapter for the EF600M 105 (2 mL vials) was designed according to the 24 well format
(SBS microplate). Resulting in 6 vials in x-direction and 4 vials in y-direction. A mask
with 24 circles with a diameter of 90 pixels was generated and automatically drawn onto
the image. Mask generation was done by user-defining the centre of the vial at the top
end on the left. The same was done for the centre of the vial at the bottom end on the
right. The distance between the two markers was calculated in the x- and y-direction. The
distance between the two vials was then divided by the number of vials in the appropriate
direction. The design of the EF600M 106 (1 mL vials) is based on a cubic close packing
of 55 vials, where each vial was represented by a circle with a diameter of 60 pixels.The
centre of each analysed vial was user-defined. Circles, with a diameter of 60 pixels, were
subsequently drawn onto the image. For the detection of the frozen over state (ii) one
snapshot per second was taken and analysed. For each vial and snapshot, the mean pixel
intensity of the defined image area was calculated with the function mean available in
MATLAB and plotted over time (mean pixel intensity curve). The mean pixel intensity was
chosen because it correlates with cristallization activity during freezing. A floating mean
value filter (20 values) was applied to smooth data. With the smoothed data, the inflection
point was determined. The inflection point was defined as the slope maximum of the mean
pixel intensity curve. The inflection point was used as reference point for determination of
start and end point of cryomedium water cristallization. Crystallization activity is low at
the beginning and end of sample freezing and was defined as 1 % difference to the inflection
point slope. Crystallisation started when the difference value was < 1 % the difference
value of the inflection point to the left. The sample is frozen over (end of crystallisation)
was reached when the difference value is < 1 % the difference value of the inflection point
to the right. In some cases a spline interpolation needed to be done before the slope was
calculated. For example when a small rotating ice block was observed in a vial during
visual examination of the video. Here, a small artificial peak in mean pixel intensity was
observed, which was automatically detected and the peak width was calculated. The spline
interpolation was then performed for the peak width with a margin of 20 values before
and after the peak gap. The (i) pre-processing and freezing analysis (ii) is shown in figure
fig. 8.2 A & B.
A similar pre-processing (i) appraoch was used to determine the thawed state time point.
For analysis (ii), the mean intensity value of the defined image area for each vial and
snap-shot was also calculated and plotted over time (mean pixel intensity curve). The curve
was then smoothed with a floating mean value filter (20 values) and slope was calculated.
Endpoint of thawing was assumed when the slope of the curve is < 0.02 unit, since the
curves did not show an characteristic inflection point. The mean pixel intensity plot for
thawing is shown in fig. 8.2 C.
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Figure 8.2: Video analysis example of 2 mL vials for freezing and thawing. A Pre-processing
of snap-shot data. Mask with 24 circles was automatically drawn into the snap-shot, each circle
represents the image area of one vial. B Freezing pixel intensity curve of one well. Depicted is
the calculated mean pixel intensity, smoothed with a floating mean value filter (20 values),
over time. cyan: freezing start point; green: inflection point (slope maximum); magenta:
freezing end point. The threshold for the start and end point of water crystallisation was
defined as a 1 % difference to the inflection point. C Thawing pixel intensity curve. Depicted
is the calculated mean pixel intensity, smoothed with a floating mean value filter (20 values),
over time. magenta: thawing end point. Thawing end point was defined for a curve slope
< 0.02.
8.2.5 Cell Culture
The study was preformed with the β-model cell line INS-1E [198], kindly provided by Prof.
Maechler from the Department of Cell Physiology and Metabolism at the University of
Geneva Medical Centre, Switzerland. Cells were cultivated in culture media at 37 °C in a
humidified incubator with 5 % CO2. Cell culture was split every 7 days to a concentration
of 6.6 x 104 cells/cm2, media was exchanged after 3 days.
8.2.6 Cell Freezing
Cell freezing was perfomed according to the freezing evaluation study using the EF600M
(105 and 106) and applying an identical freezing profile (table 8.1). Cells were suspended
in cryomedium to a final concentration of 6 x 106 cells/mL and directly transfered to the
EF600M (105 or 106). All runs were performed under sterile conditions and cryovials were
stored after finishing the freezing profile (table 8.1) at - 80 °C for 24 h and transferred
to - 196 °C (Arpege 70, Air Liquide Medical GmbH, Düsseldorf, Germany) for 7 days.
Transportation was done using a pre-cooled aluminium block (- 80 °C) for both working
volumes (1.0 mL and 2.0 mL).
8.2.7 Cell Thawing
After storage of the cryosamples for 7 days at - 196 °C, thawing was performed in a 37 °C
pre-warmed water bath. Transportation from the storage tank to the water bath was
done using a pre-cooled aluminium block (- 80 °C) for both working volumes (1.0 mL
and 2.0 mL). After thawing, cell suspension was quickly transferred in 20 °C pre-warmed
culturemedia (1:20) and incubated for 5 min at room temperature (RT), followed by a
washing step with PBS (1:10). Finally, cells were resuspended in 7 mL culturmedia and
transferred in a culture flask with an area of 25 cm2. Cells were cultivated for 7 days, with
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a media exchange after 3 days. Intact viable cell concentration was estimated by trypan
blue exclusion direct after thawing and after 7 days of cultivation by haemocytometer
counting.
8.2.8 Statistical Data Analysis
Mean comparison was performed by applying an unequal variances Students t-test, since
unequal variances were asserted by an F -test.
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8.3 Results
We developed a video analysis-based tool for the characterisation of freezing and thawing
behaviour in cell cryopreservation processes. Briefly, video data was acquired during freez-
ing and thawing and oﬄine image processing was used to determine the end point of sample
freezing or thawing. The development was done with a model process where cells were
suspended in cryo-media, followed by a controlled freezing step to - 80 °C. After a 24 hour
incubation at - 80 °C, samples were stored for 7 days at - 196 °C. Subsequently, samples
were thawed and the cell were cultivated for 7 days. Additionally, samples were taken
before and after freezing and after cultivation to monitor intact viable cells. An overview
of the cryopreservation process is shown in fig. 8.3. Cryopreservation was preformed with
1.0 mL and 2.0 mL working volume to demonstrate the versatility of the developed tool
and sample volume influence on cell recovery and proliferation.
cell suspension 
in cryo-media
controlled 
freezing
thawing cultivation
(7 days)
storage
-196 ˚C
Cell Viability Monitoring
before 
freezing
after 
thawing
after 
cultivation
Cryopreservation Process
Video Analysis-based Tool
freezing thawing
video image 
processing
end point 
determination
Figure 8.3: Overview of the cell cryopreservation process. Cells were suspended in cryo-media
and directly frozen to - 80 °C in a controlled manner. After 24 h at - 80 °C the cryo-samples
were transferred in the storage tank (- 196 °C). After 7 days of storage, the samples were
thawed and cultivated for 7 days. Samples for intact viable cell monitoring were taken before
freezing, after thawing and after cultivation. Additionally, the freezing and thawing process
steps were analyzed using the developed video analysis-based tool. Here, a video was taken
during freezing and thawing. The video was then analysed via automatic image processing to
determine the end point of the freezing and thawing of the samples.
Exemplarily, video analysis is shown in fig. 8.2 for a 2.0 mL working volume freezing
and thawing. Pre-processing shown in fig. 8.2 A was performed, for both freezing and
thawing videos, to define the image area for each vial. Pre-processing was followed by
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mean pixel intensity calculation for the image area of each vial. In fig. 8.2 B, smoothed
(floating mean value filter, 20 values) mean pixel intensity data is plotted over time during
freezing. Depicted is the freezing start point (cyan), the curve inflection point (green)
and the freezing end point (magenta). The threshold for the start and end point of water
crystallisation was defined as a 1 % difference compared to the inflection point. fig. 8.2 C
depicts the mean pixel intensity over time during thawing, where the thawing end point
(i.e., curve slope of less than 0.02) is highlighted in magenta.
The results of characterisation of the freezing and thawing behaviour are shown in fig. 8.4.
Freezing was performed in a controlled manner for both working volumes as described in
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Figure 8.4: Freezing study results with 1 and 2 mL working volume. A Freezing profile from
20 °C to -80 °C as described in table 8.1 (royal blue curve). Additionally, the mean freezing
start and end point for both working volumes are depicted as bars. cyan: 1 mL working
volume; blue: 2 mL working volume B Bar chart of the calculated freezing end temperatures
for 1 and 2 mL working volume.
table 8.1. In fig. 8.4 A, the employed freezing profile from 20 °C to - 80 °C is shown in
royal blue, while the total sample freezing time is shown as vertical bars. The left border of
the vertical bar represents the mean start freezing time and the right border of the vertical
bar represents the mean end freezing point (n = 9). Freezing data for 1.0 mL working
volume and 2.0 mL working volume is shown in cyan and blue, repsectively. Comparing
the freezing behaviour of the two working volumes in fig. 8.4, freezing starts earlier for
1.0 mL working volume compared to 2.0 mL. Additionally, the total freezing time is also
8.3 Results 89
shorter for 1 mL working volume than 2.0 mL working volume samples. With the video
timestamp and freezing profile tracking, mean crystallization end temperature could be
determined. fig. 8.4 B shows that samples with 1.0 mL working volume are frozen over at
- 26.7 °C (± 3.7), while 2.0 mL samples reach the frozen over state later at - 45.1 °C (± 3.2).
Thawing behaviour was also evaluated with the digital image processing tool. Thawing
was done via incubating the frozen vials in a pre-heated (37 °C) water bath. The results
are shown in fig. 8.5 as bar chart of the mean thawing time (n = 9). Samples with 1.0 mL
working volume were completely defrosted after 2.2 min (± 0.2), while defrosting of 2.0 mL
samples took 5.9 min (± 0.2). The second part of the study was the intact viable cell
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Figure 8.5: Thawing time analysis. Bar chart of the thawing end time for 1 and 2 mL working
volume in minutes.
number monitoring during the cryopreservation process as a function of working volume.
Samples were analysed before freezing, after thawing and after 7 days of cultivation. Three
runs were performed, each with a technical triplicate (ntotal = 3 x 3 = 9). For comparison
of the results of the two working volumes, normalization of the live cell number was done
according to eq. (8.1):
(live cells)N = live countsworking volume [cells/mL] (8.1)
The results of the process robustness evaluation are shown in fig. 8.6. Normalized live cell
number is shown over the performed runs. The horizontal bar represent the total variance
(n = 9). The upper line of the bar represents the mean + SD, while the bottom line
represents mean - SD. The robustness evaluation showed no trend and the relative standard
deviation was < 11 % for over all time points and both working volumes. Both working
volumes showed similar normalized live cell numbers (n = 9) with 5.45 x 106 cells/mL
(± 0.51 x 106) for 1.0 mL working volume and 5.05 x 106 cells/mL (± 0.39 x 106) for
2.0 mL working volume before freezing. However, the cell number differed after thawing.
While the cell number for 1.0 mL working volume only decreased to 5.09 x 106 cells/mL
(± 0.52 x 106), cell number dropped to 3.08 x 106 cells/mL (± 0.15 x 106) for 2.0 mL
working volume. After 7 days of cultivation the cell number increased for 1.0 mL working
volume to 10.85 x 106 cells/mL (± 1.14 x 106) and to 5.35 x 106 cells/mL (± 0.53 x 106)
for 2.0 mL working volume. The summary of these data is shown in fig. 8.7 A, where
non-cryopreserved control data is represented as horizontal bar. Additionally, two critical
90 Chapter 8
before
freezing
after 
thawing
after
cultivation
(l
iv
e
 c
e
lls
) N
 [
c
e
lls
/m
L
]
0
2
4
6
8
10
12
14 x 10
6
(l
iv
e
 c
e
lls
) N
 [
c
e
lls
/m
L
]
0
2
4
6
8
10
12
14 x 10
6
1 32
run
1 32
run
1 32
run
1 mL
working volume
2 mL
working volume
A B C
D E F
Figure 8.6: Robustness evaluation of cell cryopreservation process. Three runs were performed
per experiment, each with a technical triplicate (ntotal = 3 x 3 = 9). Normalized live cell
number is shown over the performed runs. The horizontal bar represent the total variance
(n = 9). Upper line = mean + SD; bottom line = mean SD. Evaluation of robustness was done
for each process step: A before freezing with 1 mL working volume (WV); B after thawing
with 1 mL WV; C after cultivation of 7 days with 1 mL WV D before freezing with 2 mL WV
E after thawing with 2 mL WV F after cultivation of 7 days with 2 mL WV.
process numbers, namely cell recovery and biomass increase, were calculated in order to
evaluate process performance. Evaluation was done based on the normalized cell number
(n = 3 x 3 x 3 = 9). Cell recovery was calculated according to eq. (8.2), the results are
shown in fig. 8.7 B.
RN =
after thawing
before freezing
(8.2)
Cell recovery of RN = 0.94 (± 0.14) was observed for 1.0 mL working volume, while 2.0 mL
working volume showed RN = 0.61 (± 0.05). Cell biomass increase was calculated according
to eq. (8.3), the results are shown in fig. 8.7 C.
BN =
after cultivation
before freezing
(8.3)
The biomass increase of 1.0 mL working volume BN = 2.01 (± 0.34) indicates a cell doubling
compared to initial live cell number, while 2.0 mL working volume process showed no
increase of initial cell number with a BN = 1.06 (± 0.13).
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Figure 8.7: Summary of cryopreservation process (ntotal = 9). A Normalized live cell number
over process steps is shown. The gray horizontal bar represents the control cell number of
non-cryopreserved cells (upper line: mean + SD; bottom line: mean - SD). B Bar chart of
the cell recovery factor (RN) for 1 and 2 mL working volume (WV). C Bar chart of the
cell proliferation factor (BN) for 1 and 2 mL WV. Asterisks indicates statistical significance
(unequal variances Students t-test; p < 0.0001).
8.4 Discussion
Cooling and heating rates, among other process parameters, have been described as
important factors concerning post-thawing cell viability [73, 74, 77, 84–86] and need to be
optimized for each cell line individually [72, 74, 75, 86]. The aim of the present study was
to develop a tool for the characterisation of freezing and thawing behaviour, applicable for
cell cryopreservation process development.
The tool was realised as oﬄine analytic, using a video analysis approach to detect both the
frozen over state and the thawing end point. Automatization of the video-based analytic
was done in MATLAB by evaluating the mean pixel intensity, as this variable changes
with ice formation or thawing. A pre-processing step, where the image area of each vial is
defined, allows individual analysis of several samples in parallel, followed by calculation of
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the mean pixel intensity of each sample. The formation of ice is represented by an increase
of mean pixel intensity, while ice thawing will lead to a decrease. When plotted over time,
characteristic curves for freezing and thawing occur, which are used for the calculation of
the beginning and ending of ice formation. In the present study, cryopreservation was done
with two different working volumes to investigate the flexibility of the tool. Pre-processing
of video data was unique for each working volume concerning image area and vial assembly
which highlights the flexibility of the tool and indicates fast adaptation to new applications.
The performance of the tool was demonstrated with a case study where the influence of
scale up (1.0 mL and 2.0 mL working volume) on freezing and thawing behaviour was
analysed. The performance was evaluated based on cell recovery and biomass increase.
A conventional cryopreservation process was performed using the model cell line INS-1E.
Freezing was done in a controlled manner using the EF600M freezing equipment (20 to
- 80 °C) and 7 day storage at - 196 °C, followed by a fast thawing step in a 37 °C pre-warmed
water bath. DMSO was used as cryoprotectand as it is commonly used for cryopreservation
of mammalian cell lines. [72, 74]
In the first part of the study, the developed video-based tool was used to evaluate the
freezing and thawing behaviour considering a scale up from 1.0 mL to 2.0 mL working
volume. It has been widely reported in literature that controlled freezing is favourable for
cell cryopreservation concerning cell viability and for process quality control for cell-based
products or cell banks for biopharmaceutical production. [73, 74, 77, 81, 84, 89] For both
working volumes the same controlled freezing profile was performed using the EF600M. The
EF600M is a nitrogen and ethanol free device for controlled freezing and has already been
used for cryopreservation studies. [73, 83] In the present study, the EF600M 106 was used
for freezing of 1.0 mL working volume, while the EF600M 105 was used in combination with
a customized adapter for freezing 2.0 mL samples. Here, vials for tissue cryopreservation
were used, leading to an adapter design based on 24 well microplate format (SBS). The
results have shown that ice formation starts earlier with 1.0 mL working volume and the
time to reach the frozen over state is also faster. For better comparison the crystallisation
end point was calculated, which represents the profile temperature of the process and not
the sample temperature. While 1.0 mL working solution samples were frozen at - 26.7 °C
(± 3.7), the 2.0 mL working solution samples reach that status at - 45.1 °C (± 3.2). It is
assumed that the observed crystallization end point differences occur due heat transfer
effects caused by different EF600M approaches and cryovial geometry. The EF600M 106
used for 1.0 mL working volume cryovials is used without an additional adapter. This
means that the cooling head is in direct contact with the cryovials. In comparison, the
EF600M 105, used for the 2.0 mL working volume cryovials, needs an additional adapter
which is not actively cooled. This might lead to delayed heat transfer into the sample.
Additionally, the two cryovials differ in geometry. Both are cynlidrical but the 1.0 mL vial
has a height to diameter ratio of 3.3 while a ratio of 1.73 is used for the 2.0 mL vial. This
ratio difference has been reported in literature as negative effect in scale up. [73, 75, 82] It
is also assumed that volume increase and cryovial geometry difference are the major causes
for the delayed thawing time of the 2.0 mL samples. The 1.0 mL working samples are
completely ice free after 2.2 min (± 0.2), while defrosting of 2.0 mL samples took 5.9 min
(± 0.2). This shows that the developed tool is capable of automatically detecting well
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described freezing and thawing behaviour.
To investigate the influence of the working volume on cell cryopreservation, a intact viable
cell monitoring during the process was performed. Samples were taken before freezing,
after thawing and after 7 days of cultivation. Three runs were done per experiment, each
with a technical triplicate (ntotal = 3 x 3 = 9). The robustness evaluation has shown no
variations of intact viable cell number between the runs and the relative standard deviation
was < 11 % for all time points and both working volumes. Therefore, the process is in
control and the observed differences comparing the two working volumes are valid. Two
critical process parameter were defined for process evaluation and comparison of the two
working volumes: cell recovery and biomass increase. While the cell recovery indicates the
direct influence of cryopreservation on intact viable cell number, the second critical process
parameter indicates the ability to increase the total biomass. Cryopreservation had a minor
influence on cells use a 1.0 mL working volume with a cell recovery of 0.94 (± 0.14). The
cell number doubled after 7 days of cultivation (BN = 2.01 (± 0.34)), which is in compliance
with the non-cryopreserved control sample. In contrast, only 61 % (RN = 0.61 (± 0.05)) of
the cells were recovered when cryopreserved in 2.0 mL working volume. These samples
showed no increase in total cell number (BN = 1.06 (± 0.13)).
In summary, a successful tool validation was performed by analysing freeze and thawing
behaviour for a scale up from a 1.0 mL working volume to a working volume of 2.0 mL.
Using the developed tool, a delay in freezing and thawing was observed with the 2.0 mL
working volume, which is in agreement with literature [73, 75, 77, 82, 83]. Subsequently,
cryopreservation process performance was evaluated via intact viable cell monitoring. Here,
a negative effect represented by declining cell recovery and proliferation was observed
due to working volume scale up. These findings correspond with literature data and
thereby demonstrate the usefulness of the developed video-based tool in cryopreservation
process development. Additionally, fast and easy adaptation of the method concerning new
applications like scale up and change in devices is another advantage. The development
of the tool for evaluation of freezing and thawing behaviour is the groundwork for future
studies concerning adapter and freezing profile optimization for 2.0 mL working volume.
This tool could also be applied to screen cryoprotectant agents and concentrations, since
these process parameters also influence the freezing and thawing behaviour and have a
direct influence on cell viability. [71, 74, 87] The developed tool can facilitate a more
knowledge-based cryopreservation process development in research and development of the
pharmaceutical industry.
8.5 Conclusion
A video analysis-based tool for knowledge-based cell cryopreservation process development
was designed. It was realised as oﬄine video analytic, using an inexpensive automated
digital image processing approach. The developed tool allows for the characterisation of
freezing and thawing behaviour through evaluation of the mean pixel intensity represented
by a cryosample in video snapshots. Plotting the mean pixel intensity of a cryosample over
time results in characteristic curves for freezing and thawing. Freezing of samples lead to
an increase in pixel intensity and subsequent thawing is represented by a decrease. These
characteristic curves were used to determine the frozen over state and complete thawing of
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samples.
Performance of the tool was demonstrated by a cryopreservation scale up case study with
a model process using the mammalian β-cell line INS-1E. Here, cells were slowly frozen
in a controlled manner using DMSO as cryoprotectant, stored at ultra-low temperatures
for 7 days, followed by rapid thawing in a pre-warmed (37 °C) water bath. The process
was performed with two working volumes (1.0 mL and 2.0 mL) in order to evaluate the
flexibility of the tool. It was found that an increase of working volume from 1.0 mL to
2.0 mL results in a delay in freezing and thawing behaviour of cryosamples. This is in
good agreement with literature [73, 75, 77, 82, 83], thereby confirming the performance
of the developed tool. Additionally, the influence of working volume on cell recovery
and proliferation was analysed. Intact viable cell monitoring showed an influence on cell
post-thaw behaviour, underlining the need for a knowledge based process evaluation.
We believe that the integration of the developed video-based tool, for characterisation
of freezing and thawing behaviour, can facilitate a more systematic cryopreservation
process development. Furthermore, using the developed tool in combination with a
systematic screening approach would lead to a deeper process knowledge, necessary in a
good manufacturing practice (GMP) environment for cell-based products. Comprehensive
studies should focus on different video material e.g. using a thermal imaging camera would
allow for a closed container set up.
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Abstract
Cryopreservation is a well described method for cell long-term storage. However, when
applied in a good manufacturing practice (GMP) production of e.g. biopharmaceuticals
or cell-based products in regenerative medicine, more sophisticated requirements need to
be met. A major focus for the GMP production is on the cryomedia composition, since
they need to be chemically defined and free of toxic or animal-derived compounds. Hence,
the commonly used cryoprotectants dimethyl sulfoxide (DMSO) and fetal bovine serum
(FBS) are excluded. In this article, we describe an analytical tool box for the prediction of
media cell cryopreservation process performance by characterization of media properties,
freeze/thaw behaviour and media toxicity. We demonstrate the usefulness of the tool
box in a case study with the β-model cell line INS-1E, where four media were screened
including a positive and negative control in addition to two commercially available DMSO
and FBS-free cryomedia. The tool box data indicated that the commercial Biofreeze®
media shows inferior performance for INS-1E, while the second commercial cryomedia
CryoSOfreeTM is clearly a possible candidate. These findings were confirmed by a conven-
tional viability monitoring study during the cryopreservation process. We believe that the
tool box facilitates a fast pre-selection of possible candidates with a small number of cells,
shortening the overall process development time. Hence, the tool box is highly beneficial.
However, the predictive power needs to be proven in further extended experiments.
Keywords: cell cryopreservation, long-term storage, predictive tool box, pre-selection,
process development, cryomedia formulation
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9.1 Introduction
Efficient long-term storage of eukaryotic cell lines is an essential issue in many biotechno-
logical application fields e.g. cell line maintenance for routine cell culture applications [72],
biopharmaceutical production [74, 75], reproductive medicine [71, 76] and cell therapy in
the field of regenerative medicine [1, 73, 84]. Here, continues supply of cells with constant
genetic and metabolic features is crucial and often solved by the concept of cell banking.
Meaning cryopreservation of cells with subsequent storage at ultra-low temperatures in
highly controlled process environment, while monitoring critical cell characteristics. [1,
72, 74, 75, 77, 78] The concept of cell cryopreservation is well described in literature and
general protocols are available. A common approach to avoid severe cell damage during
freezing and thawing, due to extra- and intracellular ice formation as well as osmotic
effects [72, 79, 90, 94, 251], is the use of dimethyl sulfoxide (DMSO) as cryoprotectant,
slow freezing rates and a fast thawing protocol. [72, 74, 75, 88, 91, 92] However, success-
ful post-thaw cell survival needs to be optimized individually for every cell line and is
influenced by a number of process parameter. [75, 86, 95] These parameter include cell
loading [80], cell characteristics e.g. suspension cells, monolayer or colony growth [78, 81,
240], cryoprotectant agents and concentration [71, 87], process volume (scale up) [73, 75,
77, 82, 83] and freezing/thawing rates [73, 74, 77, 84–86]. Preferable is a process with
controlled freezing, especially in a good manufacturing practice (GMP) environment. [73,
74, 77, 81, 84, 88, 89, 252] When developing a process for the cryopreservation of clini-
cal applications e.g. biopharmaceuticals of cell-based products, a major focus is on the
optimization of the cryomedia composition. Here, chemically defined media are required
by authorities without any toxic or animal-derived components, which exclude the well
described cryoprotectants DMSO and the addition of fetal bovine serum (FBS). [90–93,
96–98, 253–256] FBS is commonly added to the media to protect cells from free oxygen
radicals associated with freezing and could be replaced by serum from other sources e.g.
recombinant produced serum. [79, 92, 257] Additionally, numerous cryoprotectans have
already been described in literature. They can be divided in extracellular and intracellular
cryoprotectant agents. [91, 93–98] Extracellular cryoprotectant agents are mostly sugars or
high molecular weight polymers e.g. polyethylene glycol (PEG) and do not penetrate the
cell membrane. Prominent examples of membrane penetrating intracellular cryoprotectant
agents are DMSO, glycerol or 1,2-propanediol [91, 93, 98], which differ in up take rates [95].
However, the selection of a cryoprotectant agent and concentration cannot be optimized
independently, since other process parameter e.g. freezing rate might be influenced as
well. [71] Hence, a systematic empirical screening is necessary for a more directed process
development. [71, 72, 74, 75, 241] The screening for alternative cryoprotectant agents with
optimal concentrations have already been described for different cell lines. [100–102, 253]
However, a rather traditional cryopreservation screening is time and material consuming. A
predictive tool for the preliminary exclusion of non-applicable cryoprotectant agents would
be highly beneficial. A pre-screening would not only narrow down possible cryoprotectant
agent candidates, additionally, process knowledge could be gathered in parallel, necessary
in a GMP environment.
In this study, we describe an analytical tool box for the prediction of cryomedia process
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performance by characterization of media properties, freeze/thaw behaviour and cell re-
sponse to cryomedia exposure (toxicity). The predictive power was evaluated in a case
study with the β-model cell line INS-1E, where four different media were screened for
cryopreservation application. The screening compromised a DMSO containing cryomedia
as positive control, the culture media as negative control and two commercially available,
DMSO- and serum-free cryomedia. The media process performance was evaluated by a
viability monitoring during the cryopreservation process with subsequent calculation of the
critical process parameter cell recovery and proliferation. Finally, the applicability of the
four screened cryomedia for the use in a cryopreservation process for the cell line INS-1E
was evaluated.
9.2 Materials and Methods
9.2.1 Stock Solutions
Cell culture reagents were purchased from Thermo Fisher Scientific (Waltham, USA), unless
otherwise stated. Culture media consisted of RPMI 1640 with GlutaMAX supplemented
with 10 (v/v) % FBS, 1 (v/v) % sodium pyruvate, 1 (v/v) % Penicillin / Streptomycin,
10 mM HEPES, 2 mM L-Glutamine and 50 µM β-mercaptoethanol (Sigma-Aldrich, St.
Louis, USA). The culture media was also used as negative control in the cryopreservation
study. Additionally, three cryomedia were used, two commercially available, DMSO-
free cryomedia, namely, CryoSOfreeTM (Sigma-Aldrich, St. Louis, USA) and Biofreeze®
(Biochrom GmbH, Berlin, Germany) and as control a DMSO containing cryomedia. The
DMSO containing cryomedia consisted of RPMI 1640 with GlutaMAX supplemented
with 20 (v/v) % FBS, 1 (v/v) % sodium pyruvate, 10 (v/v) % DMSO (Sigma-Aldrich),
1 (v/v) % Penicillin / Streptomycin, 10 mM HEPES, 2 mM L-Glutamine and 50 µM
β-mercaptoethanol (Sigma-Aldrich). All media were stored at 8 °C. Phosphate-buffered
saline (PBS) was purchased from Thermo Fisher Scientific and stored at room temperature.
All stock solutions were kept under sterile conditions.
9.2.2 Software and Data Processing
The software iTools Version 9.57.11 (Eurotherm, Worthing, UK), was used to control the
EF600M 106. BD LSR Fortessa Cell Analyzer was controlled by BD FACSDiva 8.0 (BD
Biosciences, San Jose, USA). Flow cytometry data were analysed and visualised using
FlowJo V10 (Tree Star Inc., Ashland, USA). For data storage Excel 2013 (Microsoft,
Redmond, WA, USA) was used. MATLAB R2015a (The MathWorks, Inc., Natick, USA)
was used for data evaluation and visualization. Radar plots were generated using RStudio
Version 1.1.383.
9.2.3 Cell Culture
The β-model cell line INS-1E [198] was kindly provided by Prof. Maechler from the
Department of Cell Physiology and Metabolism at the University of Geneva Medical
Centre, Switzerland. Cells were seeded with a concentration of 6.6 x 104 cells/cm2 every
7 days, media exchange was performed after 3 days. The cultivation was done in a
humidified incubator with 5 % CO2.
9.2 Materials and Methods 103
9.2.4 Cell Cryopreservation
Cryopreservation was done with all 4 media, namely, cell culture media (RPMI), DMSO
containing (DMSO), CryoSOfreeTM (Sigma) and Biofreeze® (Merck) with a 1 mL working
volume using 1.8 mL cryovials (VWR International GmbH, Bruchsal, Germany). Cell
cryopreservation was performed according to a previous study. [258] Briefly, cells were
suspended in cryomedia to a final concentration of 6 x 106 cells/mL and frozen to - 80 °C
in a controlled manner using the EF600 M 106 (55 x 1.8 mL cryovials, 1.0 mL max. fill;
Grant Instruments, Cambridgeshire, UK). The freezing profile is listed in table 9.1. After
a 24 h incubation at - 80 °C, samples were stored for 7 days at - 196 °C (Arpege 70,
Air Liquide Medical GmbH, Düsseldorf, Germany). Followed by a fast thawing step in a
37 °C pre-warmed water bath. Cells were then quickly transferred for 5 min in a 20 °C
pre-warmed culture media (1:20) and washed once with PBS (1:10). Then, cells were
cultivated for 7 days in 7 mL culture media using a culture flask with an area of 25 cm2.
Media was exchanged after 3 days. Viability monitoring was performed by estimating intact
live cell concentration using haemocytometer counting. Trypan blue dye exclusion was used
to distinguish between intact live cells and damaged/dead cells. Samples were analysed
after cell suspension in cryomedia, direct after thawing and after 7 days of cultivation.
Table 9.1: Freezing profile
Increments Temperature
start temp. 20 °C
cool from 20 to - 5 °C at 2 °C min-1
cool from - 5 °to - 7 °C at 1 °C min-1
hold at - 7 °C for 10 min
cool from - 7 °to - 80 °C at 1 °C min-1
hold at - 80 °C
9.2.5 Characterization of Freezing and Thawing Behavior
Freezing and thawing behaviour of the used media for cryopreservation was analysed using a
video-based tool previously described. [258] Here, an automated image processing approach
is used to determine the state of frozen over or complete defrosting of a sample. Videos
were taken with a GoPro Hero4 (GoPro, Inc., San Mateo, USA) controlled via the GoPro
App version 2.6.3.312 (GoPro, Inc.) and a Samsung Galaxy Note Pro SM-P900 (Samsung,
Seoul, South Korea). Following camera settings were applied: field of view: narrow;
resolution: 1080 p; frames per second: 25.
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9.2.6 Media Characterization
Viscosity measurements were done using an Anton Paar Physica MCR 301 rheometer
(Anton Paar GmbH, Grax, Austria) equipped with a 50 mm diameter parallel plate
geometry (PP50). Shear stress was increased from 10 - 20 Pa (300 data points).
Osmolarity was analysed using a vapour pressure osmometer model VAPRO® 5600 (Wescor
Inc., Logan, USA). Viscosity and osmolartiy was measured at room temperature.
9.2.7 Cell Response Characterization
For the evaluation if the process time has an effects on cells suspended (c = 6 x 106 cells/mL)
in cryomedia, a kinetic study was performed. Here, damaged/dead cell ratio was determined
using a haemocytometer counting in combination with trypan blue dye exclusion. Samples
were analysed at regular intervals for 250 min. Damaged/dead cell ratio was plotted over
time and validated. If there was a change in the ratio over time it was rated 1 (yes),
otherwise with a 0 (no).
Flow cytometry was used to evaluate cryomedia toxicity. Here, cells were analysed in
cryomedia (c = 6 x 106 cells/mL) using an LSR Fortessa by BD Bioscience. Additionally,
a diluted cell sample (1:8, in PBS) was analysed to evaluate the cell response to osmotic
pressure changes. A gating strategy (fig. 9.1) was applied for both sample types (undiluted
& diluted) were the control population was defined by means of a control sample (undiluted
cells in culture media). Then, cell loss was calculated on basis of the control sample.
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Figure 9.1: Gating strategy for undiluted and diluted cell samples. Only single cells were
evaluated, a control population gate was defined by means of a positive control (cells in culture
media). FSC-A: forward scatter peak area, SSC-A: side scatter peak area.
9.2.8 Data Normalization
Tool box data was displayed as radar charts. For this reason, data was normalized according
to table 9.2.
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Table 9.2: Summary of tool box parameter and normalization
Parameter Unit Normalization
Media Properties osmolarity [mmol/kg] x‘ = (x - xmin)/(xmax - xmin)
viscosity [mPa*s] x‘ = (x - xmin)/(xmax - xmin)
Physical Behaviour freezing end temp. [°C] x‘ = a + ((x - xmin) (a+b)/(xmax - xmin))
thawing end time [min] x‘ = a + ((x - xmin) (a+b)/(xmax - xmin))
Cell response kinetic
1/0
(yes/no)
-
cell loss (undiluted) (%) x‘ = x/100
cell loss (diluted) (%) x‘ = x/100
a = 0.5, b = 0.3
9.3 Results
In the present work, we describe a tool box for the prediction of media process performance
in cell cryopreservation. The tool box compromises the characterization of media proper-
ties, freezing and thawing behaviour and cell response to media. The applicability of the
tool box was evaluated in a case study with the β-model cell line INS-1E, screening four
cryopreservation media. Additionally, the cryomedia process performance was evaluated
via a cell viability monitoring during the cryopreservation process in order to validate
the predicted process performance. The media screening included a DMSO containing
media since it showed a good process with the cell line INS-1E performance in a previous
study [258], the culture media without any cryoprotectant (as negative control) and two
commercially available, DMSO-free cryomedia. The tool box was applied, thus, characteri-
zation of media properties, freezing and thawing behaviour and cell response to media was
performed. Characterization of media properties included the measurement of osmolarity
and viscosity. For the characterization of freezing and thawing behaviour the previously
developed video-based tool [258] was used. Cell response was analysed by flow cytometry
and a simple kinetic study. An overview of the screening procedure is depicted in fig. 9.2.
Additionally, the process performance was determined as previously described. [258] Briefly,
cryopreservation process was performed and samples were taken for the viability monitoring
before freezing, after thawing and after cultivation (7 days).
In the first part of the study, characterization of media properties, freezing and thawing
behaviour and cell response to media was done by using the described tool box, in order
to evaluate if a prediction of media process performance is possible. Media property
characterization included osmolarity and viscosity measurements. The osmolority range for
the four tested media was from 293 mmol/kg to 1832 mmol/kg and the viscosity range from
1.07 mPa*s to 5.3 mPa*s. Freezing and thawing behaviour was characterized as previously
described. [258] Freezing was performed in a controlled manner using the EF600 M 106
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as described in table 9.1 from 20 °C to - 80 °C. Due to the video timestamp and the
cell suspension 
in cryo-media
controlled 
freezing
thawing cultivation
(7 days)
storage
-196 C
Cryopreservation Process
Cell Viability Monitoring
before 
freezing
after 
thawing
after 
cultivation
Tool Box
Media Properties
- osmolarity
- viscosity
Cell Response
- viability
- kinetic
Physical Behavior
- freezing
- thawing
Figure 9.2: Overview of the cryomedia screening. Four media were screened regarding the
use for cryopreservation of the β-model cell line INS-1E. The cryopreservation process was
performed with the selected media. Cells were suspended in cryo-media and directly frozen to
- 80 °C in a controlled manner. After 24 h at - 80 °C the cryo-samples were transferred in the
storage tank (- 196 °C). After 7 days of storage, the samples were thawed and cultivated for
7 days. Samples for intact cell viability monitoring were taken before freezing, after thawing and
after cultivation. Additionally, a tool box was used for the characterization of the cryomedia.
The tool box was applied to characterize media propteries, cell response and physical behaviour.
It facilitates the measurement of osmolarity and viscosity, the cell response, namely, viability
in the media and a kinetic study and the characterization of freezing and thawing behaviour.
freezing profile tracking, mean crystallization end temperature could be determined. To
note, this represents the profile temperature of the process and not the sample temperature.
The range of the crystallization end temperature was between - 20.5 °C and - 32.6 °C for
the tested media. Additionally, the thawing end time was analysed and the range was
from 2.0 min to 4.1 min. For the characterization of cell response caused by the media,
two different approaches were performed. First, a simple kinetic study of cell death was
done in order to evaluate the influence of process time on intact cell viability. Therefore,
damaged/dead cell ratio was determined and plotted over time (supplementary data
9.3). The kinetic results were classified as 0 when a constant cell damaged/death ratio
was observed and classified as 1 if there was an increase in cell damaged/death ratio. No
increase in cell damaged/death ratio was observed, except for the the Biofreeze® media
(Merck), here, an increase could be seen. For the evaluation of media toxicity (undiluted)
and cell response to changes in osmotic pressure (diluted), a flow cytometry analysis was
performed with undiluted and diluted samples. The results are shown in fig. 9.4, here, the
dotplot of the FSC-A and SSC-A signal of the single cell population is shown. Cell loss
[%] was determined on the basis of the control population of the control sample (fig. 9.4
C). The cell loss for the undiluted samples were between 0.0 % and 10.9 % and for the
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diluted samples from 0.0 % to 56.2 %.
0
20
40
60
80
100
A
0 50 100 150 200 250
B
0
20
40
60
80
C
time [min] 
0 50 100 150 200 250
D
d
a
m
a
g
e
d
/d
e
a
d
 c
e
lls
 [
%
]
kinetic:
no = 0
kinetic:
no = 0
kinetic:
no = 0
kinetic:
yes = 1
Supplementary Data 9.3: Process time evaluation regarding intact cell viability. Kinetic
study of cell death in cryopreservation media (n = 3). The ratio of damaged/dead cells [%] is
plotted over time [min] for A cryomedia containing DMSO (DMSO), B culture media (RPMI),
C CryoSOfreeTM (Sigma) and D Biofreeze® (Merck). The data is evaluated if there is an
increase in damaged/cell death ratio: no = 1, yes = 1.
The tool box data is summarized as radar charts in fig. 9.5. The solid lines represent the
mean, while the standard deviation is plotted as black circles and dashed lines. All data
were normalized (range [0 1]) according to table 9.2. The cryomedia containing DMSO
(DMSO) (fig. 9.5 A) showed a high value for osmolarity, medium values for freezing and
thawing behaviour and low values for viscosity, kinetic, cell loss undiluted and diluted.
The negative control culture media (RPMI) (fig. 9.5 B) featured extremely low values
for all tested parameter, except for the freezing and thawing behaviour, here, medium
values were observed. The CryoSOfreeTM media (Sigma) (fig. 9.5 C) featured high values
for osmolarity and viscosity, medium values for freezing and thawing and low values for
the kinetic, cell loss undiluted and diluted. The Biofreeze® medium (Merck) (fig. 9.5 D)
featured high values for osmolarity and kinetic, medium values for freezing, thawing and
cell loss (diluted) and low values for viscosity and cell loss (undiluted). Comparing the
two commercially available cryomedia, with yet unknown process performance, with the
positive and negative controls, the assumption was made that the CryoSOfreeTM media
(Sigma) are applicable for cryopreservation with the cell line INS1-E, while the Biofreeze®
medium (Merck) showed toxic effects and is likely to exhibit a poor process performance.
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Figure 9.4: Flow cytometry data. Evaluation of media toxicity (undiluted) and cell response
to changes in osmotic pressure (diluted). Dotplot of the FSC-A and SSC-A signal of single cell
population. The depicted control population was gated according to the control sample (C).
Dotplots of undiluted samples are depicted on the left, while dotplots of the diluted samples
are depicted on the right. A & B cryomedia containing DMSO (DMSO), C & D culture
media (RPMI), E & F CryoSOfreeTM (Sigma) and G & H Biofreeze® (Merck). FSC-A:
forward scatter peak area, SSC-A: side scatter peak area.
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Figure 9.5: Summary of the characterization of the selected cryomedia using the described
tool box. Analyzed were the media properties osmolarity and viscosity, the freezing and
thawing bahaviour and the cell response, namely, kinetic study and cell loss (of undiluted and
diluted cell samples). All data were normalized (range [0 1]) according to table 9.2. The
data is shown as radar charts for A cryomedia containing DMSO (DMSO), B culture media
(RPMI), C CryoSOfreeTM (Sigma) and D Biofreeze® (Merck). The solid lines represent the
mean, while the standard deviation is plotted as black circles and dashed lines.
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In the second part of the study, cell viability monitoring during the cryopreservation process
was performed with subsequent evaluation of the process performance of each tested media.
For comparison of the results, normalization of the live cell number was done according to
eq. (9.1) [258]:
(live cells)N = live countsworking volume [cells/mL] (9.1)
Intact cell viability was determined before freezing, after thawing and after 7 days of
cultivation. The summary of the viability monitoring is displayed in fig. 9.6 A. The
normalized intact live cell number is plotted over process steps (n = 9). The gray horizontal
bar represents the control cell number of non-cryopreserved cells (upper line: mean + SD;
bottom line: mean - SD). All four media showed similar live cell numbers before freezing
[(4.15 - 5.45) x 106 cells/mL]. While the cell number stays approximately the same for
the DMSO containing media (DMSO) and CryoSOfreeTM (Sigma) after thawing, there
is a decrease in intact live cell number to 1.2 x 106 cells/mL for the Biofreeze® media
(Merck). No intact live cells were detected after freezing for the culture media (RPMI).
After 7 days of cultivation the intact live cell number increased to 10.85 x 106 cells/mL
(± 1.14 x 106) for the DMSO containing media (DMSO), for the CryoSOfreeTM media
(Sigma) to 8.34 x 10 cells/mL (± 1.05 x 106) and for the Biofreeze® media (Merck) to
3.85 x 106 cells/mL (± 1.00 x 106). No intact live cells were detected after cultivation for
the culture media (RPMI).
Subsequently, two critical process parameter, namely cell recovery and cell biomass increase,
were determined for evaluation of media process performance. Evaluation was done based
on the normalized cell number. Cell recovery was calculated according to eq. (9.2) [258].
RN =
after thawing
before freezing
(9.2)
Cell biomass increase was calculated according to eq. (9.3) [258].
BN =
after cultivation
before freezing
(9.3)
The results are summarized as dotplot in fig. 9.6 B. Cell biomass increase is plotted
over cell recovery for the evaluation of process performance. High cell recovery with
RN = 0.94 (± 0.14) and cell biomass increase BN = 2.01 (± 0.34) was observed for the
DMSO containing media (DMSO). Followed by the CryoSOfreeTM media (Sigma) with
RN = 0.84 (± 0.11) and BN = 1.75 (± 0.38). In comparison, Biofreeze® media (Merck)
showed a relatively low cell recovery with RN = 0.22 (± 0.03) and BN = 0.95 (± 0.25).
No live cells were recovered for the culture media (RPMI), subsequently no cell biomass
increase was shown.
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Figure 9.6: Cell viability monitoring of the cryopreservation process with the cell line INS-1E.
A Normalized live cell number over process steps is shown (n = 9). The gray horizontal bar
represents the control cell number of non-cryopreserved cells (upper line: mean + SD; bottom
line: mean - SD). B Dotplot of the cell recovery factor (RN) and the cell biomass increase
factor (BN) for the evaluation of media process performance.
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9.4 Discussion
We investigated if a prediction of media process performance in cell cryopreservation can
be accessed through the characterization of media properties, freezing/thawing behavior
and the media toxicity. The characterization methods are summarized as tool box which
comprises an osmolarity and viscosity measurement for media characterization, the previ-
ously developed video-based tool [258] for the characterization of the freezing and thawing
behaviour, a simple kinetic study and flow cytometry for the analysis of media toxicity. A
case study with the β-model cell line INS-1E was performed, screening four cryopreser-
vation media. A process performance prediction using the described tool box, was done.
Additionally, the prediction was validated via a conventional viability monitoring during
cell cryopreservation, with a subsequent calculation of the critical process performance
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parameter cell recovery and cell biomass increase.
In the first part of the study, the predictive power of the described tool box, concerning
media cryopreservation process performance for the β-model cell line INS-1E, was inves-
tigated. In literature, various factors influencing post-thawing intact cell viability are
described. [71, 72, 74, 75, 78, 80, 81] Hence, the tool box needs to cover several aspects of
the cryopreservation process, namely, media properties, freezing/thawing behaviour and
media toxicity. Osmolarity is a media property closely related with supplementation of
cryoprotectants, resulting in an increase in osmolarity. [259–263] Additionally, the media
viscosity was measured. To our knowledge, the influence of viscosity on post-thawing cell
viability was not reported so far. However, the use of polymers or other high molecular
weight molecules as cryoprotectant agents may increase the media viscosity, leading to a
more complex process for big scale production. In our experience, the automatic handling
of viscous fluids needs to be additionally optimized, especially the cell resuspension in such
a media. [200] Thus, media viscosity might have not a direct influence on cell post-thaw
survival, but can cause issues concerning automatization and up scaling, which is a valuable
insight in early process development stage. The cryomedia composition can also have an
influence on freezing behavior. [260] Since the optimal freezing and thawing profile is crucial
for a successful cell cryopreservation [73, 74, 77, 84–86, 90, 94, 95, 98], the characterization
of freezing and thawing behaviour was implemented in the tool box by using the previously
developed video-based tool [258]. Another crucial issue in cell cryopreservation is the
cryoprotectant toxicity. [88, 100, 101, 255] This was addressed by a flow cytometry analysis
and a simple kinetic study. Flow cytometry analysis was performed with undiluted samples
and in PBS diluted samples. While the analysis of undiluted samples provides conclusion
of instant media composition toxicity, the analysis of diluted samples indicates if the
cells can cope fast changes in osmolarity, which simulates the washing step after thawing.
Briefly, cryomedia are associated with higher osmolarity [259–263], when diluted in PBS
the osmolarity is decreased to an almost physiological value (PBS osmolarity according to
manufacturer: 270 - 300 mOsm/kg). It is also reported in literature, that cryoprotectant
exposure time may influence intact cell viability. [98] Consequently, a simple kinetic study
was implemented in the tool box, where intact cell viability was measured over 250 min by
haemocytometer counting in combination with trypan blue dye exclusion. The described
tool box was applied for the characterization of all four media.
The DMSO containing media (DMSO), which is considered as an example for good process
performance [258], displayed the following features: high osmolarity, low viscosity, medium
freezing and thawing behavior, additionally no toxic effects were observed. These data
are in good agreement with the CryoSOfreeTM media (Sigma) results, except the high
viscosity value. Thus, a high process performance was predicted. As previously described,
we think that the viscosity is a soft parameter, meaning that viscosity is not influencing
process performance directly, but might increase process complexity. The culture media
without any cryoprotection supplemented (RPMI; negative control) displayed, in contrast
to all the other media, a low osmolarity. All other features were similar to the results of
the DMSO containing media. This was in good agreement with the expectation, since
the only difference between those two media is the addition of DMSO and additional
serum as cryoprotectants, which causes an increase in osmolarity. [259–263] The lack of
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cryoprotectant, however, results in severe cell damage during freezing/thawing resulting in
extremely poor process performance, which is also in good agreement with literature [93].
The Biofreeze® media (Merck) displayed the same characteristics for media properties
and freezing/thawing behaviour than the DMSO containing media. In contrast, some
toxic effects were observed. The kinetic study showed an increase of damaged/death
cell ratio over time and the diluted flow cytometry sample showed a cell loss of 44.63 %
(± 13.11). These finding might indicate that this commercial media contains intracellular
cryoprotectants which are slowly taken up and the release during the washing might not
be fast enough. Thus, a poor process performance was predicted.
In the second part of the study, the tool box predictions were validated through a conven-
tional intact cell viability monitoring during the cryopreservation process. In a previously
study [258], a DMSO and fetal bovine serum containing culture media (DMSO) showed a
RN = 0.94 (± 0.14) and BN = 2.01 (± 0.34) for the β-cell line INS-1E. For this reason,
the media was included in the screening as an example for good process performance.
Culture media without any cryoprotectant agent (RPMI) was used as example for extremely
poor process performance (RN = 0.0; BN = 0.0). [93] Further, the study comprised two
commercially available, DMSO-free and serum-free cryomedia, since cryopreservation for
clinical applications requires non-toxic cryoprotectant agents and the use of non-animal-
derived substances. [90–93, 96–98, 254–256] Both commercial cryomedia are, according
to manufacturer, chemically defined, serum- and DMSO-free and has been successfully
applied for mammalian cell lines, which makes them good candidates for clinically relevant
applications. [79, 264–266] The media are, however, not described in detail by the man-
ufacturer. While the CryoSOfreeTM media (Sigma) showed a good process performance
with INS-1E (RN = 0.84 (± 0.11); BN = 1.75 (± 0.38)), Biofreeze® media (Merck) showed
a relatively poor process performance (RN = 0.22 (± 0.03); BN = 0.95 (± 0.25)). The
evaluation of the process performance showed the following ranking: DMSO > Sigma >
Merck > RPMI. These findings are in compliance with the tool box predictions.
In summary, the four screened cryomedia showed different process performance which were
correctly predicted via the tool box characterization. Thus, the tool box offers a great
opportunity for prediction of process performance if a positive and negative example is avail-
able and fully described. In this case study, the positive example was the DMSO containing
culture media and the negative example culture media without any cryoprotectant. Two
commercially available, DMSO- and serum-free cryomedia were tested displaying different
process performance. The CryoSOfreeTM media showed a good process performance which
was successfully predicted via the tool box, since it displayed similar characterized features
than the positive control, except the viscosity. However, viscosity is considered as a soft
parameter, only important for process development considerations. The Biofreeze® media
(Merck), on the other hand, showed poor process performance and displayed some toxic
effects on the β-model cell line INS-1E, which makes it not applicable for that specific cell
line and would be excluded from further cryopreservation optimization process by the tool
box characterization.
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9.5 Conclusion
A tool box for the prediction of media process performance for cell cryopreservation was
described. The toolbox comprises the characterization of media properties, freezing/thawing
behavior and cell response to cryomedia exposure (toxicity). The predictive power is
based on the characterization of positive and negative controls. By comparison of the
data of media formulations with unknown process performance with the controls, the
process performance may be estimated. In this study, four media were screened for the
applicability in a cryopreservation process for the β-model cell line INS-1E. The screening
comprised a DMSO containing cryomedia as positive control, the culture media as negative
control and two commercially available DMSO and serumfree cryomedia with unknown
process performance. Using the described tool box, the commercial available cryomedia
Biofreeze® media was identified as non-applicable due to cell toxicity effects, while the
second commercial available cryomedia CryoSOfreeTM was identified as possible candidate.
However, the tool box reliability, sensitivity and robustness needs to be further proven in a
study comprising more data. We believe that the described tool box could contribute to
faster and more directed process development for cell cryopreservation. Using the tool box
a pre-selection of possible candidates could be done with a small amount of cells in short
time, shortening the time to market for clinical applications. Additionally, the tool box in
combination with multivariate data analysis (MVDA) could contribute to a deeper process
knowledge, which is also important for a GMP production of clinical applications. Another
advantage of the tool box is the easy adaptation to new projects by implementing the
measurement of e.g. critical cell criteria. The usage of flow cytometry analysis allows an
additional measurement of e.g. specific cell markers important for cell therapeutic safety
and effect especially in stem cell applications.
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Abstract
The importance of 3D printing technologies increased significantly over the recent years.
They are considered to have a huge impact in regenerative medicine and tissue engineering,
since 3D bioprinting enables the production of cell-laden 3D scaffolds. Transition from
academic research to pharmaceutical industry or clinical applications, however, is highly
dependent on developing a robust and well-known process, while maintaining critical cell
characteristics. Hence, a directed and systematic approach to 3D bioprinting process
development is required, which also allows for the monitoring of these cell characteristics.
This work presents the development of a flow cytometry-based analytical strategy as a tool
for 3D bioprinting research.
The development was based on a model process using a commercially available alginate-
based bioink, the β-cell line INS-1E, and direct dispensing as 3D bioprinting method. We
demonstrated that this set-up enabled viability and proliferation analysis. Additionally,
use of an automated sampler facilitated high-throughput screenings. Finally, we showed
that each process step, e.g. suspension of cells in bioink or 3D printing, cross-linking of
the alginate scaffold after printing, has a crucial impact on INS-1E viability. This reflects
the importance of process optimisation in 3D bioprinting and the usefulness of the flow
cytometry-based analytical strategy described here. The presented strategy has a great
potential as a cell characterisation tool for 3D bioprinting and may contribute to a more
directed process development.
Keywords: 3D bioprinting; process development; flow cytometry; cell viability, cell
proliferation
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10.1 Introduction
The possibility to build three-dimensional (3D), cell-laden constructs by three-dimensional
bioprinting had a major impact in life science research and is expected to be a key technology
in the field of tissue engineering and regenerative medicine [103–105]. Currently, academic
research is focusing on developing human diseases 3D tissue models or models for drug
discovery screenings [267, 268] and, in the long term, for transplantation of e.g. artificial
pancreatic tissue [114] or structural cartilage repair [269]. Although 3D bioprinting is a
relatively young research field, various 3D bioprinting technologies are available and have
been used already, including robotic dispensing, inkjet printing, and stereolithography. [106,
109] A common feature of these technologies is the use of so-called "bioinks" as scaffold
materials. Cells are resuspended in the bioink and 3D-printed in a layer-by-layer manner.
Hydrogels are prevalently used as bioinks, since these are known to provide a cell-friendly
environment and have often been applied in the field of tissue engineering. Additionally,
they need to be printable when used as bioinks. Each technology has different requirements
regarding e.g. rheology, shape fidelity, and the ability of cross-linking the bioink. [106, 109,
112, 113] Moreover, the post-printing behaviour of the scaffold needs to be considered.
Depending on the tissue, different mechanical strengths and stiffnesses must be guaranteed
to generate a functional, artificial 3D tissue model. Bone tissue, for example, differs
extremely from cartilage tissue. Hence, 3D bioprinting is a highly multidisciplinary field,
where biologists, materials scientists, and mechanical engineers need to cooperate closely
together in order to develop a strategy for each 3D tissue model as regards the post-printing
biological function, 3D printing technology, and bioink compatibility, the objective being to
meet biological needs and ensure printability. [104, 109, 113, 270]Malda et al. [109] proposed
the concept of the biofabrication window, which summarises the relations between bioink
properties, keeping shape fidelity, polymer concentration of the hydrogel components, and
post-printing cell viability. In general, higher polymer concentrations in the bioink translate
into good shape fidelity, but might produce hydrogels too stiff for post-printing cell survival,
and proliferation. [109] Therefore, a systematic approach to bioink development has been
pursued. [271–274] Many publications cover the relationship between bioink properties,
printing parameters, and cell survival. [275–279]
For a successful transition from academic research to pharmaceutical industry or clinical
applications, a general and deeper process knowledge and directed process development
are essential. Hence, using a systematic high-throughput process development (HTPD)
approach would be highly beneficial. [114–116] High-throughput screening (HTS) technology
has already been state-of-the-art in process development of pharmaceutical industry for
many years and has already proven that it is a powerful tool to reduce development
time and gain a deeper process knowledge, especially in combination with sophisticated
statistical analysis. [140, 141, 143, 144, 149] HTS platforms are also available for stem cell
research [136, 137] and downstream process development for cell-based products [200]. A
major part in the development of these platforms is the integration of an appropriate and
HTS-capable analytical method. When developing a 3D bioprinting process, it is extremely
important to analyse the influence of this process on cell behaviour. Two general concepts
can be applied: non-destructive testing, e.g. metabolic cell assays, where a supernatant
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sample is analysed or destructive testing, e.g. qPCR or flow cytometry. While simple
metabolic assays or DNA quantification methods, which provide only cumulative signals,
are suited for screenings with only one non-differentiable cell line, flow cytometry or qPCR
can be applied, if a more complex cell characterisation is needed. In both cases, the
capability of the assay must be validated and optimised for a 3D printing approach. For
example, metabolic assays might be insufficient for 3D tissues, since diffusion might be
limited [106, 276, 280, 281]. When using flow cytometry, it must be possible to dissolve
the 3D structure and obtain a single cell suspension. Flow cytometry has already proven
that it is a powerful tool in cell-therapy process development [27, 128], which indicates
that it might also be an essential tool in 3D bioprinting process development, since it
is HTS-capable and variable in terms of measurable cell characteristics, although it is a
destructive method.
Here, development of a flow cytometry-based analytical strategy for 3D cell printing
applications is reported. The strategy encompasses a proliferation and live/dead ratio
analysis. The method developed was evaluated based on a case study using the β-model
cell line INS-1E and a commercially available alginate-based bioink. For 3D printing,
the direct dispensing method was applied. The process consisted of the following steps:
suspending cells in bioink, 3D bioprinting, post-printing cross-linking of the bioink by ionic
gelation, dissolution of 3D structures by the means of de-gelation, and analysis. First, we
evaluated the CellTraceTM Violet-based proliferation analysis for bioprinted INS-1E cells.
Subsequently, we evaluated the analytical strategy developed using 3D-printed fluorescence
beads and fixed cells. Using the two artificial samples, effects of the printing process on
living cells were excluded. The evaluation covered the applicability of 3D-printed samples
and HTS capability, with the goal to verify suitability of the method for 3D bioprinting.
Finally, the influence of each process step on the β-model cell line INS-1E was evaluated
using the developed flow cytometry method.
10.2 Materials & Methods
10.2.1 Stock solutions
The fixation buffer consisted of phosphate-buffered saline (Thermo Fisher Scientific,
Waltham, USA) supplemented with 3.6 (v/v)% formaldehyde (Sigma-Aldrich, St. Louis,
USA). Storage buffer consisted of phosphate-buffered saline (Thermo Fisher Scientific) sup-
plemented with 1 (v/v)% bovine serum albumin (Miltenyi, Bergisch Gladbach, Germany).
Both buffers were kept under sterile conditions and stored at 8 ◦C. The de-gelating solution
was prepared with ultra-pure water (0.55 µS/cm) obtained from an Arium®proUV water
system (Sartorius Stedim Biotech, Goettingen, Germany). The solution consisted of 50 mM
trisodium citrate (Sigma-Aldrich) and 104 mM NaCl (Merck KGaA, Darmstadt, Germany)
and was sterile filtered (Ø 0.22 µm, VWR International GmbH, Bruchsal, Germany) after
preparation (storage temperature: room temperature). In this study, the commercially
available bioink CellINK (CellINK AB, Gothenburg, Sweden) was used. The bioink was
previously optimized towards printability and shape fidelity by adding nano-cellulose. [272–
274] CellINK was stored at 8 ◦C. The cross-linking solution (CaCl2) was purchased as part
of the bioink kit from CellINK AB (CellINK AB) and stored at room temperature.
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10.2.2 Software and data processing
The 3D DiscoveryTM was controlled by the HMI (Human Machine Interface) Software
(regenHU 3D Discovery 8.23.9.38, regenHU, Villaz-St-Pierre, Switzerland). G-code genera-
tion was done using a revised version of the ’Scaffold Designer’ developed by Ruiz-Cantu
et al. [282]. It was customized for the use of the regenHU print-head CF-300N in order
to generate round scaffolds. The ’Scaffold Designer’ was complemented by the use of a
Matlab-based script to increase labware flexibility. The script enables use of 6-well plates
by calculating the centre of the wells used and amplifying the scaffold g code. Excel 2013
(Microsoft, Redmond, USA) was used for data storage. Data evaluation and visualisation
were performed with Matlab R2015a (The MathWorks, Inc., Natick, USA). BD LSR
Fortessa Cell Analyzer was controlled by BD FACSDiva 8.0 (BD Biosciences, San Jose,
USA). Flow cytometry data were analysed and visualised using Flow Jo V10 (Tree Star
Inc., Ashland, USA).
10.2.3 Cell culture
The β-cell line INS-1E [198] was kindly provided by Prof. Maechler from the Department of
Cell Physiology and Metabolism at the University of Geneva Medical Centre, Switzerland.
Cell culture reagents were purchased from Thermo Fisher Scientific, unless stated otherwise.
Cells were cultivated in RPMI 1640 with GlutaMAX supplemented with 10 % FBS, 1 %
sodium pyruvate, 1 % Penicillin/Streptomycin, 10 mM HEPES, 2 mM L-Glutamine and
50 µM beta mercaptoethanol (Sigma-Aldrich) at 37 ◦C in a humidified 5 % CO2 incubator.
The cell culture was split every 7 days to a concentration of 6.6 x 104 cells/cm2, the medium
was exchanged after 3 days.
10.2.4 Cell staining & fixation
Prior to cell staining with CellTraceTM Violet (Thermo Fisher Scientific), cells were
trypsinized. Staining was performed with a working concentration of 5 µM dye according
to the manufacturer’s instructions. The dye belongs to the group of carboxyfluorescein
succinimidyl ester (CFSE)-like dyes which enables proliferation by dye dilution. [283, 284]
For viability studies, cells were stained with 7-Aminoactinomycin D (7-AAD) (Biolegend,
San Diego, USA) according to the manufacturer’s instructions. It bedlongs to the group
of DNA binding dyes which is excluded by live cells. The dead cell control sample
was generated by heat treatment (70 ◦C, 10 min). Cell fixation was done for evaluating
experiments by incubation of stained cells in fixation buffer (c = 1 x 106 cells/mL, 15 min, at
room temperature). Fixed cells were stored at 8 ◦C in storage buffer (c = 1 x 106 cells/mL)
in the dark prior to use.
10.2.5 Flow cytometric analysis
Flow cytometry is a single cell analytic method that facilitates multivariate analysis depend-
ing on cell morphology and fluorescence staining. Briefly, cell samples are hydrodynamically
focuse. Thus, single cells pass by laser beams, placed orthogonal to the sample stream. The
light emitted from the sample is detected via optical filters and array of photo-detectors.
Detected singe cell fluorescence signals are visualized as histogram or dot-plots when looking
at two signals. [134] The analysis was performed using an LSR Fortessa by BD Bioscience
126 Chapter 10
equipped with a BDTM high-throughput sampler. Unless stated otherwise, flow cytometry
analysis was performed using the high-throughput sampler in combination with 96-well
U bottom plates (BD FalconTM, Franklin Lakes, USA). When using the high-throughput
sampler, a defined sample volume of 100 µL was analysed and the following settings were
applied: sample flow rate: 3 µL/s, sample volume: 100 µL, mixing volume: 100 µL, mixing
speed: 250 µL/s, four mixing cycles and a wash volume of 800 µL.
10.2.6 Proliferation analysis
Cell proliferation was analysed in triplicates (biological triplicates; n = 3) with 5 µM
CellTraceTM Violet stained, and for control with unstained, cells in culture flasks with
an area of 25 cm2 for a period of 5 days. The cultivation was done according to the cell
culture protocol. Both unstained and stained cells were trypsinized prior to analysis. Cell
concentration was estimated by haemocytometer counting. Trypan blue dye exclusion
was used to distinguish live/dead cells. Flow cytometry analysis was performed with
CellTraceTM Violet-stained cell samples (non-fixed), without the use of the high-throughput
sampler. A validation culture (5 µM CellTraceTM Violet-stained cells, flask area = 175
cm2, n = 1) was analysed after 3 days of cultivation.
10.2.7 3D Bioprinting
First, CellTraceTM Violet-stained cells or beads were suspended in the CellInk bioink
(CELLINK AB) using the CELLMIXER (CELLINK AB) until a final concentration of
5.7 x 106 cells/mL or 1.48 x 106 beads/mL (Count BrightTM absolute counting beads,
Thermo Fisher Scientific) was reached. When using fixed cells, 38 % of the cells were
dead-stained using 7-AAD, while cell-free culture media was used as negative control.
3D printing was performed using a 3D Discovery system (regenHU Ltd.) enclosed in
a sterile hood and equipped with a micro valve-based inkjet print-head (CF-300N), a
pneumatically driven print-head for direct, time-pressure-dependent printing (DD-135N), a
screw-driven extrusion deposition-based print-head (HM-300H), and a UV cross-linking
unit (UV-365NM). Printing experiments were exclusively performed with the valve-based
CF-300N print-head with a 300 µm diameter nozzle (inner diameter = 300 µm, external
diameter = 500 µm, length = 2.4 mm) and a matching valve for direct dispensing (inner
diameter = 300 µm, stroke = 100 µm). All removable parts of the CF-300N (inlet adapter
with o-ring, luer-lock adapter, valve, and nozzle) were autoclaved (LSVA 40/60, ZIRBUS
technology GmbH, Bad Grund, Germany) before utilisation. Round scaffolds of 9 mm in
diameter and 4 horizontal and vertical lines (line spacing 2.25 mm) were printed up to a
height of 3 mm directly into 6 well glass bottom plates (Cellvis, Mountain View, USA).
Printing was performed with the following parameters: dosing distance: 0.05 mm, valve
opening time: 1200 µs, valve closing time: 2000 µs, dispensing pressure: 0.029 - 0.034 MPa,
printing speed: 11 mm/s. After printing, the scaffolds were incubated separately in 1 mL
cross-linking solution (CELLINK AB) for 20 min at room temperature. Scaffolds were
stored in 3 mL phosphate-buffered saline (Thermo Fisher Scientific) at 8 ◦C in the dark
prior to use.
For flow cytometry analysis, scaffolds were cut into small pieces using a scalpel (VWR) and
incubated in 4 mL de-gelating solution for 30 min at 37 ◦C. After incubation, samples were
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resuspended until no solid particles were visible. Samples containing non-fixed cells were,
additionally, stained with 7-AAD for live/dead discrimination according to manufacturers
instructions.
10.3 Results
We developed a flow cytometry-based analytical strategy as a tool for cell characterization
in 3D bioprinting process development. This was done based on a model process using
a commercially available, alginate-based bioink, the β-cell line INS-1E, and the direct
dispensing method for 3D bioprinting (fig. 10.1). Briefly, the cells were stained with
CellTraceTM Violet dye and resuspended in bioink prior to printing. Due to the use of
an alginate-based bioink, cross-linking of the alginate scaffolds was accomplished after
printing by ionic gelation. Cell analysis was performed using a flow cytometry approach.
Hence, de-gelation of the cell-laden scaffold was required prior to analysis. Use of the
CellTraceTM Violet dye and 7-AAD staining facilitated cell proliferation and viability
determination. Additionally, data deconvolution was done based on cell staining to elim-
inate bias caused by the bioink component. The selected commercially available and
ready-to-use bioink had been optimised previously in terms of printability. In order to
obtain a higher shape fidelity, nano-cellulose was added to the bioink as thickener. [272–274]
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Figure 10.1: Overview of the process strategy used for the case study. INS-1E cells were
stained with CellTraceTM Violet and suspended in an alginate-based bioink before 3D cell-laden
scaffolds were printed. After printing, the alginate-based bioink was gelated using divalent
cations in order to obtain scaffold stability. Cell analysis was performed using flow cytometry.
First, scaffolds were de-gelated in order to obtain a cell suspension. After data deconvolution,
cell proliferation and the live/dead ratio could be determined.
The nano-cellulose fibres are non-soluble by de-gelation and are, hence, present in de-gelated
scaffolds samples (fig. 10.2 A). A picture of a 3D-printed scaffold is shown in fig. 10.2
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B. As can be seen in the light microscopy of a de-gelated scaffold (fig. 10.2 A) and the
light microscopy image of trypsinized INS-1E cells (fig. 10.2 C), the sizes of the fibres
vary over a wide range and sometimes even correspond to the sizes of cells. For this reason,
a gating strategy (fig. 10.4) was developed to eliminate the flow cytometry signals of the
fibres.
250 µm
1000 µm
A
B
C
250 µm
Figure 10.2: A Light microscopy image of a de-gelated cell-free scaffold. The 3D structure
is completely dissolved except for the nano-cellulose fibres used as thickeners in the bioink.
B Image of the 3D-printed scaffold with a diameter of 9 mm. C Light microscopy image of
trypsinized INS-1E cells for size comparison.
The first part of the study was aimed at evaluating the CellTraceTM Violet-based prolifera-
tion analysis for the cell line INS-1E. Unstained and stained cells were cultivated over a
duration of 5 days. Every day, the cell density and the mode of the CellTraceTM Violet-A
signal were determined. As can be seen in fig. 10.3 A, the intensity of the CellTraceTM
Violet-A signal decreased over cultivation time. The mode of each intensity peak was
determined using the software Flow Jo V10 (Tree Star) and plotted against cultivation
days. The signal decreased exponentially over the cultivation time (fig. 10.3 B). Data
could be fitted to eq. (10.1) with r2 = 0.9874.
y = a× exp(b× x) (10.1)
Using the empirically determined equation, the duration of cultivation of a validation
sample was determined correctly (day 3). In contrast to the decreasing signal intensity,
cell density in both cultures increased over time (fig. 10.3 C). The growth curve of the
stained cells was lower than that of the unstained culture over the observed cultivation
time. This was expected since cell staining represents cell stress. Still, the validation
sample cell density matched the growth curve of the unstained culture.
Applying this CellTraceTM Violet-based proliferation analysis to 3D bioprinted samples,
however, requires data deconvolution to eliminate the flow cytometry signal of the fibres
added to the bioink as thickener. The gating strategy for data deconvolution is shown
in fig. 10.4. Single cells are gated for CellTraceTM Violet staining and, based on a 7-
AAD staining, into live/dead populations. The bioink component signal is located in the
unstained-live gate, whereas the signal of the stained cells is located in either the stained-
dead or stained-live gate. For the proliferation analysis, the ’stained -live’ population is
additionally displayed as histogram of the CellTraceTM Violet signal.
The second part of the study was aimed at evaluating the developed flow cytometry strategy
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Figure 10.3: Proliferation analysis of CellTraceTM Violet-stained cells using flow cytometry.
A Histogram of the CellTraceTM Violet signal of growth curve samples (day 1-5). Histograms
without filling represent calibration samples and the histogram with filling the validation sample.
Evaluation of the proliferation analysis: B mode of the CellTraceTM Violet signal plotted over
the cultivation time with exponential regression (y = a × exp(b × x). Fit parameters of the
regression with 95 % prediction bounds (shown in parentheses) and r2: a = 4898 (4444, 5352),
b = -0.6285 (-0.6879, -0.5691), and r2 = 0.9874 (n = 3, biological triplicate). Purple circles
represent stained cell data and filled purple circles show data of stained validation samples.
C Growth curve of unstained and CellTraceTM Violet-stained cells over the cultivation of
5 days (n = 3, biological triplicate). Grey stars represent data points of unstained control
cells. Purple circles represent stained cell data and filled purple circles show data of stained
validation samples.
using two artificial test samples (fluorescence beads and fixed cells), since the influence
of the process on the cells was unknown. Meaning, the analysed cell characterisitcs e.g
viability or cell size could be altered by the printing process. For this reason, the artificial
on-living test samples were used.
First, the strategy was evaluated with respect to HTS compatibility. Both validation test
sets showed a linear correlation between total counts and stained (live & dead) counts
over the calibration range of 5,000 - 150,000 total counts (n = 3; biological triplicate)
with r2 = 0.9952 for the bead test data set and r2 = 0.9757 for the fixed cells data
set. (fig. 10.5) The spillover of the bioink signal into the stained gates (populations:
stained-live + tained-dead) was determined to be below 0.06 % over the calibration range
from 5,000 - 150,000 counts (n = (3x3) 9 per calibration point (8-point calibration)).
The spillover was determined by analyzing cell- and bead-free samples. Secondly, the
influence of the printing process on beads and fixed cells was evaluated. In fig. 10.6 the
results after each process step are shown for both beads and fixed cells. On the left the
results of the beads and on the right the results of the fixed cells test set. The control
samples being A & B, C & D samples after suspension of beads or fixed cells, E & F after
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Figure 10.4: Deconvolution method for de-gelated cell-laden 3D printed scaffolds. Single cells
are gated for CellTraceTM Violet staining (stained) and divided into live/dead populations by
7-AAD staining. The bioink component signal is located in the unstained-live gate, whereas
the signal of the stained cells is located in either the stained-dead or stained-live gate. For the
proliferation analysis, the stained-live population is additionally displayed as histogram of the
CellTraceTM Violet signal and dot plot of the forward and sideward scatter. FSC-A: forward
scatter peak area, SSC-A: side scatter peak area, FSC-H: forward scatter peak height.
printing, and G & H after gelation and de-gelation. The dot plot of single cells and the
respective dot plot of the FSC-A and SSC-A signal for each sample are depicted (bead
samples: stained-dead gate, fixed cell samples: stained-live gate). The location of the bead
population (stained-dead) does not change in terms of the 7-AAD signal and CellTraceTM
Violet signal over all process steps. However, there is a tail of the bead population that
extends towards the bioink population (unstained-live) after suspension of the beads in
bioink (fig. 10.6 C) and after gelation and de-gelation (fig. 10.6 G). The dot plot of the
FSC-A and SSC-A signals of the bead population (stained-dead) indicates higher light
scattering of the beads after all process steps. These findings correlate with the results
of the fixed cell test data set, except for the change in the 7-AAD signal. The bioink
population is located in the unstained-live gate after all process steps and the intensity
of the CellTraceTM Violet signal is not changed as a result of the process. Nevertheless,
the live and dead populations merge more and more after each step, which is reflected by
a change in the 7-AAD signal. When looking at the dot plot of the FSC-A and SSC-A
signals of the stained and live cells, a higher increase of light scattering can be observed.
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Figure 10.5: Evaluation of HTS flow cytometry for de-gelated 3D printed samples with beads
and fixed cells over a range of 5,000 - 150,000 counts (8-point calibration with n = 3 per point).
As an example of printed bead samples, the dot plots of the FSC-A and SSC-A, A for 150,000
and B for 5,000 counts, are shown. Additionally, the dot plots of the 7-AAD and CellTraceTM
Violet signals of the single bead population are shown for C 150,000 and D 5,000 counts. E
Linear regression (y = ax+b) of stained counts (populations: stained-live + stained-dead) with
bead-containing samples. Fit parameters of the regression with 95 % prediction bounds (shown
in parentheses) and r2: a = 0.004589 (0.004451, 0.004727), b = -10.77 (-20.71, -0.8225), and r2
= 0.9952 (n = 3, biological triplicate). As an example of printed fixed cell samples, the dot
plots of FSC-A and SSC-A are shown F for 150,000 and G for 5,000 counts. Additionally,
the dot plots of the 7-AAD and CellTraceTM Violet signals of the single cell population are
shown for H 150,000 and I 5,000 counts. J Linear regression (y = ax+b) of stained counts
(populations: stained-live + stained-dead) with fixed cell-containing samples. Fit parameters
of the regression with 95 % prediction bounds (shown in parentheses) and r2: a = 0.005979
(0.005562, 0.006396), b = -27.49 (-57.58, 2.598), and r2 = 0.9757 (n = 3, biological triplicate).
Additionally, the spillover of the bioink signal into the stained gates (populations: stained-live
+ stained-dead) was determined to be smaller than 0.06 % over the calibration space 5,000
- 150,000 counts (n = 9 per calibration point (8-point calibration)). FSC-A: forward scatter
peak area, SSC-A: side scatter peak area.
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Figure 10.6: Evaluation of the influence of process steps on flow cytometry for de-gelated
printed samples with beads and fixed cells. Shown is the dot plot of the 7-AAD signal and
CellTraceTM Violet signal of the single cell population with the corresponding dot plot of
the FSC-A and SSC-A signal (bead samples: stained-dead population, fixed cell samples:
stained-live population). A bead control sample, B fixed cell control sample, C bead sample
after suspension in bioink, D fixed cell sample after suspension in bioink, E bead sample after
printing, F fixed cell sample after printing, G bead sample after gelation and de-gelation, H
fixed cell sample after gelation and de-gelation. FSC-A: forward scatter peak area, SSC-A:
side scatter peak area.
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In the third part of the study, the developed flow cytometry analysis strategy was used to
evaluate the model printing process (fig. 10.1) for the β-cell line INS-1E (CellTraceTM
Violet stained). When using alginate-based bioink, cross-linking is achieved by ionic gelation
with divalent cations after printing, which is reversible and can also be de-gelated via e.g.
a citric acid buffer. First, the influence of the two process buffers, namely, cross-linking
solution (CaCl2) and de-gelating solution (50 mM trisodium citrate), on cell viability
was evaluated. Cells were incubated in the solutions according to the process procedure.
In fig. 10.7 the dot plot of the 7-AAD signal and CellTraceTM Violet signal of the single
cell population is shown. Incubating cells in cross-linking solution for 20 min (RT) caused
a viability loss of 34 % (fig. 10.7 A). No viability loss was observed when cells were
incubated for 30 min in de-gelating solution (37 ◦C) (fig. 10.7 B). Viability loss was
calculated in comparison to the PBS control. Additionally, the influence of each process
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Figure 10.7: Evaluation of cross-linking for the alginate-based bioink using the INS-1E
cell line. The dot plot of the 7-AAD signal and CellTraceTM Violet signal of the single cell
population is shown. The ratio of live and dead cells is indicated. A after 20 min incubation
in cross-linking solution (RT) (live: 59.99 %, dead: 38.00 %), B after 30 min incubation in
de-gelating solution (37 ◦C) (live: 94.83 %, dead: 5.23 %). Control sample in PBS (live:
94.22 %, dead: 5.84 %). RT: room temperature.
step (suspension in bioink, printing, gelation & de-gelation) on the INS-1E cells was
screened. The screening results are shown in fig. 10.8. The dot plots of the single cell gate
of the 7-AAD and CellTraceTM Violet signals (left) and the dot plot of the SSC-A and
CellTraceTM Violet signals of the same gate (right) are depicted to obtain information
about changes in light scattering. The data of the control sample (fig. 10.8 A & B) reveal
three clearly separated populations for bioink (unstained-live gate), live-stained cells, and
dead-stained cells. A time control sample was also measured to exclude any influence of
process time on cell behavior, meaning a cell suspension aliquot was taken after cell harvest
and kept under process conditions (room temperature) without any further processing
until analysis. (fig. 10.8 C & D) The data show a minor loss of viability of 5.74 % due to
process time, no changes in the CellTraceTM Violet signal or light scattering were observed.
However, no live cell population was detected after suspension of the cells in bioink, a shift
of the dead cell population in the CellTraceTM Violet signal was observed. The populations
of the dead cells and the bioink signal are located closely to each other and not completely
separated, as the CellTraceTM Violet signal has decreased and the 7-AAD signal of the
bioink component has shifted towards higher signal intensities. (fig. 10.8 E) This is also
true for light scattering. Here (fig. 10.8 F), two closely located populations are visible
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with an increased light scattering tendency. These observations are also made for the
samples after printing (fig. 10.8 G & H) and after gelation and de-gelation (fig. 10.8 I
& J). However, the shifting of the signal increase with every process step. In comparison,
the bioink and cell signals are not shifted when analyzing fixed cell samples after gelation
and de-gelation. (fig. 10.8 K & L) There is only a shift of the 7-AAD signal which leads
to a merged live/dead population, as already mentioned (fig. 10.6). Two completely
separated populations for bioink and fixed cells can be seen, which also have a higher light
scattering signal.
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single cell population (right). A & B control samples, C & D time control samples (meaning:
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10.4 Discussion
The aim of the present work was to develop a flow cytometry-based analytical strategy
for use in high-throughput processes development for 3D cell printing applications. For
this purpose, a case study was performed using the β-cell line INS-1E and a commercially
available, alginate-based bioink. In addition, cell proliferation and the live/dead ratio of
the printed cells were to be analysed in a high-throughput manner.
In the first part of the study, we evaluated the applicability of the proliferation analysis using
the cell staining dye CellTraceTM Violet. The dye belongs to the group of carboxyfluorescein
succinimidyl ester (CFSE)-like dyes and enables proliferation analysis by fluorescence dye
dilution and flow cytometry. [283, 284] It has been widely used for proliferation analysis [285–
287] and performed great concerning tolerance, brightness of cell labelling, and uniformity.
Performance, however, can differ for each cell line [288]. The data obtained for the model
cell line INS-1E demonstrated suitability of this proliferation analysis method as part of a
flow cytometry-based analytical strategy. The model cell line INS-1E showed an exponential
decrease in the mode of the CellTraceTM Violet signal over 5 days of cultivation. Stained
cells showed lower cell densities over time, although a validation test sample was determined
correctly. Additionally, CellTraceTM Violet staining was found to allow for the elimination
of the solid bioink component signal by applying a gating strategy (fig. 10.4). This
signal elimination is crucial when de-gelated, cell-laden 3D printing samples are analysed,
since the fraction of solid bioink components is much higher than that of the cells in the
de-gelated sample.
For 3D cell printing process development, a systematic approach is highly recommended
to obtain reproducible and robust results with high cell viability rates. Hence, a high-
throughput approach is favourable. It was demonstrated earlier that high-throughput flow
cytometry is an excellent tool in downstream process development, even if the instrument
is not equipped with precision pumps [60].
In the second part of this study, we evaluated if this is also true for 3D cell printing process
development. For this purpose, we used test samples to exclude the process influence on
living cells. Fluorescence beads with a diameter of approximately 7 µm, showing a bright
fluorescence signal in both channels (CellTraceTM Violet & 7-AAD), were used as test
sample with only one population. To increase the test samples’ complexity, fixed cells with
38 % dead cell population were used. The results of both test samples demonstrated the
suitability of the method for high-throughput applications, since a low spillover of the
bioink signal in the cell gates was observed and a linear correlation between stained counts
and total counts was shown. The linear correlation enables the opportunity to implement
cell quantification using flow cytometry in future studies, as previously demonstrated. [128]
Additionally, we evaluated the process influence using both test samples. The beads showed
no signal shift in both channels and only a slight increase in light scattering, which indicated
no influence of the process steps on the beads. The results of the fixed cell samples, however,
reflected an influence of the process on the fixed cells. The FSC/SSC pattern of the process
samples deviated from that of the control sample (fig. 10.6). Furthermore, a shift of the
7-AAD signal for the live, fixed cell population was observed. Signal intensity increased
with every process step until the printing sample exhibited a completely merged live and
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dead population (fig. 10.6 H). We assume that this signal shift is related to the process,
since the control sample shows two separate populations for live and dead cells. Briefly,
7-AAD staining is normally not suitable for cell fixation since the procedure compromises
the cell membrane leading to dye uptake by "living" cells. However, the short timescales in
the present study meant that no dye uptake by "living" cells was displayed by our control
samples. This indicates that the suspension and printing process were responsible for
enhanced 7-AAD uptake, potentially due to mechanical stress. In further experiments,
actinomycin D should be added to the samples to prevent 7-AAD leaking in fixed cell
samples. [289]
In the third part of this study, we used the developed flow cytometry-based strategy to
investigate the influence of each process step (suspension of cells in bioink, 3D printing,
and cross-linking) on the model β-cell line INS-1E. Our data revealed a drastic decrease of
cell viability, whereas the time control showed no viability loss. Additionally, a decrease in
the CellTraceTM Violet signal of the cell population and a change in the FSC/SSC pattern
were observed. These features were not found in the dead cell control sample (fig. 10.8 A
& B), where only a slight change of the FSC/SSC pattern and no shift in the CellTraceTM
Violet signal were observed. We assume that a leakage of CellTraceTM Violet-labelled
proteins and an additional adsorption of these proteins by the soluble bioink components
occurred. The same signal shifts were seen for the samples after printing (fig. 10.8 G &
H) and after gelation and de-gelation (fig. 10.8 I & J). Additionally, buffer evaluation
showed that the used de-gelating solution has no influence on cell viability, while incubating
cells in cross-linking solution causes a 34 % loss in cell viability (fig. 10.7).
In summary, the data of the case study reflect a strong need for process optimization
when using the model β-cell line INS-1E and a commercially available bioink. Using the
knowledge, gatheres during the present work, will assist future work immensely. In order
to make it assecible, the findings of the current research are summarized in table 10.1.
Thus, it can be used as a guidance for future cell printing studies. Here, different options
for process optimization are listed with their potential relationships and the potential
influence on critical parameter. The critical parameters are further divided into critical
process related parameters and critical cell parameters, which can be measured via the
developed flow cytometry-based tool. Although the influence between parameters will
vary for different applications, this table gives an indication of where the most important
dependencies exist. In the present proof of concept study, the process strategy (fig. 10.1)
was meant to be simple and easy to implement. For this reason, a commercially available
bioink, optimized for printing without the need of a sacrificial material, was chosen. What
became apparent, however, is that the overriding critical process parameter (CPP) is cell
viability in respect to the different additives and bioink, as well as mechanical stress during
printing. When looking at the data for the suspension of the cells in bioink, it is unclear
whether the viability loss and change in the CellTraceTM Violet signal are caused by the
mechanical stress of the mixing process or by the contact with the bioink itself. This needs
to be addressed by further investigations that are to include a toxicity study of the bioink,
followed by an evaluation of the mixing process. Several static mixer designs are to be
evaluated with respect to mechanical stress. Moreover, the cross-linking strategy should be
optimized. In this study we used the cross-linking solution delivered with the commercial
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bioink. The alginate-based bioink is cross-linked by ionic gelation using calcium chloride.
The incubation with the cross-linking solution causes a viability loss and also calcium is
involved in the insulin secretion of β-cells [198]. Hence, it should be replaced by other
divalent cations. Alginate can be gelated using other divalent cations which, however, might
change the hydrogel properties that can influence cell proliferation within the 3D printed
scaffolds. [290–293] This highlights the need of a systematical screening for crosslinking
divalent cations. The developed analytical strategy can be used to optimize hydrogel
crosslinking by performing a simple toxicity test with different cations, in combination
with post-printing cell proliferation analysis. Using the same analytical method for early
studies e.g. the toxicity test and post-printing studies e.g. proliferation analysis is also an
advantage and might lead to a deeper process knowledge.
10.4 Discussion 139
Ta
bl
e
10
.1
:
M
at
rix
of
in
flu
en
cin
g
Cr
iti
ca
lP
ro
ce
ss
Pa
ra
m
et
er
s
(C
PP
)*
C
ri
ti
ca
l
P
ro
ce
ss
R
el
at
ed
P
ar
am
et
er
s
C
ri
ti
ca
l
C
el
l
P
ar
am
et
er
s
O
p
ti
on
s
In
te
rr
el
at
io
n
s
P
ri
n
t
In
te
gr
it
y
P
ro
ce
ss
C
om
p
le
x
it
y
C
el
l
V
ia
b
il
it
y
C
el
l
P
ro
li
fe
ra
ti
on
3Dprintingstrategy
3D
pr
in
ti
ng
te
ch
ol
og
y
bi
oi
nk
+
+
+
±
+
+
+
ce
ll
st
re
ss
±
sa
cr
ifi
ci
al
m
at
er
ia
l
pr
in
ti
ng
m
et
ho
d,
ob
je
ct
ge
om
et
ry
+
+
+
+
+
+
ad
di
ti
on
al
pr
oc
es
s
st
ep
fo
r
re
m
ov
al
±
ce
ll
to
xi
ci
ty
±
ce
ll
to
xi
ci
ty
ob
je
ct
ge
om
et
ry
pr
in
ti
ng
m
et
ho
d,
bi
oi
nk
&
sa
cr
ifi
-
ci
al
m
at
er
ia
l
±
pr
in
te
r
re
so
lu
ti
on
et
c.
±
±
±
ox
yg
en
/n
ut
ri
en
t
su
p-
pl
y
Material
bi
oi
nk
pr
in
ti
ng
m
et
ho
d
&
ce
ll
lin
e
+
+
+
±
+
+
+
ce
ll
to
xi
ci
ty
+
+
+
bi
oi
nk
po
st
-
pr
oc
es
si
ng
be
ha
vi
ou
r
cr
os
sl
in
ki
ng
pr
in
ti
ng
m
et
ho
d
&
bi
oi
nk
+
+
+
ad
di
ti
on
al
pr
oc
es
s
st
ep
±
ce
ll
to
xi
ci
ty
+
+
+
bi
oi
nk
po
st
-
pr
oc
es
si
ng
be
ha
vi
ou
r
CellCulture
ce
ll
lin
e
de
pe
nd
en
t
on
ti
ss
ue
w
hi
ch
sh
ou
ld
be
m
im
ic
ke
d
&
bi
oi
nk
+
+
+
ac
ce
pt
ab
le
m
ec
h.
st
re
ss
±
+
+
+
+
+
+
ce
ll
lo
ad
ce
ll
cu
lt
ur
e
&
ce
ll
m
ix
in
g
±
bi
oi
nk
vi
sc
os
it
y/
de
n-
si
ty
±
±
+
+
+
ce
ll
m
ix
in
g
ce
lls
in
bi
oi
nk
or
ce
ll
gr
ow
th
on
ob
-
je
ct
su
rf
ac
e
±
bi
oi
nk
vi
sc
os
it
y/
de
n-
si
ty
ad
di
tt
io
na
l
pr
oc
es
s
st
ep
+
+
+
sh
ea
r
st
re
ss
+
+
+
gr
ow
th
be
ha
vi
ou
r
ce
ll
st
ai
ni
ng
as
pa
rt
of
an
al
yt
ic
al
st
ra
te
gy
-
ad
di
ti
on
al
pr
oc
es
s
st
ep
±
ce
ll-
sp
ec
ifi
c
op
ti
m
iz
a-
ti
on
±
ce
ll
gr
ow
th
ra
te
*
ba
se
d
on
ex
pe
ri
en
ce
ga
in
ed
fr
om
cu
rr
en
t
w
or
k
+
+
+
hu
ge
im
pa
ct
;
±
m
ig
ht
ha
ve
an
in
flu
en
ce
;
-
lit
tl
e
in
flu
en
ce
140 Chapter 10
10.5 Conclusion
A flow cytometry-based analytical strategy for 3D bioprinting process development was
developed. The strategy was validated using a model process with the β-cell line INS-1E,
an alginate-based, commercially available bioink, and a direct dispensing 3D bioprinter.
Flow cytometry represents a destructive analysis method in the field of 3D bioprinting.
For this reason, de-gelation using citric acid was performed to dissolve the cell-laden 3D
alginate scaffolds. The de-gelating solution was found to have no effect on cell viability.
The developed strategy enables a CellTraceTM Violet-based cell proliferation analysis and
a 7-AAD-based live/dead recognition. Data deconvolution was done to eliminate the
bias caused by fibers added to the commercially available bioink as thickener. Use of
an automated sampler was found to enable high-throughput analysis. The strategy was
validated using two artificial test samples, namely, fluorescence beads and fixed cells. No
process influence on bead signals was observed, whereas a 7-AAD und SSC-A signal shift
was detected for fixed cells. Additionally, process influence on the β-model cell line INS-1E
was evaluated using the flow cytometry-based strategy developed. The data indicated a
major process influence on cell viability. Further optimisation of the 3D bioprinting process
is necessary.
A systematic approach to 3D printing process development is highly recommended to obtain
reproducible and robust results with high cell viability rates. It would also be favourable
to apply the same analytical method in all process development stages, from early phase of
bioink cross-linking evaluation to the late stage, where the cells post-printing behaviour in
culture needs to be analysed. We consider flow cytometry to be a powerful tool to study
global process influence on cell characteristics. For detailed structural analyzis of the 3D
printed objects, an microscopic approach as orthogonal method must be implemented in
addition. However, flow cytometry allows for the specific development of a 3D bioprinting
process, in particular when complex cell characterisation of e.g. in case of printed stem
cells or simultaneous printed multiple cell lines is needed in a high-throughput manner.
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CHAPTER 11
Conclusion & Outlook
Translating cell-based therapeutics from academia towards a commercial/clinical applica-
tion still represents a challenging and interdisciplinary task. The focus of this doctoral
thesis was the development and implementation of process development tools, contributing
to a more directed and systematic process development approach. Using such tools would
be highly beneficial in order to tackle a major obstacle of this therapeutic class: the inherent
complexity of living cells in combination with the limited experience/process knowledge.
In order to demonstrate the power, applicability and variety of process development tools
for cell-based therapeutics, this thesis covered several unit operations. The first part of the
thesis focused on the unit operation cell separation, while the second part focused on cell
formulation unit operations, namely, cell cryopreservation and bioprinting.
The first part of this thesis covered the unit operation cell separation. Here, a previously
developed HTS platform was used to investigate the influence of the critical parameter
TLL and molecular weight on cell partitioning in PEG-dextran ATPS buffered with NaPi.
First, a cell barcoding strategy was implemented enabling a fast and multiplex cell analysis.
Subsequently, a case study was performed with five model cell lines showing that ATPS
containing low PEG molecular weights and high dextran molecular weights facilitate high
cell line resolution. Hence, the presented case study demonstrated the applicability of the
HTS platform in combination with CCD-modeling for the investigation of cell partitioning
in ATPS, which strongly indicates the usefulness of this approach as cell downstream
processing development tool allowing for a systematic and directed screening. However,
clinically relevant cell populations might be more complex which highlights the need for
comprehensive screenings.
Furthermore, a technology transfer was performed based on a case study using the model
cell line HL-60. A process set up, allowing for the investigation of cell partitioning in
ATPS in a microfluidic flow-through mode, was successfully developed. The development
was done within the DMAIC framework using additive manufacturing technologies as
tool for the fast, cheap and easy realization of tailored equipment complementing stan-
dard laboratory equipment. Using only inexpensive bench top 3D printer and service
contractors, the development of the microfluidic process set up with integrated video-based
analysis could be realized with low investment. Additionally, a root-cause investigation
was performed to evaluate parameter, causing poor microfluidic process performance in
comparison to the batch HTS data. On that basis, two main factors were identified: (1)
fluctuating cell number due to cell sedimentation and aggregation in tubing; (2) decreased
cell viability in dependence to fluid velocity which also had a negative influence on cell
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partitioning behavior. In general, the presented case study approved the usage of 3D
printing technologies as effective process development tools, shortening development time
line while simultaneously increasing creativity in process setup when combined with a
structuring approach like the DMAIC framework.
The second part of this thesis was centered around cell formulation unit operations. First,
a video-based tool was developed allowing for the characterization of the critical cryop-
reservation process parameter freezing and thawing behavior. The tool performance was
successfully confirmed by a cryopreservation scale up study from 1 to 2 mL working volume.
Using the tool, a delay in freezing and thawing behavior due to working volume increase
was detected which is in good agreement with literature. Additionally, a conventional
cryopreservation, monitoring cell viability and proliferation, was performed highlighting
the need for optimization since the 2 mL samples with a delayed freezing behavior showed
poor survival and proliferation rates. Thus, the integration of the developed tool would
be highly beneficial for cryopreservation process development for cell-based therapeutics
allowing for a systematic screening. It would also contribute to the intended QbD approach
since it also generate deeper process knowledge.
Subsequently, the developed video-based tool was implemented in a predictive tool box
enabling the prediction of media process performance for cell cryopreservation by charac-
terization of media properties, freezing/thawing behavior and cell response to cryomedia
exposure (toxicity). Screening for alternative cryomedia formulations (without any toxic
or animal-derived components) is essential for cell-based therapeutics since it needs to
be in accordance with GMP requirements. A case study was conducted aiming at the
evaluation of the applicability of two commercial DMSO-free cryomedia for the β-model
cell line INS-1E. Additionally, the cryomedia screening included a positive control (DMSO
containing cryomedia) and a negative control (without any cryoprotectant). Applying
the tool box in combination with process knowledge of the positive and negative control,
the commercial available cryomedia Biofreeze® media was classified as media with inferior
performance. The second commercial available cryomedia CryoSOfreeTM was, at the same
time, identified as possible candidate for the β-model cell line INS-1E. These findings
highlight the need for a systematic screening for effective cryomedia formulation for each
cell application. While the tool box needs to be evaluated more closely in a comprehensive
study in order to prove its performance (reliability, sensitivity and robustness), it could
contribute to faster and more directed process development for cell cryopreservation. In
future, the described tool box could be used for pre-selection of possible candidates since it
would streamline sample volume, as well as, development time. An additional advantage
of the described tool box is the usage of flow cytometry analysis for toxicity evaluation.
Hence, it could easily be adapted to new projects by implementing the measurement of e.g.
critical cell criteria which is highly beneficial for clinical applications.
Monitoring critical cell characteristics (CCC) during process development or manufacturing
is essential for cell-based therapeutics since changes are directly linked to therapeutic
efficiency and patient safety. This is especially important for the process development of
enabling technologies like bioprinting. Hence, a flow cytometry-based analytical strategy
was developed for bioprinting applications. The development was done based on a model
process using the β-model cell line INS-1E, an alginate-based, commercially available
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bioink, and a direct dispensing 3D bioprinter. The strategy includes cell staining, 3D object
deconstruction, flow cytometry analysis using an autosampler, as well as, data deconvolu-
tion. Two cell dyes were used allowing for the analysis of the CCC cell viability (7-AAD
staining) and proliferation (CellTraceTM Violet-based). The 3D object deconstruction is
necessary since flow cytometry is a single cell analysis method. In the presented case study,
de-gelating of the alginate-based bioink could be successfully performed using citric acid
without a decrease in cell viability. However, the used commercial bioink contained fibers
as thickener to improve the printability which could not be dissolved. For this reason, a
data deconvolution strategy was implemented in order to eliminate the bias caused by
the fiber signal. A successful strategy validation was performed using two artificial test
samples. Subsequently, bioprinting process monitoring was performed. The monitoring
indicated a major process influence on the β-model cell line INS-1E viability, highlighting
the need for process optimization. Using the developed flow cytometry-based analytical
strategy for bioprinting process development applications would contribute to a more
directed and systematic approach. Additionally, the developed analytical strategy allows
for high-throughput analysis due to the use of an automated sampler. Another advantage
of the developed strategy is the simple implementation of additional CCC measurements
allowing for complex cell characterization e.g. when printed multiple cell lines simultane-
ously or stem cells.
In conclusion, the doctoral thesis has shown that general process development tools and
strategies from the pharmaceutical industry are applicable for cell-based products. Sev-
eral process development tools and strategies have been developed within this doctoral
thesis facilitating an advance in cell-based therapeutic process development. Using the
presented approaches would be highly beneficial since they follow the general principle of
miniaturization and automation enabling a simplified, accelerated, systematic and more
directed process development. The presented work has demonstrated the applicability of
those principles for inherent complex products like living cell material and might routinely
be implemented in cell therapeutic industry process development campaigns. Hence, future
projects will involve comprehensive studies with clinically relevant material.
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CHAPTER 13
Abbreviations
ADA-SCID adenosin-desaminase severe combined immunodeficiency
ATMP Advanced Therapy Medicinal Product
ATP adenosine triphosphate
ATPS aqueous two-phase systems
BSA bovine servum albumin
CAD computer-aided design
CAR-T cells chimeric antigen receptor T cell
CCC critical cell characteristic
CCD countercurrent distribution
CFSE carboxyfluorescein succinimidyl ester
cGMP current Good Manufacturing Practice
CoGs cost of goods
CPP critical process parameter
CQAs critical quality attributes
CT computed tomography
DMSO dimethyl sulfoxide
DSP downstream processing
EMA European Medicines Agency
EU European Union
FACS fluorescence activated cell sorting
FBS fetal bovine serum
FDA Food and Drug Administration
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FDM fused deposition modelling
FSC-A Forward scatter peak area
FSC-H Forward scatter peak height
GMP Good Manufacturing Practice
GvHD graft-versus-host-disease
HMI Human-Machine Interface
HTPD high-throughput process development
HTS high-throughput screening
ICH international council for harmonisation of technical requirements
for pharmaceuticals for human use
IPPD integrated product and process development
LPLD Lipoprotein lipase deficiency
MAA marketing authorization application
mAb monoclonal antibody
mAbs monoclonal antibodies
MACS magnet activated cell sorting
MCB master cell bank
MRI magnetic resonance imaging
MTT 3-(4&5-dimethylthiazole-2-yl)-2&5-diphenyl- tetrazoliumbromide
NaCl sodium chloride
NaPi sodium phosphate
PBS phosphate-buffered saline
PEG polyethylene glycol
QbD Quality by Design
QCA critical quality attribute
QTPP Quality Target Product Profile
R&D research and development
SSC-A side scatter peak area
TLL tie-line length
177
US United States
USP upstream processing
UV ultraviolet
WCB working cell bank
WV working volume
3D three-dimensional
7-AAD 7-Aminoactinomycin D
